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Abstract 
Introduction: Glucose-regulated protein 78-kDa (GRP78) is an endoplasmic 
reticulum (ER)-resident molecular chaperone that is essential for correct protein 
folding and assembly in the ER lumen. Micro-environmental stress and a 
requirement for increased protein synthesis, typical of solid tumours, leads to a 
disruption of ER homeostasis, and accumulation of misfolded proteins. The ability of 
GRP78 to dissociate from several important ER-resident transmembrane proteins 
under conditions of ER stress leads to a cascade of signal transduction pathways, 
known as the unfolded protein response (UPR), that modulate cell survival or, if the 
stress is significantly severe, apoptosis. GRP78 has been found to be overexpressed 
in a variety of cancers compared with benign tissue and has been associated with 
poor outcome. In-vitro data indicate that GRP78 expression is often associated with 
aggressive phenotype and drug resistance. Thus, GRP78 has potential as a biomarker 
for tumour behaviour and treatment response. 
For stage III colorectal cancer, there is overwhelming evidence to recommend the 
use of fluoropyrimidine-based adjuvant chemotherapy. Unfortunately, a large 
proportion of patients do not benefit from adjuvant chemotherapy, and biomarkers 
that can determine the likelihood of response to chemotherapy remain elusive. The 
benefit of chemotherapy in stage II disease is less certain and markers that could 
reliably predict benefit would be particularly useful in this population. This study 
explores a potential mechanistic relationship between GRP78 and 5-FU sensitivity 
using both siRNA transfection and treatment with an engineered fusion protein, 
epidermal growth factor (EGF)-SubA, which has been demonstrated to cause highly 
selective cleavage of GRP78 at a single amino acid point. It was then examined 
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whether GRP78 may have prognostic or predictive value in the context of colorectal 
cancer patients treated with fluoropyrimidine-based chemotherapy. The potential 
therapeutic value of targeting GRP78 in vitro using EGF-SubA is also examined. 
 
Methods: Colon cancer cell lines were used to examine response to 5-FU upon 
modulation of endogenous GRP78 using siRNA technology and EGF-SubA. 
Apoptosis and cell cycle progression were assessed using flow cytometry. 
Immunohistochemistry was used to characterise GRP78 expression in a large cohort 
of colorectal cancers on tissue microarrays and the results were correlated with 
clinicopathological parameters and with 5-year survival for the whole cohort and 
those treated with fluoropyrimidine-based (5-FU) adjuvant chemotherapy. The action 
of EGF-SubA upon colon cancer cells was examined using western blotting, MTT 
assay and flow cytometry. 
 
Results: GRP78 promotes apoptosis in response to 5-FU. Better overall 5-year 
survival was associated with high GRP78 expression (P=0.036). Stage III patients 
with high GRP78 showed significant benefit from adjuvant chemotherapy (P=0.026), 
whereas patients with low GRP78 failed to benefit (P=0.805). Low GRP78 was an 
independent poor prognostic indicator of overall 5-year survival (P=0.005; 
HR=1.536; 95%CI 1.139-2.122). Colon cancer cells expressing EGFR were highly 
sensitive to EGF-SubA, demonstrating reduced proliferation and cell cycle arrest. 
However, EGF-SubA did not induce significant apoptosis and reduced the 
effectiveness of 5-FU in vitro. 
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Conclusion: This study demonstrates a mechanistic relationship between GRP78 
expression and response to 5-FU. GRP78 expression may provide a useful additional 
risk stratification to inform the adjuvant treatment of colorectal cancer. EGF-SubA 
does not have therapeutic value in colorectal cancer but is a useful tool for studying 
GRP78 and the UPR. 
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1.1 Colorectal Cancer 
1.1.1 Demographics 
In the 21
st
 century, colorectal cancer remains an important disease causing significant 
morbidity and mortality. Colorectal cancer is the third most common cause of cancer 
related death (after breast and lung cancer) in the United Kingdom and the second 
commonest in non smokers. Over 100 new cases of colorectal cancer are diagnosed 
each day in the UK. Around 40,000 new cases of colorectal cancer (2/3 in the colon 
and 1/3 in the rectum) are registered in the United Kingdom each year and 
approximately 16,000 deaths,(1-4) but there has been a substantial improvement in 
five year survival, from 22% to 50% over the last 30 years.(5, 6) Worldwide, there 
are approximately 1.2 million cases of colorectal cancer and over 600,000 people die 
each year.(7) The incidence of colorectal cancer rises with age with 84% of cases 
arising in people who are 60 years or older (Figure 1.1.1-1). 
Rates are similar for males and females until age 50 and thereafter males 
predominate. The lifetime risk of being diagnosed with colorectal cancer in the UK is 
estimated to be 1 in 14 for men and 1 in 19 for women.(8) 
In Europe in 2008, colorectal cancer was the most common cancer with 436,000 new 
cases and the second most common cause of cancer death with 212,000 deaths. The 
incidence of colorectal cancer has increased modestly in most European countries, 
especially in men, although mortality rates have in general declined.(9)  
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Figure 1.1.1-1: Age-specific incidence of colorectal cancer in the UK in 2011, for men 
and women.(8) 
There is a wide geographical variation in distribution of colorectal cancer globally 
with almost 60% of cases occurring in the more affluent developed countries such as 
North America, Australia/New Zealand, Western Europe and Japan, with lower 
incidence seen in Africa, Asia and South America.(10) This large geographical 
variation is probably due to environmental exposures.  
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Figure 1.1.1-2: Geographical distribution of colorectal cancer in 2011.(8) 
1.1.2 Molecular basis of colorectal cancer 
For decades, our understanding of colonic carcinogenesis has been underpinned by 
the concept of the ‘adenoma-carcinoma’ sequence, as first discussed in 1951 by 
Jackmann and Mayo.(11) Evidence supporting the adenoma-carcinoma hypothesis is 
based on strong but circumstantial observations. Supporting evidence includes: 
 The prevalence of adenomas is very similar to that of carcinomas and the average 
age of adenoma patients is approximately 5 years younger than carcinoma 
patients.(12) 
 Remnants of adenoma are often found in resected colon cancer, particularly 
adjoining small early cancers.(13) 
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 Familial adenomatous polyposis (FAP) is unequivocally pre-malignant and the 
adenomas resulting from this condition are identical to sporadic adenomas.(14, 
15) 
 Cellular atypia and gene mutations are more common in large adenomas than 
small. Adenomas greater than 2cm have a 50% chance of containing foci of 
invasive cancer.(16-18) 
 The distribution of adenoma throughout the colon is almost identical to that of 
carcinomas.(17-19) 
 Synchronous adenomas may be found in a third of colorectal cancer surgical 
resections.(20, 21) 
 Endoscopic removal of adenomatous polyps reduces the long term risk of 
colorectal cancer.(22, 23) 
It was felt however that this simple hypothesis could not account for all cases of 
colon cancer. Contemporary genetic analysis has subsequently expanded our 
knowledge of this pathway. 
1.1.2.1 The chromosomal instability pathway 
The seminal paper by Vogelstein et al.,(24) described the accumulation of genetic 
mutations leading to the formation of a benign adenoma and subsequent 
transformation to invasive malignancy. The chromosomal instability pathway 
identifies inactivating mutations of the adenomatous polyposis coli (APC) tumour 
suppressor gene on chromosome 5q21, implicated in cell to cell adhesion, is found in 
60% of all adenomas and carcinomas, and probably occurs early.(25) Activating 
mutations of the KRAS oncogene, responsible for activating growth factor signal 
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transduction, is also a common finding,(26) but more so in larger adenomas and may 
represent a later event.(24) A deletion on chromosome 18q is seen in 70% of 
carcinomas and in almost 50% of late adenomas. The region lost includes the deleted 
in colorectal cancer (DCC) tumour suppressor gene, which encodes proteins involved 
in cell adhesion. The DCC gene is expressed in normal mucosa but expression is 
reduced or absent in the majority of colorectal carcinomas.(27) The loss of a large 
portion of chromosome 17p, containing the p53 tumour suppressor gene, is seen in 
more than 75% of colorectal carcinomas, but is rare in adenomas at any stage.(24, 
28) p53 mutation is therefore thought to represent a late event in the transition from 
adenoma to high-grade dysplasia and lays the stage for malignant transformation. A 
suggested model of the series of genetic events involved in the adenoma-carcinoma 
sequence is shown below. 
 
Figure 1.1.2-1: Proposed adenoma-carcinoma sequence in colorectal cancer.(29) 
Many other genetic abnormalities are described in colorectal cancer but there is no 
single mutation common to all cancers. The sequence proposed above represents one 
possible scenario. 
Germline mutation of the APC gene leads to familial adenomatous polyposis (FAP). 
FAP is a dominantly inherited condition characterised by the appearance of multiple 
adenomatous polyps throughout the colon which inevitably lead to colorectal cancer 
by the fourth decade of life. The severity of polyposis varies depending on the 
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specific mutation, with mutation at codon 1309 (exon 15) being associated with a 
very dense polyposis. FAP accounts for 1% of all colorectal cancers. Patients require 
a colectomy at the age when polyps start to develop, usually in late teenage years and 
early 20s.(30) 
1.1.2.2 Microsatellite instability pathway and Lynch syndrome 
Whilst 85% of sporadic colorectal cancers display chromosomal instability, the 
remaining 15% demonstrate a microsatellite instability (MSI) phenotype.(31) Whilst 
sporadic cancers caused by MSI are usually attributable to somatic hypermethylation 
of the promoter region of MLH1gene, up to 4% of colorectal cancers are caused by 
Lynch syndrome, an autosomal-dominant cancer predisposition characterised by 
insertion-deletion germline mutations of short tandemly repeated nucleotides 
(microsatellites) caused by defects in DNA mismatch repair (MMR) genes (MLH1, 
MSH2, MSH6, PMS1 and PMS2). Chromosome losses are rarer in these tumours 
and in contrast to the aneuploidy or polyploidy karyotypes seen in tumours 
displaying chromosomal instabilility, MSI tumours are typically diploid.(32) 
Histologically, tumours with MSI differ from typical CIN cancers in that they are 
often proximally located, poorly differentiated and of ‘signet ring’ appearance, 
mucinous, and show marked lymphocytic infiltration.(33) 
Lynch syndrome (previously known as hereditary non-polyposis colorectal cancer or 
HNPCC) is the most common hereditary colon cancer syndrome and is associated 
with a lifetime risk of colorectal cancer of around 80%, plus an increased risk of a 
variety of other cancers (endometrial, ovarian, gastric, small bowel, and ureter).(34) 
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Before wide availability of genetic testing, those at risk of Lynch syndrome were 
identified on the basis of clinical and family history criteria (Amsterdam II or revised 
Bethesda criteria). 
Table 1.1-1: Amsterdam II criteria (35) 
Amsterdam II criteria for gene testing for Lynch syndrome 
At least 3 relatives with a Lynch-associated cancer (colorectal, endometrial, small bowel, 
ureter, renal pelvis) 
One affected family member is a first-degree relative of the other two 
At least two successive generations affected 
At least one diagnosed before age 50 years 
Familial adenomatous polyposis has been excluded 
Tumours are verified by pathological examination 
 
Table 1.1-2: Modified Bethesda guidelines (36) 
Modified Bethesda guidelines for testing colorectal tumours for microsatellite 
instability 
Diagnosed with colorectal cancer before the age of 50 years 
Synchronous or metachronous colorectal or other HNPCC-related tumours (which include 
stomach, bladder, ureter, renal pelvis, biliary tract, brain (glioblastoma), sebaceous gland 
adenomas, keratoacanthomas and carcinoma of the small bowel), regardless of age 
Colorectal cancer with a high-microsatellite instability morphology that was diagnosed 
before the age of 60 years 
Colorectal cancer with one or more first-degree relatives with colorectal cancer or other 
HNPCC-related tumours. One of the cancers must have been diagnosed before the age of 50 
years (this includes adenoma, which must have been diagnosed before the age of 40 years) 
Colorectal cancer with two or more relatives with colorectal cancer or other HNPCC-related 
tumours, regardless of age 
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The Amsterdam criteria were the first diagnostic guidelines to be developed with the 
aim of determining whether a family should be classified as having HNPCC. The 
Bethesda guidelines were developed with a different objective to the Amsterdam 
criteria and are useful in deciding whether individuals with cancer in families that do 
not fulfil Amsterdam criteria should undergo genetic testing (Figure 1.1.2-2).(37) 
 
Figure 1.1.2-2: Strategy for genetic testing of affected individuals from families with 
suspected hereditary non-polyposis colorectal cancer.(37) 
To limit the expense of performing full germline mutational analysis of all candidate 
patients, preselection is performed based on biomarkers. Using PCR, MSI can be 
detected by analysis of a panel of 5-10 microsatellite sequences in the DNA of a 
tumour compared with the DNA of normal adjacent mucosa.(37) Tumours fall into 
one of three categories: MSI-High (MSI-H), unstable for 30% of markers used; MSI-
Low (MSI-L), unstable for 10-30% of markers; or microsatellite stable (MSS), for 
cases with no MSI. Immunohistochemistry for lack of expression of MMR proteins 
(primarily MLH1 protein) is also diagnostic for defective mismatch repair and can be 
used as an alternative to PCR.(38) Although these techniques can determine the 
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presence of mismatch repair deficiency, they are not able to distinguish Lynch 
syndrome cancers from sporadic MSI cancers. It is now known that BRAF mutation 
is associated with MLH1 promoter region hypermethylation and not germline 
mutations in the mismatch repair (MMR) genes.(39) Therefore it is possible to 
distinguish between sporadic MSI tumours and those due to Lynch syndrome using a 
simple algorithm (Figure 1.1.2-3). 
 
Figure 1.1.2-3: Algorithm for genetic testing for Lynch syndrome. Modified from (40) 
1.1.2.3 The epigenetic pathway to colorectal cancer 
Non-Lynch MSI tumours are similar to Lynch-associated colorectal cancers 
histologically and in that they are more likely to occur in the right colon and have a 
better overall prognosis.(41) However, these sporadic MSI tumours do not 
demonstrate a strong inheritance pattern and do not occur at a young age. Unlike 
Lynch syndrome, gene mutations are not present and the MSI is known to be due to 
hypermethylation of the promoter region of MLH1 leading to its inactivation. This 
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overlaps with the observation that some colonic polyps and cancers are characterised 
by hypermethylation of a large number of genes, a process termed the CpG 
(Cytosine-phosphate-Guanine) island methylator phenotype (CIMP).(42) CpG island 
hypermethylation is a critical mechanism for tumour-suppressor gene silencing.(43) 
1.1.3 Pathology 
Among the earliest premalignant lesions in colorectal cancer are aberrant crypt foci. 
Dysplastic aberrant crypt foci (ACF), also referred to as adenomatous crypts or micro 
adenoma, frequently show loss of heterozygosity in the APC gene. ACF are widely 
believed to be precursors to adenomatous polyps. In normal tissue, colonic stem cells 
at the bottom of crypts divide continually in an asymmetric manner, feeding cells 
into the proliferative zone of the crypt. This preserves the stem cell and gives rise to 
a daughter committed to differentiation and death. Following APC gene mutation, an 
initiated stem cell may lose the ability to divide asymmetrically and occasionally 
divides symmetrically giving rise to two initiated daughter cells which retain the 
ability of clonal expansion. As these cells divide and move from the stem cell zone to 
the proliferative zone of the crypt, they become freed from the microenvironmental 
constraints of the crypt and are free to expand clonally via symmetric divisions. If 
not compensated for by apoptosis, altered stem cells may accumulate. A further 
genetic event, such as a mutation of one copy of the p53 gene acting in a dominant 
negative manner, may be the catalyst for subsequent malignant transformation of 
these initiated stem cells.(44)  
Adenomas are present in around 30% of the population,(45) and can be classified 
histologically as tubular, tubulo-villous, or villous. Dysplastic change may be classed 
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as low grade or high grade based on the degree of architectural abnormality and 
cellular atypia. More than 90% of adenomas are small (< 1 cm in diameter) and do 
not progress. Risk factors for malignant progression include the presence of multiple 
adenomas, size greater than or equal to 1 cm, and villous histology or severe 
dysplasia in adenomas of any size. 
Colorectal cancers are typically described as polypoidal, ulcerating, annular or 
mucinous. The intraluminal part of tumour may be large, filling the entire lumen, so 
as to cause obstruction. The vast majority of cases of colorectal cancer are 
adenocarcinoma and are commonly subdivided into well, moderate or poorly 
differentiated depending on the degree of cellular atypia, mitotic rate and glandular 
architecture. Generally, well differentiated tumours have a better prognosis and 
poorly differentiated the worst prognosis but in practise most tumours are moderately 
differentiated. 
The commonest tumour type is adenocarcinoma. Most are moderately differentiated 
and tend to demonstrate cribiform patterns with central necrosis. Mucinous 
adenocarcinoma is a subtype that secretes extracellular mucin, and may be associated 
with microsatellite instability. Medullary carcinoma is an important subtype of 
colorectal cancer with a specific phenotype – right sided tumours with sheets of cells 
and numerous tumour-infiltrating lymphocytes on microscopy. Medullary carcinoma 
is associated with HNPCC. Less common tumours include signet ring cell 
carcinoma, with distinctive intracytoplasmic mucin; and small cell carcinoma, a 
poorly differentiated neuroendocrine carcinoma.(46)  
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The majority of colorectal cancers occur in the sigmoid colon or rectum. The 
descending and transverse colon are involved infrequently with the ascending colon 
and caecum affected more often (Figure 1.1.3-1). 
 
Figure 1.1.3-1: Distribution of colorectal cancers.(8) 
1.1.3.1 Histopathological staging 
The purpose of staging is to allow the clinician to advise the patient as to prognosis 
and as a guide to the most appropriate form of treatment, as well as allowing a 
meaningful comparison of the outcomes of treatment between similar groups of 
patients. The most common staging systems are Dukes and the TNM system. 
1.1.3.2 Dukes system 
In 1932, the British pathologist Cuthbert Dukes published his classification system 
for colorectal cancer.(47) It is based on the depth of invasion of the cancer through 
the bowel wall and lymph node involvement and was originally described for rectal 
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resections but is extrapolated to colonic resections. The system has subsequently 
been modified somewhat but still retains the basic ABC classification: 
 Stage A, tumour confined to the bowel wall (including muscularis mucosa) 
 Stage B, tumour penetrating the muscularis mucosa 
 Stage C1, regional lymph nodes involved by tumour but not affecting the node 
closest to point of ligature 
 Stage C2, lymph node at the point of ligature involved by tumour 
 Stage D, distant metastasis (not part of Duke’s original classification) 
1.1.3.3 TNM Staging 
The tumour, node, metastasis (TNM) staging system (Figure 1.1.3-2) of the 
American Joint Committee on Cancer (AJCC) and the International Union Against 
Cancer (UICC)
 
is now the standard for colorectal cancer staging. In the TNM system, 
pathologic staging information derived from surgical resection specimens is 
considered the most accurate determination of local extent of disease. In rectal 
cancer, in particular, the macroscopic features of the resection specimen and the 
microscopic status of the circumferential resection margin are powerful predictors of 
risk of both local recurrence and overall survival. 
The “T” designation refers to the local extent of the untreated primary tumour at the 
time of diagnosis. The “N” designation refers to the status of regional lymph nodes 
and “M” refers to distant metastasis. The prefix “p” may be used to imply the 
pathological determination of the TNM (e.g. pT1) as determined by gross and 
microscopic examination of the resection specimen of a previously untreated primary 
tumour. Clinical classification of TNM, giving the “c” prefix (e.g. cT1), is based on 
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evidence from a variety of techniques such as physical exam, radiological imaging, 
endoscopy, biopsy and surgical exploration.  
 
Figure 1.1.3-2: AJCC TNM staging of colorectal cancer.(46)  
 
Stage T N M
0 Tis N0 M0
I T1 N0 M0
T2 N0 M0
IIA T3 N0 M0
IIB T4 N0 M0
IIIA T1-2 N1 M0
IIIB T3-4 N1 M0
IIIC Any T N2 M0
IV Any T Any N M1
Primary tumour (T):
Tx – primary tumour cannot be assessed
T0 – no evidence of primary tumour
Tis – carcinoma in situ: intraepithelial or invasion of lamina 
propria
T1 – tumour invasion of submucosa
T2 – tumour invasion of muscularis propria
T3 – tumour invasion through muscularis propria into the 
subserosa, or into nonperitonealized pericolic or perirectal
tissues
T4 – direct tumour invasion of other organs or structures, 
and/or perforates the visceral peritoneum
Regional Lymph Nodes (N):
Nx – regional lymph nodes cannot be assessed
N0 – no regional lymph node metastases
N1 – metastases in 1-3 regional lymph nodes
N2 - metastases in 4 or more regional lymph nodes
Distant Metastases (M):
Mx – distant metastasis cannot be assessed
M0 – no distant metastasis
M1 – distant metastasis
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A recent modification of the Stage III category, previously a single group, has been 
made following evidence that the combined depth of involvement and number of 
involved mesenteric lymph nodes is an important prognostic index. Stage III disease 
has now been divided into 3 distinct subcategories as follows: Stage IIIA (T1/2, N1), 
Stage IIIB (T3/4, N1), and Stage IIIC (any T, N2). The 5-year observed survival rate 
for these three subcategories were 59.8%, 42.0% and 27.3%, respectively.(48) As the 
Stage III group relies on quantification of mesenteric lymph nodes, it is influenced 
by the quality of surgical resection and patient factors. The American Joint 
Committee on Cancer and the College of American Pathologists, and more recently 
the UK National Institute for Health and Clinical Excellence, recommends that a 
target of at least 12 lymph nodes need to be examined to determine Stage III 
identification.(49, 50) 
Invasion of the lamina propria (the part of the mucosa surrounding the colorectal 
crypts) is called in situ disease, designated pTis in the TNM classification. Invasion 
of the submucosa is required to diagnose invasive carcinoma (pT1). The reason for 
this is that the lamina propria lacks lymphatics, so disease confined to this layer has 
no means by which to spread.  
Lymphovascular invasion is a further important histological prognostic factor, which 
may occur independently from lymph node invasion. The potential for metastatic 
spread is increased and T4 tumours with lymphovascular invasion are a high risk 
group that might benefit from adjuvant chemotherapy.(46) 
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1.1.4 Modes of spread 
Colorectal cancer may spread by local extension, lymphatic spread, haematogenous 
spread, and by spread through the peritoneal cavity.  
Direct extension may occur into any structure intimately related to the position of the 
colonic tumour. Depending upon the location, this may involve adjacent small 
intestine, stomach, pelvic organs or abdominal wall, and retroperitoneal extension 
can invade the ureter, kidney or duodenum. 
The lymphatic drainage of the colon follows its blood supply so for caecal tumours, 
lymph node metastasis occur along the ileo-colic vessels, for tumours of the 
ascending colon along the right colic, for tumours of the transverse colon along the 
middle colic and for tumours of the sigmoid and rectum along the inferior colic 
vessels. Further spread from para-colic nodes eventually reaches the para-aortic 
nodes in advanced disease. Rectal tumours also drain to lymph nodes within the 
mesorectum. 
Haematogenous spread occurs via the portal system and consequently the liver is at 
most risk of distant metastasis. The next most common site for haematogenous 
spread is the lung. 
Transperitoneal spread is generally rare for colorectal cancer but if present is 
associated with an extremely poor prognosis. Mucinous cancers are the most likely to 
spread in this manner.(51) 
1.1.5  Presentation 
Colorectal cancer may present with either chronic symptoms or as an emergency. 
Left sided tumours typically present with a change in bowel habit and rectal 
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bleeding. Right sided tumours often present late as tumours can grow quite large 
without causing pain or change in bowel habit due to the liquid consistency of stool 
and distensible right colon. In these cases, right sided tumours may be detected 
incidentally as a result of investigations for iron deficiency anaemia. Up to 30% of 
patients present as an emergency due to obstruction or perforation.(52) Perforation 
can occur through the tumour itself or proximally at the caecum as a result of a 
closed loop obstruction when the ileocaecal valve is competent. 
1.1.6 Screening 
As most cancers arise from pre-existing adenomas, screening has the potential to 
reduce cancer related deaths. Following the success of a bowel cancer screening pilot 
study conducted between 2000 and 2007,(53) the NHS Bowel Cancer Screening 
Programme now offers screening using a guaiac smear faecal occult blood test 
(Haemoccult) every two years to all men and women aged 60 to 75. A positive test is 
followed by invitation to attend for colonoscopy. The guaiac test reacts to the 
peroxidase activity of heam, but this makes the test liable to reaction with other 
peroxidases in the faeces, such as those from certain fruits, vegetables and red meat. 
Dietary restrictions are therefore necessary to avoid false positive results. The 
sensitivity of a onetime test is only 50%–60%. Low sensitivity leads to a high 
number of false negative results and the impact of receiving a false reassurance. The 
majority of cases identified by faecal occult blood are false positive cases and these 
will be subjected to unnecessary further investigations, usually colonoscopy.(54) 
Nevertheless, the guaiac-based faecal occult blood tests have been shown to reduce 
colorectal cancer mortality by about 16%,(55) and the main challenge is increasing 
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screening uptake within the population and increasing the specificity and sensitivity 
of the screening test. There is increasing interest in faecal immunological testing 
(FIT) for blood which is reported to have a higher accuracy than the guaiac test. (56) 
The recent results of a large randomised controlled trial offering once only flexible 
sigmoidoscopy to people aged between 55 and 64 years showed that after 11.2 years, 
colorectal cancer incidence was reduced by 23% and mortality by 31% in intention-
to-screen analyses and by 33% and 43%, respectively, in per-protocol analyses. 
Introduction of such a screening programme nationally is now in the pilot phase and 
may prove to be economically viable given the reduction in incidence.(22) 
1.1.7 Diagnosis 
Diagnosis should be confirmed by colonoscopy and biopsy of suspicious lesions. A 
CT colonography may be offered as an alternative mode of investigation for patients 
with major comorbidity and is largely replacing the practise of flexible 
sigmoidoscopy and barium enema as it provides a similarly sensitive, less invasive 
alternative to colonoscopy.(57) The choice is often based on local guidelines and 
availability. With the exception of patients requiring emergency surgery, computed 
tomography (CT) of the thorax, abdomen and pelvis, and in the case of rectal cancers 
magnetic resonance (MR) scans, are used to stage tumours and plan treatment. 
Patients with early rectal cancers that may be amenable to local excision by MRI 
criteria are offered endorectal ultrasound scan.(58) 
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1.1.8 Treatment 
1.1.8.1 Surgery 
Surgery is the mainstay of treatment for colorectal cancer, and remains the only 
modality to offer potential cure. Radical resection of the affected segment of colon 
with its vascular pedicle and accompanying lymphatic drainage is performed. In the 
case of rectal cancer, resection technique appears to be of great importance. 
Following colonic resection, most recurrences occur due to disseminated disease, 
however in rectal cancer, isolated local recurrence tends to occur with wide variation 
of recurrence rate between individual surgeons.(59) Complete excision of the 
mesorectum with a clear circumferential resection margin (CRM) is associated with a 
low rate of local recurrence,(60, 61) illustrating the importance of surgical technique. 
Despite the removal of visible tumour, cancer may recur in up to half of rectal 
patients undergoing surgery, usually within 2 years.(62) 
The management of stage IV disease is generally palliative with surgical bypass of 
local obstruction and chemoradiation for local control. In the case of incurable stage 
IV rectal cancer, removal of the primary tumour may be performed to prevent local 
invasion of pelvic structures and provide good palliation. With the use of newer 
generation chemotherapeutic agents, patients with disseminated disease are living 
longer and may not require palliative surgery for their primary rectal tumour. In a 
study to examine what happened to the primary rectal tumour in patients with 
synchromous metastatic disease who were not operated on, the combination of 
oxaliplatin- or irinotecan-based combination therapy with or without bevacizumab 
resulted in a median survival of 18 months and 93% of patients never required any 
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intervention for their primary tumour.(63) This would support a policy of initial non-
operative management for asymptomatic rectal cancers with synchronous stage IV 
disease with the advantage of prompt initiation of systemic chemotherapy. In the 
case of patients with stage IV colonic tumours and unresectable distant metastases, 
recent evidence from a multicentre trial suggests a survival advantage for selected 
patients fit to undergo resection of the primary followed by chemotherapy in 
association with targeted therapy.(64) However, surgery can be curative in highly 
selected patients with resectable hepatic or pulmonary metastases.(65, 66) Fit 
patients with potentially operable metastatic disease of the liver have improved 
progression free survival after pre and postoperative treatment with FOLFOX4 
(Oxaliplatin injection combined with 5-FU and leucovorin) compared with surgery 
alone.(67)  
A summary of current commonly used chemotherapy regimens is displayed in the 
Appendix to this thesis. 
1.1.8.2 Neoadjuvant chemotherapy in colon cancer 
Neoadjuvant chemotherapy is not routinely given to patients with colon cancer at the 
present time. However, the rationale for neoadjuvant chemotherapy in colon cancer 
appears an attractive one. Adjuvant (post-operative) chemotherapy is not usually 
started until 2-4 months after the initial diagnosis of cancer and such a delay may 
reduce the likelihood of chemotherapy eradicating micrometastasis.(68) It is also 
reported that surgery enhances growth factor activity in the early post-operative 
period that may promote tumour cell seeding and growth.(69) Thus, pre-operative 
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chemotherapy can be started earlier and may potentially eradicate micrometastases 
reducing the risk of local and distant recurrence. 
The FOxTROT (“Fluoropyrimidine Oxaliplatin and Targeted Receptor Pre-Operative 
Therapy”) trial began recruiting patients in 2008 and is designed to evaluate whether 
giving part of a chemotherapy regimen pre-operatively will improve outcomes and 
also whether the addition of an EGFR targeted monoclonal antibody (Panitumumab) 
can increase tumour shrinkage in KRAS wild-type tumours. The study design also 
includes an assessment of potential biomarkers. 
1.1.8.3 Fluorouracil-based adjuvant therapy 
Despite potentially curative surgery, around 40% of colorectal cancer patients will 
eventually relapse. The benefits of a six month adjuvant regimen of bolus 5-
Fluorouracil (5-FU) and folinic acid (FA) for stage III disease are well established, 
with reduction in risk of recurrence and improvements in survival by 5-10 per 
cent.(70-72) 5-FU, an analogue of uracil, is an antimetabolite drug whose 
cytotoxicity results from the misincorporation of its active metabolites into RNA and 
DNA and its inhibition of thymidylate synthase, an important enzyme that catalyses 
the production of thymidylate, which is necessary for DNA replication and 
repair.(73) Despite being in use for nearly 50 years in metastatic disease, it was not 
until the 1990’s that the benefit of 5-FU in the adjuvant setting was firmly 
established.(74, 75)  With only limited response rates as a single agent, 5-FU has 
remained the main agent for treatment of advanced colorectal cancer due to 
modulation strategies that have increased its anticancer activity. 5-FU is usually 
administered with the biomodulator leucovorin (folinic acid), a reduced form of 
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folate, that enhances the stabilisation of the 5-FU and thymidylate complex, thus 
enhancing cytotoxicity.(76) Another approach has been the development of 
Capecitabine, a 5-FU prodrug that is taken orally and is activated within tumour 
tissue. This avoids the problem associated with intravenous delivery of 
dihydropyrimidine dehydrogenase (DPD) degradation of 5-FU in the liver resulting 
in poor bioavailability. Clinical trials with Capecitabine report that it is at least as 
effective and better tolerated than intravenous 5-FU/FA (Mayo Clinic regimen) in the 
adjuvant setting,(77) with benefits maintained at 5 years.(78) Capecitabine has not 
yet been compared with less toxic weekly 5-FU schedules however. 
Overwhelming evidence from large multicentre trials, MOSAIC (Multicenter 
International Study of Oxaliplatin/5FU-LV in the Adjuvant Treatment of Colon 
Cancer)(79) and National Surgical Adjuvant Breast and Bowel Project (NSABP) C-
07,(80) support the use of combination therapy based on oxaliplatin plus 5-FU/FA 
for stage III disease. Both trials showed similar 20% reduction of the risk of relapse 
and 15% reduction of the risk of death without increased toxicity. Oxaliplatin is a 
platinum derivative that forms bulky DNA adducts, and ultimately induces cell 
death. Importantly, it may also down-regulate thymidylate synthase, thereby 
potentiating the effect of 5-FU.(81) As a single agent, oxaliplatin has limited 
efficacy, but is most effective in combination with 5-FU/FA in the FOLFOX 
regimen.(82) Unfortunately, the addition of Oxaliplatin does come at the price of 
increased toxicity with significant neutropenia and sensory neuropathy being the 
biggest problems in the MOSAIC trial.  Based on these results, the combination of 
oxaliplatin and 5-FU/FA has become the standard adjuvant treatment for fit patients 
with high risk (e.g. heavily node positive) stage III colon cancer who accept the 
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toxicities. For remaining patients, 6 months of 5-FU/FA or Capecitabine is the 
preferred option by many oncologists.  
The benefit of adjuvant therapy in stage II disease is more difficult to ascertain and 
markers that could reliably predict response to 5-FU/FA would be particularly useful 
in this population. A final analysis of mature data from the MOSAIC trial showed no 
survival benefit in stage II patients,(79) and the UK QUASAR (Quick and Simple 
and Reliable) trial, despite showing a 22% reduction in recurrence, demonstrated 
only a modest survival benefit (3·6% improved overall survival) of adjuvant 5-
FU/FA,(83) and large pooled analyses have failed to show a significant benefit for 5-
FU based chemotherapy for stage II disease,(84) even in those patients with high risk 
clinicopathological factors.(85) Conventional clinicopathological high risk features 
for stage II disease include elevated carcinoembryonic antigen (CEA), obstruction or 
perforation, T4 stage, inadequate nodal resection (<12 nodes), lymphovascular 
invasion and high grade disease.(84-86) This suggests that the current practise of 
crude stratification of patients with stage II disease based upon clinicopathological 
parameters (86, 87) is only able to identify a subgroup of patients who will achieve a 
small (less than 4%) benefit from treatment. There is a need to identify new 
prognostic tools that will help identify a high risk subgroup of patients with stage II 
disease in order to justify the toxicity, inconvenience and cost of adjuvant 
chemotherapy.(84, 85) At present, patients with stage II disease are individually 
counselled by an oncologist with regard to their level of risk and the possible benefits 
of chemotherapy.  
In the 2013 national bowel cancer audit, 29,445 patients were diagnosed with 
colorectal cancer in England and Wales. Two out every five patients did not undergo 
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surgery for a number of different reasons including early stage of disease, patient 
frailty, or advanced disease.(88) Around a quarter of those operated will potentially 
be candidates for adjuvant chemotherapy. Globally, it is estimated that 230,000 cases 
are eligible for adjuvant chemotherapy.(77) However, the proportion of patients who 
are deemed suitable for adjuvant therapy but do not receive it is reported from 17-
42.5%.(89, 90) Common reasons for failure to receive adjuvant therapy include co-
morbid illness, advanced age and patient refusal. In clinical trials of adjuvant 
therapy, only 58-87%% of patients complete the full course of treatment.(83, 91-93) 
The potential toxicity of post operative adjuvant chemotherapy must not be 
underestimated, occuring in over 90% of patients,(92) and these are severe grade 3-4 
adverse events in up to 54% of cases.(93) The commonest side effects are 
gastrointestinal, cardiovascular, dermatological, haematological, and neurologic. 
Regimens combining 5-FU and folinic acid with oxaliplatin come with the risk of 
significant neutropenia and sensory neuropathy,(79) the latter of which can be very 
debilitating and prolonged for many years after completion of treatment.(94) Safety 
must be a significant consideration in choosing adjuvant chemotherapy, in particular 
for patients at low risk of recurrence. Further data is required to facilitate the 
selection of those subgroups of patients whom are likely to receive the most benefit 
from adjuvant therapy after potentially curative resection of cancer. 
1.1.8.4 Adjuvant therapy with biologic targeted agents 
Molecular targeted agents have improved the outcome of patients with metastatic 
colorectal cancer (95) and it was therefore expected that the addition of agents such 
as bevacizumab might also improve outcomes in stage II and III colon cancers when 
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used in addition to a standard FOLFOX regimen. Unexpectedly, results from 2 large 
multicentre trials (National Surgical Adjuvant Breast and Bowel Project (NSABP) C-
08 trial and Adjuvant FOLFOX4 Versus Bevacizumab and FOLFOX4 Versus 
Bevacizumab, Oxaliplatin, and Capecitabine in Patients With High-Risk Stage II or 
Stage III Colon Cancer (AVANT) trial)(96, 97) suggest that combining bevacizumab 
with conventional regimens (FOLFOX or XELOX) does not extend disease free 
survival. Overall, CO-8 found no difference in the proportion of patients who were 
still alive and free from disease between the control group and the bevacizumab 
group (75.5% vs 77.4%). Furthermore, the results from AVANT numerically 
favoured chemotherapy alone (the control arm). Similarly, the North Central Cancer 
Treatment Group (NCCTG) Intergroup Phase III Trial N0147 (Adjuvant 
mFOLFOX6 plus or minus cetuximab in patients with KRAS mutant resected stage 
III colon cancer)(98) showed that addition of Cetuximab led to worse disease free 
and overall survival with increase toxicity (contrary to its observed benefit in 
metastatic disease). These data reinforce the notion that primary tumours and 
metastatic lesions represent distinct diseases that require different treatments.(99) 
Hypothetically, localised colon cancers may not be as dependent upon signalling via 
EGFR or VEGF as in the metastatic setting and based upon these reports, Cetuximab 
or Bevacizumab are not recommended for use with adjuvant chemotherapy. 
1.1.8.5 Adjuvant therapy with Irinotecan 
Topoisomerase I is an enzyme that catalyses unwinding and rejoining of DNA by 
single-chain cleavage during DNA replication. The active metabolite of Irinotecan 
(7-ethyl-10-[4(1-piperidino)-1-piperidino] carbonyloxycamptothecin) SN38 is a 
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Topoisomerase I inhibitor with antitumour properties.(100) Irinotecan can result in 
significant improvement in progression free survival and response rate when 
combined with 5-FU/FA in patients with metastatic colorectal cancer.(101) Yet, as in 
the case of Bevacizumab and Cetuximab discussed above, this agent performs very 
differently in the adjuvant setting. Two phase 3 trials, FNCLCC 
Accord02/FFCD9802(102) and the Cancer and Leukaemia Group B study 89803 
(CALGB 89803),(103) failed to show a benefit of adding irinotecan to 5-FU/FA in 
stage III cancers and in both cases were associated with a significant increase in 
severe toxicity. As articulated by Saltz et al: “..this demonstrates that advances in the 
treatment of metastatic disease do not necessarily translate into advances in adjuvant 
treatment, and it reinforces the need for randomized controlled adjuvant 
studies.”(103) In another phase 3 trial comparing biweekly infusional fluorouracil 
(FU) and leucovorin (LV) alone or with irinotecan in the adjuvant treatment of stage 
III colon cancer, the Pan European Trials in Adjuvant Colon Cancer (PETACC)-
3,(93) the primary endpoint of improved disease free survival was not met, and 
neither was there any benefit to overall survival. Although subgroup analysis 
revealed a significant advantage for the irinotecan group in relapse-free survival and 
in disease free survival after adjustment for imbalance of TNM status between 
groups, the authors were careful not to over interpret these unplanned analyses and 
concluded that the study did not support the use of irinotecan-based regimens in the 
adjuvant setting. 
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1.1.8.6 Palliative chemotherapy 
In the palliative setting, before the 1960’s patients with metastatic colorectal cancer 
could not expect to live more than 4-6 months. The introduction of 5-FU and 
leucovorin improved survival by 3-6 months over best supportive care, as well as 
improving quality of life.(104) Modern regimens can achieve impressive results. In a 
randomized multicentre trial, the FOLFOX regimen of oxaliplatin and infused 
fluorouracil plus leucovorin was shown to deliver a median time to disease 
progression of 9 months with a median survival of 20 months. FOLFOX was 
superior to and safer than the alternate regimens that combined irinotecan and 
oxaliplatin or irinotecan and 5-FU/leucovorin.(105) 
The recent development of targeted monoclonal antibodies that may be used in 
combination with conventional regimens shows promise of further survival benefits. 
Bevacizumab (Avastin), an antibody to vascular endothelial growth factor (VEGF) 
confers an additional survival advantage of 4.7 months compared with irinotecan and 
5-FU alone and a 4.4 month increase in progression free survival.(95) There have 
however been reports of increase arterial embolic events associated with 
Bevacizumab.(106) At present bevacizumab is licensed in the UK in combination 
with intravenous 5-FU/FA with or without irinotecan for first-line treatment of 
patients with metastatic carcinoma of the colon or rectum. Cetuximab (Erbitux), an 
epidermal growth factor receptor inhibitor, used alone or in combination with 
irinotecan in irinotecan-refractory metastatic disease has clinically significant 
activity,(107) however attempts at combining bevacizumab and cetuximab have 
resulted in shorter progression-free survival and poorer quality of life.(108) At 
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present, the use of either bevacizumab or cetuximab is not supported by NICE 
outside of a clinical trial.(109) 
1.1.8.7 Radiotherapy 
1.1.8.7.1 Neoadjuvant treatment in rectal cancer 
Loco-regional recurrence after surgery for rectal cancer is difficult to treat, and is 
associated with very distressing symptoms. Preoperative radiotherapy is typically 
offered to patients with stage II or stage III rectal cancer, however, pelvic 
radiotherapy is not without its morbidity,(110) so targeting radiotherapy to those at 
high risk of recurrence is an attractive option. It is also important to acknowledge 
that any improvement in disease free or overall survival following pre-operative 
radiotherapy is marginal at best.(111) Accurate pre-operative staging with high-
resolution MRI for rectal cancers can help stratify patients with stage II and III 
disease into those who require neo-adjuvant radiotherapy and those in whom total 
mesorectal excision alone is adequate to prevent loco-regional recurrence. The 
Magnetic Resonance Imaging and Rectal Cancer European Equivalence 
(MERCURY) study group recommend offering neo-adjuvant radiotherapy 
selectively to patients with MRI-defined poor prognostic factors as follows; potential 
CRM positive (<1mm), intersphincteric plane involved by tumour (for low rectal 
cancers), T3 tumour spread more than 5mm, evidence of extramural venous invasion, 
and lymph node involvement.(112) 
Several large trials have shown that local recurrence rates in the region of 5-10% can 
be achieved with appropriate patient selection. Short course preoperative 
radiotherapy (SCPRT) followed by TME surgery reduces the risk of local recurrence 
Introduction 
____________________________________________________________________ 
30 
 
(Dutch TME and MRC CR07).(111, 113) SCPRT delivers a lower dose, 25 Gy, but 
within a short duration of 5 daily fractions over 1 week. Surgery is performed on the 
following week, before the onset of acute side-effects of radiotherapy. The short 
interval between commencing radiotherapy and surgery (usually less than 10 days) 
means that SCPRT does not achieve any significant tumour shrinkage prior to 
surgical resection and is only appropriate for tumours deemed clinically and 
radiologically resectable (i.e. CRM not involved). Preoperative long course 
chemoradiotherapy (CRT) followed by surgery can be used to shrink a tumour prior 
to resection in the case of a threatened or involved CRM (EORTC 22921; FFCD 
9203; GAO/ARO/AIO-94).(114-116) This consists of doses ranging from 45-50 Gy 
in 25 daily fractions over 5 weeks followed by surgery 4-8 weeks after completion of 
radiotherapy, allowing maximal tumour shrinkage. This is more effective with the 
addition of synchronous 5FU-based chemotherapy,(114, 115) which is given either 
on the first and fifth week of radiotherapy or as a continuous infusion throughout the 
duration of radiotherapy.  
Elderly patients with poor performance status or with other major medical co-
morbidities may not be suitable for pre-operative CRT. Some recent data from 
Uppsala in Sweden(117) and from Leeds(118) suggest that such patients may receive 
a similar benefit to CRT from short SCRPRT followed by an elective delay of 6-8 
weeks prior to surgery and this strategy may be a useful alternative in high risk 
patients with a threatened CRM. 
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1.1.8.7.2 Postoperative chemoradiotherapy 
Involvement of the CRM, defined as tumour present 1mm or less from the radial 
margin, is associated with a high risk of local recurrence and poor survival.(119) In 
cases with well established predictive factors of local recurrence (e.g. evidence of 
tumour at the circumferential resection margin, mesorectal lymph node involvement 
and extramural vascular invasion), post operative chemoradiotherapy is considered 
for patients who have not received pre-operative radiotherapy. A dose of 45Gy in 25 
fractions over 5 weeks with a planned boost dose of 5.4-9Gy in 3-5 fractions is 
recommended by The Association of Coloproctology of Great Britain and 
Ireland.(120) 
Post operative chemoradiotherapy has a much smaller effect on local recurrence than 
preoperative therapy and no effect on disease-free or overall survival. (Colorectal 
Cancer Collaborative Group, 121) 
1.1.9 Biomarkers in colorectal cancer 
The era of stratified medicine is upon us and it is important that we choose the right 
drug for the right patient and reduce treatment failure rates. Colorectal cancer is a 
complex disease characterised by multiple lesions in key molecular and genetic 
pathways. Some of these pathways are clinically useful, in particular we are now 
familiar with treatment pathways such as the EGFR signalling pathway and drugs 
which target these pathways, such as Cetuximab, are used successfully in advanced 
disease. However, knowledge of the molecular and genetic makeup of a tumour may 
also help decide how a particular patient may respond to a certain drug and so called 
‘predictive’ pathways are probably more useful than ‘prognostic’ pathways.  
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At present, the only biomarker sufficiently validated for routine clinical use for 
determining treatment is KRAS in the setting of metastatic colorectal cancer, with 
patients who are KRAS wild-type being offered EGFR targeted therapy. But, as will 
be discussed in section 1.1.9.2, our increasing knowledge of the EGFR-signalling 
pathways is adding increasing complexity to such decisions, especially in light of 
recent data regarding the value of other downstream mutations such as BRAF, NRAS 
and PIK3CA.(122) 
An ideal biomarker would be simple, sensitive, specific, inexpensive and 
reproducible for it to achieve use in routine clinical practise. The Cancer Research 
UK Biomarker Discovery and Development Committee have defined several 
categories of biomarkers: 
1. Risk assessment/predisposition biomarkers: e.g. APC gene mutations in the 
diagnosis of FAP. 
2. Screening/early detection biomarkers: e.g. FOB testing. 
3. Diagnostic biomarkers: e.g. CEA, PSA, CA125 to be used alongside standard 
imaging. 
4. Pharmacological biomarkers: to assess pharmokinetics or demonstrate clinical 
effects of the drug, e.g. thiopurine methyltransferase (TMPT) gene and 
azathioprine treatment in Crohn’s disease. 
5. Predictive biomarkers: e.g. KRAS and response to EGFR therapy in metastatic 
colorectal cancer. 
6. Prognostic biomarkers: to predict the course of disease and may guide treatment 
and follow up. No validated prognostic markers exist at present. 
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This thesis examines the potential of GRP78 as a predictive and prognostic 
biomarker. The Cancer Research UK Biomarker Discovery and Development 
Committee have suggested ‘roadmaps’ which define a chronological research 
pathway for identifying clinically useful predictive biomarkers. The roadmap is 
illustrated in Figure 1.1.9-1.(123) 
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Figure 1.1.9-1: The CR-UK prognostic/predictive biomarker (BM) roadmap. 
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1.1.9.1 Current status of biomarkers and decision making in the adjuvant setting 
The reported lack of benefit from molecular targeted therapy in the adjuvant 
setting,(124) as discussed in section 1.1.8.4, means that 5-FU-based regimes 
(FOLFOX) remain the backbone of adjuvant treatment.(87) Below is a summary 
regarding some of the most promising potential biomarkers to date. 
1.1.9.1.1 Thymidylate synthase 
Thymidylate synthase (TS) is a target of 5-FU. A number of preclinical biochemical 
and clinical immunohistochemical and RT-PCR studies have consistently shown that 
high TS expression predicts a poor response to 5-FU based chemotherapy.(73) 
However a recent meta-analysis cast doubt on the usefulness of TS as a biomarker 
for response as the association between high TS and survival was better for those 
treated by surgery alone than for those who received adjuvant treatment. 
Furthermore, controversy exists as to the relationship between expression of TS and 
its relationship to resistance to 5-FU therapy.(31) 
1.1.9.1.2 p53 mutation 
A potential mode of action of 5-FU may be due to its ability to stabilise p53 function 
leading to apoptosis.(125) Indeed, a number of studies have shown that disruption of 
both alleles of TP53 in vitro can make colon cell lines resistant to 5-FU.(126, 127) 
However, although there is in vitro evidence for p53 involvement in the down-stream 
response to 5-FU,(73) and p53 mutation has been associated with worse prognosis, 
reviews of p53 as a potential predictive marker suggest p53 mutation has no effect on 
outcome in patients treated with 5-FU based chemotherapy.(128) 
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1.1.9.1.3 18q-LOH/DCC 
Loss of heterozygosity on the long arm of chromosome 18 or deleted in colon cancer 
protein determination by PCR has been implicated as an important step in the 
development of many colorectal cancers.(24) Some evidence suggests it might be 
associated with worse prognosis and reduced response rates to chemotherapy.(129, 
130) However, it is difficult to draw conclusions from studies investigating 
chromosome 18q allelic instability as different methodologies and different genetic 
markers are employed to examine different regions on the chromosome. 
Additionally, the Pan European Trials in Adjuvant Colon Cancer (PETACC)-3 study 
identified a stage-specific effect of this biomarker, it showing a prognostic effect in 
stage III but not stage II disease, as well as revealing that 18q LOH status lost 
significance when MSI was included in the multivariate analysis suggesting that 
these markers do not act independently.(131) Therefore, there is insufficient 
evidence at present to support its routine use.  
1.1.9.1.4 DNA mismatch repair and microsatellite instability 
As discussed earlier, DNA MMR repairs DNA polymerase mistakes that commonly 
occur during DNA replication. Affected cells accumulate mutations that drive 
tumourigenesis and manifest the phenotype of microsatellite instability (MSI), a 
predisposition to right sided tumours and an unusual histopathological appearance. 
DNA MMR may also recognise drugs that intercalate with DNA and act as a trigger 
for apoptosis and thus, alkylation damage as a result of 5-FU incorporation into DNA 
would not be recognised by a deficient mismatch repair system. MSI may therefore 
act as a predictor of response to chemotherapy however studies investigating the role 
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of MSI in response to 5-FU have produced some conflicting data. Despite evidence 
to demonstrate better prognosis for patients with MSI, there is a body of evidence 
reporting lack of benefit and worse overall survival following 5-FU.(132, 133) 
Equally, there are reports that to suggest that benefit from 5-FU is maintained in 
patients with MSI, although some data suggest that benefit may be limited to those 
with germline rather than sporadic MSI tumour.(134) Subsequently, at present, the 
routine use of MSI status to predict response to 5-FU is not supported.(87) 
1.1.9.2 Current status of biomarkers and decision making in advanced colorectal 
cancer 
KRAS is an important intermediary in signalling via a number of growth factor 
receptors, especially epidermal growth factor (EGF) receptor signalling. Epidermal 
growth factor receptor (EGFR), is an attractive target for cancer treatment because its 
activation stimulates key processes involved in tumour growth and progression, 
including proliferation, angiogenesis, invasion, and metastasis.(135) EGFR-targeted 
monoclonal antibodies, such as Cetuximab and Panitumumab, have been extensively 
studied in metastatic colorectal cancer and shown to provide modest improvement in 
overall survival.(136, 137) Positive EGFR expression was initially a criterion for 
entry into studies evaluating EGFR antibodies, however it soon became apparent that 
positive EGFR expression was a poor marker for response to treatment as responses 
were observed in patients with low or negative expression of EGFR.(107, 138-140)  
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Figure 1.1.9-2: Representation of the EGFR signalling pathway. 
Activating KRAS mutations, present in approximately 40% of colorectal 
cancers,(141-143) result in activation of the EGF signalling pathway via the mitogen 
activated protein (MAP) kinase pathway at a point downstream of the EGFR (Figure 
1.1.9-2). A number of studies have shown that benefit from EGFR antibodies is 
confined to patients with wild-type KRAS tumours,(143-145) and based on these 
results, it is now a requirement for patients deemed suitable for EGFR antibodies to 
undergo KRAS testing and therapy is only approved for KRAS wild-type tumours at 
present. This is an excellent example of genetic tailoring of treatment in colorectal 
cancer.  
However, not all KRAS mutant tumours are the same. The reality is that response to 
EGFR targeted therapies based upon KRAS status is actually quite variable and 
KRAS mutant tumours represent a very heterogenous biological subgroup. Data is 
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emerging that some KRAS mutant tumours do respond and some KRAS wild-type 
tumours do not respond to EGFR targeted therapy.  
A study of a large cohort of patients treated with cetuximab in the pre-KRAS 
selection era (2001-2008) reveals a number of other mutations in the EGFR 
signalling pathway downstream of KRAS that are associated with low response rates. 
De Roock et al.,(122) report that KRAS mutation was present in 40% of tumours, 
14.5% had a PIK3CA mutation, 4.7% had a BRAF mutation and 2.6% had an NRAS 
mutation. In this cohort, outcome in KRAS wild-type patients was worse in the 
presence of BRAF, NRAS and PIK3CA exon 20 mutations. The PICCOLO trial 
(Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy)(146, 147) 
was a randomised clinical trial of treatment for fluorouracil-resistant advanced 
colorectal cancer comparing standard single-agent irinotecan versus irinotecan plus 
panitumumab and versus irinotecan plus ciclosporin. Following an amendment to 
protocol in 2008 to include prospective KRAS testing, the trial released results this 
year which showed a failure to meet the primary endpoint of improved overall 
survival in KRAS wild-type patients; however a planned biomarker analysis revealed 
some interesting findings. As expected, progression free survival was improved in 
patients with KRAS/BRAF wild-type tumours who received panitumumab, with no 
benefit seen in those patients with KRAS or BRAF mutated tumours. Interestingly, 
subset analysis revealed that nearly a third of the KRAS wild-type patients were 
found to have other mutations, thereby conferring drug resistance. Patients with a 
broadly wild-type profile for KRAS, NRAS, BRAF and PI3K had a good response 
from panitumumab, but those with a mutation in any of these kinases did not fare as 
well.  
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The variable response is further highlighted by additional work by De Roock et 
al.,(148) revealing better outcomes with cetuximab in patients with p.G13D-mutated 
tumours than with other KRAS-mutated tumours. In the present context of patients 
with KRAS codon 12-or KRAS codon 13-mutated tumours being excluded from 
treatment with cetuximab, this poses some serious questions regarding ongoing 
randomised controlled trials that are using KRAS status as a discriminator for 
treatment decisions and suggests that biomarker testing needs to be extended beyond 
wild-type or mutant KRAS to avoid treatment failure or resistance to EGFR therapy 
developing. 
 
Whilst many authors have investigated defects in particular molecular pathways, the 
role of the tumour microenvironment in the behaviour of colorectal cancer is 
relatively understudied. 
1.2 The tumour microenvironment 
1.2.1 Aerobic glycolysis 
In vivo experimental studies demonstrate important differences in tumour oxygen 
and glucose consumption. Both human and animal tumours display high levels of 
glucose uptake and lactate production, even in the presence of adequate oxygen. This 
phenomenon is termed the Warburg effect or aerobic glycolysis.(149) As a general 
rule, glycolysis is inhibited in the presence of oxygen in normal cells. Aerobic 
glycolysis is uniquely observed in cancers. This observation explains the results seen 
on positron emission tomography (PET) studies with 2-[18F]fluoro-2-deoxy-D-
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glucose that consistently demonstrate an elevated glucose uptake in different clinical 
tumours in vivo. In a series of important experiments, Gullino observed that in 
tumours transplanted into rats, glucose uptake was far higher than could be predicted 
by tumour growth or lactate and carbon dioxide (CO2) elimination. The oxygen 
consumption of the tumours studied was not deficient when compared with normal 
tissues with lower oxidative rates and the amount of glucose glycolysed was greater 
than that oxidised. However, tumours were not able to supplement respiration with 
glycolysis in the presence of O2 deficiency.(150) It is increasingly acknowledged 
that these fundamental principles of tumour metabolism can contribute to 
malignancy and drug resistance, but importantly, this dysregulated metabolism may 
also hold the key to therapeutic targeting of tumours.(151, 152) 
1.2.2 Response to hypoxia 
Early work by Gray identified the importance of tissue oxygenation for sensitivity to 
radiation damage. Histological assessment of lung adenocarcinoma suggested that 
due to unrestrained growth, tumour cells are forced away from their supplying 
vessels resulting in a large diffusion distance for oxygen in respiring tissue.(153) The 
importance of hypoxia in solid tumours is increasingly recognised in resistance to 
radiotherapy and chemotherapy.(154, 155) 
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Figure 1.2.2-1: Diagram of glycolysis pathway.(156) 
Enlarging tumours may result in an exponential reduction in tissue oxygenation. In 
experimental mouse tumours, bulky tumours greater than 400mm3 had median pO2 
of less than 10mmHg. At pO2 below 10mmHg, intracellular acidosis developed and 
coincided with a reduction in ATP levels, rise in inorganic phosphate and a drop in 
energy charge.(157) ATP is necessary for normal cell proliferation and survival and 
comes primarily from either glycolysis, the conversion of glucose to pyruvate in the 
cytoplasm resulting in a net 2 ATP for each glucose or, from the TCA cycle which 
uses pyruvate in a series of reactions donating electrons via NADH and FADH2 to 
respiratory chain complexes within mitochondria (Figure 1.2.2-1). This process, of 
which oxygen is the final electron acceptor, generates 36 ATP per glucose molecule. 
In low oxygen conditions, pyruvate does not enter the TCA cycle and is instead 
metabolised to lactic acid by lactate dehydrogenase, a process called anaerobic 
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glycolysis. Cancer cells consume glucose at a high rate and produce lactic acid rather 
than using the TCA cycle, even in the presence of oxygen. 
A normal cellular response to hypoxia is increased glucose utilisation as a result of 
elevated hypoxia-inducible factor 1α (HIF-1α). This in turn induces increased levels 
of glucose-transporter 1, a transmembrane protein overexpressed in many tumours 
but undetectable in normal tissues, leading to increased glucose uptake.(158) Under 
normoxic conditions, HIF-1α is continuously synthesised and degraded. Hypoxia 
stimulates anaerobic glycolysis by stabilization of HIF-1α and its transcription of 
glycolytic enzyme genes causing increased glucose uptake and lactate production. 
HIF-1α binds to the DNA sequence 5’-RCGTG-3’ and increases expression of genes 
encoding glucose transporters and glycolytic enzymes including aldoseA, enolase1, 
lactate dehydrogenase A, phosphofroctokinase L, phosphoglycerate kinase 1 and 
pyruvate kinase M, as well as angiogenic growth factors (eg VEGF), hexokinase II, 
and haemopoitic factor.(156) Even in the absence of  hypoxia, a variety of oncogenic 
induced proteins can lead to stabilization of HIF-1 or inhibition of its 
degradation.(159) Any proliferative advantage conveyed to tumours by aerobic 
glycolysis is not immediately apparent. In terms of ATP production, anaerobic 
metabolism of glucose is very inefficient, producing only 2 ATP compared with 38 
ATP per glucose with complete oxidation. In fact, this evolutionary adaptation is one 
of the earliest steps in carcinogenesis and allows tumour cells to survive beyond 
normal tissue constraints. In the 1960’s, Thomlinson and Gray observed that viable 
tumour cells were not observed greater than 160µm from blood vessels. As tumour 
cells proliferate and expand, the population inevitably moves further away from its 
blood supply, leading to reduced substrate availability.(156) Tumour angiogenesis is 
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required to permit further growth in addition to the molecular mechanisms already 
described. Angiogenic factors, such as VEGF promote increased vascularity of 
tumours. As new microvessels tend to be highly irregular and tortuous, blood flow 
and oxygen delivery tends to remain poor and hypoxia is likely to remain a strong 
selective force.(160) The ability to tolerate transient hypoxia due to the glycolytic 
adaptation contributes to metastatic potential. The increased presence of [H+] in the 
tumour microenvironment is toxic to adjacent normal cells that lack the mechanisms 
to adapt to extracellular acidosis. This allows tumours to continue to proliferate and 
may enhance invasive potential and ability to metastasize by causing degradation of 
the extracellular matrix and promoting angiogenesis.(161) 
Anaerobic glycolysis, activated by HIF1 is not sufficient for hypoxic adaptation 
alone as hypoxic stress results in the production of reactive oxygen species (ROS) by 
mitochondria that would be toxic were it not for further adaptation. Pyruvate 
dehydrogenase kinase 1 (PDK1) is a direct HIF1 target gene that inhibits conversion 
of pyruvate to acetyl-CoA, attenuating mitochondrial respiration and reducing 
production of ROS. In hypoxic conditions, HIF1α null mouse embryo fibroblasts fail 
to activate PDK-1 and undergo apoptosis with a significant rise in ROS. Forced 
expression of PDK1 by independent retroviral infection increased ATP, prevented 
hypoxia-induced ROS generation and apoptosis.(162) 
The serine/threonine kinase Akt is also associated with increased glucose uptake and 
aerobic glycolysis independent to HIF1. Akt promotes increased glucose utilization 
without increasing oxygen consumption. Akt mobilises glucose transporters and 
activates hexokinase 2 (HK2) to phosphorylate and trap intracellular glucose. 
Activation of the Atk oncogene is sufficient to cause the switch to aerobic glycolysis 
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characteristic of cancer cells, but does not increase proliferation of cancer cells in 
vivo.(163) 
In addition to the Atk oncogene, Myc can upregulate the activation of a number of 
glycolytic enzymes including Glut1,(164) PDK1,(165) LDH-A.(166, 167) Although 
the Myc transcription factor would appear to enhance the Warburg effect via 
increasing glycolysis, it has also been shown to encourage respiration in 
mitochondria leading to increased ROS which would be toxic to tumour cells.(168) 
A further adaptation of tumour cells can compensate for this however. One of the 
most frequently mutated genes, p53, can promote glycolysis by interfering with 
mitochondrial respiration. Inactivation of p53 in tumour cells can reduce 
mitochondrial respiration and this effect is mediated by synthesis of Cytochrome C 
Oxidase 2 (SCO2). SCO2 is necessary for construction of the mitochondrial 
cytochrome c oxidase (COX) complex, the major site of oxygen consumption in 
eukaryote cells.(169) Mutant p53 has also been demonstrated to promote glucose 
influx to cancer cells via increased transcription of type II hexokinase, an enzyme 
that converts glucose to glucose-6-phosphate, the initial step in glycolysis.(170) 
The ability of cancer cells to adapt to the tumour microenvironment by upregulating 
glycolysis confers an evolutionary survival advantage but overcoming problems with 
energy production alone is not the only adaptation required by malignant cells. 
1.2.3 Cellular stress response 
1.2.3.1 Heat shock proteins 
Cells exposed to environmental stress are able to demonstrate a coordinated response 
via inducible gene expression, thus protecting the cell from conditions that would 
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otherwise lead to irreversible cell damage or death. In the 1960’s, an abnormal 
chromosomal puffing pattern was observed in the salivary glands of heat stressed 
Drosophila larvae.(171) The encoded genes on these chromosomes were later 
identified as heat shock proteins (hsp’s).(172) Members of the heat shock protein 
family are broadly categorised depending on their molecular weight with the main 
families being hsp70(70kDa), hsp90(90kDa), hsp100(100kDa), small hsp’s and 
chaperones (groEL/hsp60). They first came to attention due to their induction by 
cellular thermal stress.(173) Many hsp’s also respond under a variety of other stress 
conditions, including oxygen free radicals, amino acid analogues, ethanol, heavy 
metals and ischaemia.(174) The function of hsp’s is to recognise and stabilise 
partially folded intermediates during polypeptide folding.(175) In eukaryotic cells 
exposed to heat shock, heat shock factor (HSF), usually a monomeric non DNA-
binding transcription factor, assembles into a trimer and accumulates within the 
nucleus. Here it binds to, and activates, transcription of heat shock gene promoters 
and becomes phosphorylated resulting in increased levels of hsp70 and formation of 
a HSF-hsp70 complex. Prolonged exposure to thermal stress or return to 
physiological temperatures results in dissociation of HSF from DNA and return to its 
monomeric form.(176) Hsp’s like hsp70 and hsp27 protect against programmed cell 
death or apoptosis and are found to be overexpressed in a variety of tumours,(174, 
177-182) and confer resistance to the adverse tumour microenvironment.(183, 184) 
Hsp70 can inhibit apoptosis at a number of points on the apoptotic intrinsic pathway 
including events upstream and downstream of the mitochondria. Upstream, hsp70 
can inhibit cytosolic calcium increase,(185) and prevent translocation of Bax to the 
mitochondria, thus preventing formation of pores in the mitochondrial membrane and 
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release of cytochrome c.(186) Hsp70 also inhibits cJun N-terminal kinase (JNK) 
activation,(187) required for Bid-dependent release of cytochrome c from the 
mitochondria; and stabilises lysosomes, preventing release of lysosomal enzymes 
into the cytosol that can activate multiple cell death pathways.(188, 189) 
Downstream of mitochondrial events, hsp70 can modulate function of the 
apoptosome by interacting with APAF-1.(190) Hsp70 may also inhibit the extrinsic 
pathway of apoptosis by binding to death receptors.(191) 
1.2.3.2 Glucose-regulated proteins 
Another family of stress inducible proteins are the endoplasmic reticulum (ER) 
resident glucose-regulated proteins (GRP’s). The GRP’s were first reported in the 
1970’s when it was observed that two proteins of molecular weight 78kDa and 
95kDa were produced in increased amounts in chick embryo fibroblasts transformed 
by Rous sarcoma virus. The increased levels of these proteins was noted to be 
secondary to depletion of glucose and their synthesis was arrested by restoring 
glucose to high levels.(192) As the induction of GRP’s was primarily observed in 
conditions that interfere with glycosylation,(193) it was initially thought that GRP’s 
were induced as a result of underglycosylated proteins in the ER.(194) The 
observation that GRP’s were also induced by amino acid analogues,(195-197) did 
not support this theory. Subsequent experiments revealed that induction of GRP’s 
was triggered by the presence of malfolded proteins within the ER and that the 
induction of GRP78 was not abolished by glucose supplementation. It was further 
noted that inhibitors of glycosylation within the Golgi apparatus did not induce 
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synthesis of GRP’s, whereas inhibitors of glycosylation in the ER caused significant 
induction of GRP’s.(198) 
Apart from glucose deprivation, interference with glycosylation and aminoacid 
analogues, other stimuli of GRP induction that affect ER function include calcium 
ionophores,(193, 199, 200) Thapsigargin (an ER calcium ATPase inhibitor),(200) 
tunicamycin,(198) sulfhydryl-reducing agents,(159) low extracellular pH and 
hypoxia.(201) 
1.3 GRP78 and the Unfolded Protein Response 
1.3.1 GRP78 
The best characterised GRP is GRP78, also known as BiP, the immunoglobulin 
heavy chain-binding protein. GRP78 resides primarily in the ER, an essential 
perinuclear organelle for the synthesis and folding of secretory and membrane 
proteins, which accounts for about one third of the cell’s proteins. In addition to 
facilitating proper protein folding, preventing intermediates from aggregating, and 
targeting misfolded protein for proteosome degradation, GRP78 also binds Ca2+ and 
serves as an ER stress signalling regulator.(202) BiP was identified in 1983 when it 
was observed that immunoglobulin heavy chain synthesised by pre-B cell 
lymphocytes bound to a protein that inhibited their secretion in the absence of light 
chains, thus preventing secretion of incompletely folded immunoglobulins.(203) 
GRP78 and BiP were later found to be identical ER-resident proteins that were 
abundant in antibody-secreting cells.(204) GRP78 is very similar to hsp70, sharing 
about 60% of its amino acid sequence including the ATP-binding site required for 
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their role as a chaperone in protein folding. GRP78 differs from hsp70 in two 
important aspects. First, GRP78 is primarily an ER resident protein whereas hsp70 is 
cytosolic and, second, thermal stress does not significantly induce GRP78.(205)  
1.3.1.1 Atypical GRP78 
1.3.1.1.1 Cell surface GRP78 
Although GRP78 is generally regarded as an ER resident chaperone protein, there is 
mounting evidence that GRP78 is also located on the cell surface of cancer cells but 
not normal cells, and that it can act as a receptor that regulates cellular activity.(206) 
In 1998, cell surface localized GRP78, induced by thapsigargin treatment in human 
rabdomyosarcoma cells, was confirmed by biotinylation and chromatography.(207) 
In an additional study, GRP78 was found to be expressed on the cell surface with 
MHC class1 in unstressed cells. GRP78 is known to associate with MHC class 1 
heavy chain intracellularly during folding and assembly, but on the cell surface 
GRP78 does not appear reliant on MHC class 1 and, in fact, in the absence of MHC 
class 1, GRP78 is overexpressed.(208) 
In prostate cancer cells, GRP78 acts as a high-affinity receptor for the protease 
inhibitor alpha-2-macroglobulin (α2M*) and binding of α2M* to cell surface GRP78 
can promote cellular proliferation.(209-212) In a variety of cancer cell lines, global 
profiling of the cell surface proteome revealed that GRP78, among other chaperone 
proteins, was present in all cell types tested in relatively high abundance.(213) 
Circulating antibodies to cell surface GRP78 in the serum of prostate cancer patients 
correlates with more aggressive cancer phenotype and reduced survival. As proof of 
principle that cell surface GRP78 may have potential therapeutic value, a synthetic 
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chimeric peptide with GRP78 binding motifs fused to proapoptotic sequences could 
specifically target tumour cells in vivo with minimal effect on normal tissues and in 
human cancer cells ex vivo, confirming that cell surface GRP78 is a functional 
molecule leading to internalization of GRP78 binding ligands.(214, 215) 
The question of how an ER resident protein such as GRP78 can localize to the cell 
surface is an interesting one. It has been shown that the murine tumour cell DnaJ-like 
protein-1 (MTJ-1), as well as being a transmembrane protein, also acts as a co-
chaperone to GRP78 within the ER.(216) MTJ-1 co-immunoprecipitates with GRP78 
in the plasma membranes of macrophages and silencing the MTJ-1 gene expression 
by RNA interference abolishes cell surface localization of GRP78; thus suggesting 
that MTJ-1 is essential for transport to the cell surface.(217) Another theory is that 
GRP78 is expressed to such high levels in tumours that it may oversaturate the ER 
protein retrieval mechanism, resulting in cotrafficking to the cell surface with its 
client proteins.(218, 219) In principle, drugs targeting cell surface GRP78 may have 
antitumour properties with minimal adverse effects on normal organs and tissues. 
1.3.1.1.2 Cytoplasmic GRP78 
GRP78va is a novel cytosolic isoform devoid of an ER signal sequence. It is 
generated through ER stress-induced alternative pre-mRNA splicing, a process 
through which a single gene may generate several distinct protein isoforms that may 
have diverse or even antagonistic functions.(220, 221) It is known to be elevated in 
leukaemic cell lines and in leukaemia patient samples and specifically enhances 
PERK signalling to promote cell survival under conditions of ER stress. It is not 
known which client proteins it interacts with in the cytosol. 
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1.3.1.1.3 Mitochondrial GRP78 
Cellular fractionation and protease digestion of isolated mitochondria suggested that 
a significant amount of GRP78 was localised to the mitochondria in ER stressed 
cells. This was confirmed by immunoelectron microscopy, demonstrating that during 
UPR activation, GRP78 localised to the mitochondrial membrane compartment.(222) 
Although its functions at this site are not yet understood, it is possible that it may 
modulate the mitochondrial component of the intrinsic apoptosis pathway.  
1.3.2 ‘ER’ Stress 
The induction of GRP78 is an important response to disturbance of ER 
homeostasis.(223) The ER is a unique oxidising compartment for the folding of 
membrane and secretory proteins, and has a role as a major signal-transducing 
organelle. It also provides a highly selective quality control system to ensure correct 
protein folding and assembly, and recognise unfolded proteins so that they can be 
repaired or targeted for proteosome degradation. A number of biochemical, physical 
and pathological stimuli, for example, ER calcium depletion, glucose deprivation, 
oxidative stress and DNA damage can disrupt ER homeostasis and lead to 
accumulation of unfolded or misfolded proteins in the ER – so called ‘ER stress’. 
Eukaryotic cells have evolved a coordinated cellular response to such stress termed 
the unfolded protein response (UPR).(198, 219, 224, 225) 
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1.3.3 The Unfolded Protein Response 
 
Figure 1.3.3-1: Endoplasmic reticulum (ER) stress-mediated unfolded protein response 
(UPR) signal pathways.  
In unstressed cells, GRP78 interacts with the luminal domain of IRE-1, PERK and ATF6, and negatively 
regulates them.  Increased binding of GRP78 to unfolded proteins releases binding of IRE-1, PERK and ATF6 
leading to activation of the UPR. Dissociated ATF6 is released from the ER and moves to the Golgi apparatus 
where it is cleaved by the proteases S1P and S2P, yielding an active fragment ATF6f that translocates to the 
nucleus, and binds to and activates the ER stress response element (ERSE) found on the promoters of various 
UPR target genes including GRP78, CHOP and XBP1. PERK regulated phosphorylation of elF2α attenuates 
mRNA translation apart from one mRNA encoding ATF4 which requires elF2α phosphorylation. ATF4 activates 
genes encoding proteins involved in aminoacid biosynthesis, antioxidative stress response, and ER stress-induced 
apoptosis. IRE1 homodimerizes and becomes autophosphorylated leading to activation of its endoribonuclease 
function. The endoribonuclease activity is responsible for promoting increased splicing of X-box binding protein 
1 (XBP1). This longer XBP1 protein is a potent transcriptional activator of UPR target genes involved in protein 
ER stress
Misfolded proteins
PERK
GRP78
ATF6
GRP78
IRE-1
GRP78
elf2α elf2α -P
ATF6
ATF4
Transcriptional activation
Redox
CHOP
Cell survival
ER lumen
Cytosol
Nucleus
XBP1 
mRNA
sXBP1 
mRNA
sXBP1
Translation 
attenuation
Chaperones
p58IPK
ER-Chaperones
CHOP
XBP1
Introduction 
____________________________________________________________________ 
53 
 
folding and degradation of misfolded proteins. There is a delay of the IRE-1 pathway relative to that of PERK 
and ATF6 as the substrate XBP1 mRNA is expressed at low levels in non stressed cells, but is upregulated by 
ATF6 in the presence of ER stress. These actions aim to restore ER function by blocking further accumulation of 
protein, enhancing folding capacity and initiating degradation of protein aggregates. Modified from (226) 
1.3.3.1 Cell survival/adaptation 
Tumorigenesis and proliferation of cancer cells requires increased protein synthesis, 
a physiological ER stress, which together with nutrient deprivation and hypoxia of 
the growing tumour causes further accumulation of unfolded proteins in the ER. The 
importance of the UPR in carcinogenesis, metastasis and drug resistance has become 
well recognised and intensely studied. 
A key initiator of the UPR is GRP78. The ability of GRP78 to dissociate from 
several important ER-resident transmembrane proteins under conditions of ER stress 
leads to a cascade of signal transduction pathways that modulate cell survival or, if 
the stress is significantly severe, apoptosis.(227-229) These pathways prevent 
accumulation of unfolded proteins in the ER by reducing the protein-folding load, 
increasing the ER protein-folding capacity, and increasing degradation of misfolded 
proteins through ER-associated protein degradation (ERAD) or autophagy.(230-232) 
This network of responses to ER stress is regulated by only three ER transmembrane 
proteins: inositol-requiring 1 alpha (IRE-1), double strand RNA-activated protein 
kinase-like ER kinase (PERK), and activating transcription factor 6 (ATF6).(231) 
Remarkably these 3 protein sensors are activated by a single common stimulus, the 
accumulation of misfolded proteins in the ER. Each sensor has an ER luminal 
domain sensitive to accumulation of misfolded proteins, an ER transmembrane 
domain that can target protein for localization to the ER membrane, and a cytosolic 
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functional domain.(233) In unstressed cells, GRP78 interacts with the luminal 
domain of IRE-1, PERK and ATF6, and negatively regulates them. The luminal 
domains of IRE-1 and PERK receptors that bind GRP78 are interchangeable,(234-
237) and importantly, the peptide-binding site of GRP78 that associates with the 
receptors is the same that binds to hydrophobic patches of misfolded or unfolded ER 
peptides.(229) Activation of the UPR occurs by dissociation of GRP78 from IRE-1, 
PERK and ATF6, possibly as a result of GRP78 preferentially associating with 
misfolded nascent protein rather than these 3 receptors. Increased binding of GRP78 
to unfolded proteins releases binding of IRE-1, PERK and ATF6 leading to 
activation of the UPR. IRE-1 and PERK, once released from GRP78, homodimerise 
through their luminal domains, autophosphorylate their cytosolic domains and 
become active.(234) Dissociated ATF6 is released from the ER and moves to the 
Golgi apparatus where it is cleaved by the proteases S1P and S2P, yielding an active 
fragment ATF6f that translocates to the nucleus, and binds to and activates the ER 
stress response element (ERSE) found on the promoters of various UPR target genes 
including GRP78, CHOP and XBP1.(238-241) 
Following ER stress, the first pathway to be activated, within minutes,(242) is the 
PERK regulated phosphorylation of the α subunit of eukaryotic translation initiation 
factor (elF2α) on serine 51. This interferes with global mRNA binding of ribosomal 
60s and 40s subunits, via interference with the formation of a 43s initiation complex, 
causing translational attenuation and reduction of protein synthesis, and thus reduced 
ER workload.(243-246) Although in general, phosphorylation of elF2α attenuates 
mRNA translation, one mRNA encoding ATF4 requires elF2α phosphorylation.(247) 
ATF4 activates genes encoding proteins involved in aminoacid biosynthesis, 
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antioxidative stress response, and ER stress-induced apoptosis.(248) In view of the 
action of the PERK/elF2α pathway, strict control of the phosphorylation of elF2α is 
necessary for the cell to survive. In fact, the activation of PERK by ER stress is 
rapidly reversible with activated PERK being rapidly dephosphorylated upon 
restoration of ER homeostasis. Phosphorylation of elF2α is also controlled by a 
negative feedback mechanism. Two inhibitory genes are growth arrest and DNA-
damage-inducible protein 34 (GADD34) and contituitive repressor of elF2α 
phosphorylation (CReP). Both GADD34 and CReP activate two phosphatase 
complexes that dephosphorylate elF2α. CRep is contituitively expressed at baseline 
and GADD34 is induced by elF2α phosphorylation and serves in a negative feedback 
loop.(234, 249, 250) 
After PERK activation and reduction of protein synthesis, ATF6 cleavage occurs 
next most rapidly. The relative delay is caused by the need for nuclear translocation 
of ATF6f and the induction of transcription and protein synthesis. Activation of 
ATF6 is thought to occur prior to XBP1 activation,(251) through ATF6 translocation 
to the Golgi apparatus from the ER lumen where Golgi-resident proteases cleave the 
protein to release a free-cytosolic DNA-binding portion. This form of ATF6 
translocates to the nucleus and acts as a transcription factor for genes that augment 
protein folding capacity, including GRP78.(238, 239, 241) 
IRE-1 is a type 1 transmembrane Ser/Thr protein kinase that can also function as an 
endoribonuclease (RNase).(252, 253) In mammals, two homologous genes encode 
for IRE-1; IRE-1α is expressed in all cells, and IRE-1β which is found primarily in 
intestinal epithelial cells.(253) In response to ER-stress and subsequent release from 
GRP78, IRE1 homodimerizes and becomes autophosphorylated leading amongst 
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other events to activation of its endoribonuclease function. The endoribonuclease 
activity is responsible for promoting increased splicing of a non-conventional 26-
base intron from the XBP1u mRNA that encodes a truncated  271 amino-acid 
isoform of the X-box binding protein 1 (XBP1).(254) Splicing by IRE1 results in 
expression of a longer XBP1 protein isoform of 376 amino acids as a result of a 
frameshift in  the fully-spliced mRNA (XBP1s) and this longer XBP1 protein is a 
potent transcriptional activator of UPR target genes involved in protein folding and 
degradation of misfolded proteins.(255) There is a delay of the IRE-1 pathway 
relative to that of PERK and ATF6 as the substrate XBP1 mRNA is expressed at low 
levels in non stressed cells, but is upregulated by ATF6 in the presence of ER 
stress.(254) Therefore, XBP1 mRNA is not produced in large amounts until after the 
initial induction of PERK and ATF6 UPR pathways. Spliced XBP1 mRNA encodes 
a potent basic leucine zipper (bZIP)-containing trans-activator that induces 
expression of a group of ER chaperones and enzymes that assist with protein folding, 
secretion, and degradation, including genes encoding XBP1, GRP78 and the hsp40 
like p58
IPK
 which can interact with PERK and down regulate its phosphorylation. It 
has been proposed that as p58
IPK
 is produced relatively late in the UPR pathway, it 
may serve as a limiter to turn off the UPR when the ER stress has been 
overcome.(229, 255) 
1.3.3.2 ERAD 
Another key component of the UPR is the targeting of unfolded proteins for 
degradation via the ER-associated degradation (ERAD) pathway.(256, 257) 
Unfolded proteins are selected by molecular chaperones and targeted for 
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retrotranslocation to the cytoplasm. The central component of the translocon, 
Sec61p, forms a transmembrane channel that, in the presence of GRP78, allows 
retrograde transport of proteins targeted for ERAD from the ER to the cytosol. After 
transport, substrate molecules are ubiquinated prior to proteolysis by the 26s 
proteosome.(258) Virtually all ERAD substrates are modified with ubiquitin, via ER 
ubiquitin ligases located in or near the ER membrane.(259) 
Although ERAD is a normal part of ER quality control, genes involved in ERAD are 
upregulated as part of the UPR by the IRE1/XBP1 pathway. The IRE1 pathway 
mediates induction of EDEM (ER degradation-enhancing α mannosidase-like 
protein).(251) EDEM is involved in identification and targeting of unfolded protein 
for degradation.(260) 
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1.3.3.3 Apoptosis 
In addition to supporting adaptation to, and recovery from ER stress, the UPR will 
also initiate apoptotic pathways if the cell is unable to adapt or the stress is 
prolonged. Apoptosis is an essential mechanism if disease resolution is to occur. 
The initiation of apoptosis is classically divided into intrinsic and extrinsic pathways. 
The intrinsic pathway responds to intracellular insults, such as DNA damage, and 
results in a balance shift between proapoptotic BH3-only proteins, e.g., Bad, Bak or 
Bax, and antiapoptotic proteins, e.g., Bcl-2 proteins. Bak and Bax act on the 
mitochondrial membrane to form pores, resulting in release of cytochrome-c into the 
cytosol. Cytochrome-c mediates the formation of a complex between Apaf-1 and 
procaspase-9, leading to activation of caspase-9 and subsequently the executioner 
caspase-3.(229) The extrinsic pathway responds to extracellular stimulus, e.g., 
ligation of tumour necrosis factor-α, leading to self-association of cell surface 
receptors, recruitment of caspases, and activation of a caspase-cascade resulting in 
apoptosis. The division between intrinsic and extrinsic pathways in ER-stress is not 
clear cut however, with much overlap. In fact, ER-stress is better described as an 
intrinsic apoptotic signal rather than extrinsic.(229) 
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Figure 1.3.3-2: Simplified representation of mammalian ER stress-induced apoptotic 
pathways.  
ER stress activates mitochondria-dependent and mitochondria-independent apoptotic pathways. ATF4 promotes 
transcription of CHOP, a negative regulator of the anti-apoptotic Bcl-2. In addition, activation of IRE-1 recruits 
TRAF2 and activates ASK1 forming a trimeric complex, which activates pro-apoptotic JNK-mediated signalling 
pathways. JNK promotes cell death by phosphorylation of Bcl-2 and activation of pro-apoptotic Bim. TRAF2 
may also promote caspase activation independent of mitochondrial cytochrome-c release. ER stress-induced 
conformational change in Bcl-2 family proteins including Bax and Bak leads to calcium depletion from the ER. 
This calcium flux activates mitochondrial cytochrome-c release and caspase activation. 
1.3.3.3.1 PERK/elF2α mediated apoptosis 
Under conditions of prolonged ER stress, PERK phosphorylates elF2α leading to 
attenuation of mRNA translation in general, but a few specific mRNAs require elF2α 
phosphorylation for efficient translation. The best described of these is ATF4, a 
cAMP response element-binding transcription factor (C/EBP). ATF4 induces 
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transcription of C/EBP homologous protein (CHOP), also known as GADD153, a 
known pro-apoptotic factor (261) (note that ATF6 can also induce the CHOP 
gene).(262) CHOP reduces transcription of anti-apoptotic Bcl-2,(263) promotes 
depletion of cellular glutathione, and increases production of reactive-oxygen species 
causing release of cytochrome-c from mitochondria causing apoptosis. CHOP also 
activates GADD34 which dephosphorylates elF2α, thus removing the brake from 
protein synthesis leading to further overloading of the already stressed ER. CHOP 
further promotes oxidising conditions by activating EROIα, an ER oxidase that 
causes hyperoxidization of the ER.(264)  
1.3.3.3.2 IRE-1α mediated apoptosis 
In addition to its endoribonuclease activity, IRE-1α can serve as a scaffold protein 
that recruits tumour necrosis factor (TNF)-receptor associated factor 2 
(TRAF2).(265) This interaction recruits c-Jun NH2-terminal inhibiting kinase (JIK) 
which, through interaction with IRE-1α and TRAF2, activates JUN N-terminal 
kinase (JNK)-mediated signalling pathways.(265, 266) IRE-1-TRAF2 reaction also 
activates apoptosis signal-regulating kinase-1 (ASK1). Formation of a trimeric 
complex between IRE-1α, TRAF2 and ASK1 activates ASK1 and JNK.(267) JNK 
can promote cell death by phosphorylation of Bcl-2 and BIM causing apoptosis.(268) 
TRAF2 promotes clustering of murine procaspase-12 and during ER stress, cleavage 
occurs releasing procaspase-12 for activation, presumably as a result of TRAF2 
recruitment by IRE-1α.(266) In humans, the caspase-12 gene is frequently inactive 
and it is proposed that caspase-4 mediates ER stress induced apoptosis in 
humans.(269) This pathway is independent of mitochondrial cytochrome-c release. 
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The disruption of intracellular calcium homeostasis is an additional trigger of 
apoptosis during ER stress. The Bcl-2 family proteins, including Bax and Bak, are 
associated with mitochondrial and ER membranes and undergo conformational 
change and oligomerization during ER stress. This leads to calcium depletion from 
the ER, inducing caspase-12 cleavage.(270) Cytosolic calcium activates m-calpain, a 
calcium dependent cysteine protease, which cleaves and activates procaspase-12. In 
addition, mitochondrial Bak enhances caspase-7 and PARP cleavage, leading to 
release of cytochrome-c. Caspase-7 can translocate from the cytosol to the ER 
surface and activate caspase-12, in addition to the activation by calpains.(271) 
Despite an increased understanding of the apoptotic pathways involved in ER stress, 
the control between adaptation and recovery, and apoptosis remains unclear. 
1.3.4 GRP78 and malignancy 
The UPR is essential for the survival of cancer cells through adaptation to hostile 
conditions, and is associated with upregulation of GRP78. Evidence that GRP78 is 
required for tumour growth came from the observation that GRP78 knockdown 
fibrosarcoma cells were unable to form tumours or they quickly regressed in 
vivo.(272) Increasing evidence suggests that GRP78 can play an important 
cytoprotective role in cancer as well as conferring drug resistance.(202, 218, 273) In 
addition to activation by the UPR, c-Myb, a transcription factor frequently 
overexpressed in colon cancer cell lines, can bind to sequences within and modulate 
the human GRP78 promoter, independent of UPR sequences like the ERSE 
motif.(274)  
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GRP78 has been found to be highly expressed in a number of different cell lines and 
solid tumours, and correlates with malignancy, metastasis and drug resistance.(223) 
In head and neck cancer (HNC) cell lines, GRP78 is highly expressed. Knockdown 
of GRP78 by small interfering RNA (siRNA) significantly reduced cell growth and 
colony formation, and inhibited migration and invasive ability. Subsequent xenograft 
study demonstrated that administration of a siRNA plasmid into HNC xenografts 
inhibited tumour growth in situ and liver metastasis.(275) Overexpression of GRP78 
in gastric cancer correlates with tumour size, depth of invasion, lymphatic and 
venous invasion, lymph node metastasis and stage of disease,(276) is inversely 
correlated with patient survival and GRP78 knockdown in gastric cancer xenograft 
mouse model inhibited tumour growth and metastasis.(277) In hepatocellular 
carcinoma, high GRP78 expression correlates with increasing histological grade 
(278). GRP78 expression in prostate tumours is markedly higher than in benign 
prostate tissue and the degree of expression correlates with increased risk of 
recurrence, reduced survival, and is also associated with the development of 
castration resistance.(279, 280) In patients with diffuse large B-cell lymphoma, 
overexpression of GRP78 was associated with worse overall survival and 
characterising tumours by GRP78 may thus be of value in selecting patients for 
combination therapy.(281) 
The observation that GRP78 is elevated in malignant tumours and metastasis 
suggests a role for GRP78 in improving cell motility, as well as protecting it from the 
hostile host environment. As discussed earlier, α2M* can bind cell surface GRP78 in 
1-LN human prostate cancer cells.(211) Alpha 2M* can activate 21-kDA activated 
kinases (PAK’s), which are important for cell motility(282), oncogenesis and 
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metastasis.(283) Metastatic potential may also be enhanced by the PERK/elF2α 
mediated G1 cell cycle arrest, via cyclin D1 attenuation. This allows tumours to 
remain dormant until such a time that local conditions may improve.(284) This 
mechanism is also likely to contribute to drug resistance as many anti-cancer drugs 
act on dividing cells and will therefore be ineffective against dormant cells.  
While the majority of evidence suggests that GRP78 may predict for a poor 
prognosis in solid tumours, a few exceptions do exist. There is no evidence of a 
correlation between GRP78 and pathological stage in lung cancer and, in fact, 
patients with positive GRP78 expression tend toward better prognosis.(285) In 
neuroblastoma, GRP78 expression is higher in more differentiated tumours and 
correlates with better survival for patients with both well and poorly differentiated 
tumours.(286) In primary resected oesophageal adenocarcinoma, GRP78mRNA is 
more elevated in early pT1 cancer compared with more advanced stages or normal 
oesophageal squamous epithelium. Survival analysis suggests a trend to better 
survival from oesophageal cancer in those patients with tumours expressing higher 
levels of GRP78.(287) 
1.3.4.1 GRP78 and chemosensitivity 
Overexpression and siRNA-mediated knockdown studies have established that 
GRP78 can convey resistance to a variety of anticancer therapy in tumours.(218) The 
antiapoptotic effects of GRP78 affect the efficacy of anticancer drugs, many of 
which act through inducing ER stress.  
Topoisomerase IIα (topoIIα) is an ATP-dependent nuclear enzyme important for 
DNA replication and is therefore an attractive target for actively dividing cancer 
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cells. TopoIIα active drugs such as etoposide (VP-16) become less effective with 
increasing GRP78 expression resulting in reduced topoIIα activity, although VP16 
itself does not increase GRP78 as it does not cause ER stress. Thus, in solid tumours 
with hypoxic cores that result in upregulation of GRP78, development of resistance 
to TopoIIα inhibitors is likely.(288) The mechanism of etoposide resistance is now 
understood. Etoposide induced cell death occurs via the caspase signalling cascade, 
in particular the activation of caspase-7, which is localized to mitochondrial and ER 
membranes. GRP78 overexpression suppresses caspase-7 activity via the ATP 
binding domain. Of further interest is the finding that unlike standard UPR inducers 
such as tunicamycin, that alter drug sensitivity by causing cell cycle arrest in G1, 
GRP78 overexpression does not cause any alteration of the cell cycle.(289) Caspase-
7 is the downstream executioner caspase for a number of anticancer drugs and 
GRP78 possibly confers general resistance to cancer cells.(290) 
Cisplatin is a platinum based chemotherapy drug that binds to and causes cross-
linking of DNA. In contrast to etoposide resistance, activation of the UPR, by pre-
treatment with 6-AN in colon cancer cell lines, cause increased sensitivity to DNA 
cross linking agents such as Cisplatin, melphalen and 1,3-bis(2-chloroethyl)-1-
nitrosurea (BCNU). It was shown that sensitisation was independent of the nature in 
which GRP78 was up-regulated and that the mechanism for sensitization was 
impairment of DNA cross-link repair. It is proposed that when overexpressed, some 
GRP78 can translocate to the nucleus where it attenuates the repair of DNA cross-
links.(291, 292) 
By contrast, other investigators propose that GRP78 might contribute to resistance to 
Cisplatin. In enucleated cells, Cisplatin induced calpain-dependent activation of ER 
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caspase 12 and increased expression of GRP78, both markers of ER stress. Cisplatin 
can therefore be considered as an ER-active anticancer drug. Increase in GRP78 may 
convey an antiapoptotic or protective effect contributing to cisplatin resistance.(293) 
Drugs such as combretastatin A4P (CA4P), which targets proliferating immature 
endothelial cells, have selective effects of destroying tumour vasculature, in 
particular the central, poorly perfused hypoxic regions. However, this can have the 
unintended effect of triggering a prosurvival response such as GRP78 expression. In 
a xenograft human breast cancer model, treatment with CA4P, and contortostatin, 
another antiangiogenic drug with anti-tumour properties, promoted transcriptional 
activation of GRP78 and elevated GRP78 protein in the surviving tumour cells, 
resulting in drug resistance by upregulating survival pathways.(294) 
Histone deacetylase (HDAC) inhibitors are promising drugs that cause increased 
differentiation, growth arrest and apoptosis. HDACi’s induce GRP78 but not other 
stress response pathways. Overexpression of GRP78 confers resistance to HDACi-
induced apoptosis in cancer cells, and knockdown of GRP78 by siRNA sensitizes 
cells to HDACi’s.(295) 
In human breast cancer, oestrogenic stimulation increased GRP78 in vitro and 
activated the downstream UPR regulator XBP-1. Furthermore, UPR induction by 
glucose deprivation enhanced resistance to 5-flurouracil and doxorubicin.(296) It is 
also suggested that GRP78 can contribute to resistance of breast cancers to anti-
oestrogen therapy by suppressing intrinsic apoptotic pathways.(297)   
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1.3.5 Therapeutic implications 
In view of the weight of evidence in support of UPR involvement in solid-tumour 
development and drug-resistance, targeting of the UPR and in particular GRP78 
becomes an attractive approach to develop new anticancer therapies. 
The observations that silencing GRP78 by siRNA or antisense can reverse malignant 
phenotypes suggest GRP78 as a potential anticancer target.(272, 294, 295, 298, 299) 
1.3.5.1 Novel compounds targeting GRP78 
Recently, a number of novel naturally occurring compounds have been identified 
from bacterial culture broths that can down-regulate GRP78. (-)-epigallocatechin 
gallate (EGCG), a major component of green tea, inhibits GRP78 activity and can 
increase etoposide-induced apoptosis in cancer cells. This is in addition to its activity 
on many other cellular targets.(300) Versipelostatin (VST) from Streptomyces 
versipellis,(301) Valinomycin from Actinomycete,(302) Verrucosidin from 
Penicillium verrucosum var. Cyclopium,(303) and Piericidin A from Streptomyces 
sp.(304) have all been shown to downregulate GRP78. By suppressing GRP78 
promoter activity with subsequent reduced production of UPR transcriptional 
activators, these compounds are cytotoxic to 2-DG stressed cells in vitro.(302-304) 
In xenograft models, VST showed anticancer activity at well-tolerated doses, and 
was found to have a synergistic anti-tumour effect with cisplatin suggesting a role for 
such inhibitors of ER stress to eliminate otherwise drug-resistant, hypoglycaemic 
tumour cells.(301) 
The utility of the GRP78 promoter in human cancer gene therapy has also been 
examined. GRP78 promoter-driven suicide gene therapy activated by photodynamic 
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therapy led to regression of sizable human breast cancer tumour in mouse xenograft 
models in combination with ganciclovir. The potential benefit to this therapy is that 
gene expression driven by the GRP78 promoter is minimal in most major organs and 
normal tissue.(305) 
The presence of functional GRP78 on the cell surface of cancer cells provides a 
novel therapeutic target.(208, 213, 215, 217) Using a cell surface GRP78 binding 
peptide synthesized as a chimeric peptide with a proapoptotic sequence, tumour 
growth in human prostate cancer xenografts and murine breast isogenic tumours was 
suppressed.(214) Antibodies directed against the GRP78 COOH-terminal domain 
(anti-CTD antibody) on the cell surface can upregulate p53 activity and promote 
apoptosis.(306) Furthermore, anti-CTD antibody also downregulates the UPR and 
upregulates proapoptotic protein GADD153, and the apoptotic components, cleaved 
PARP-1 and Erdj5.(307) By contrast, patients who develop autoantibodies against 
the α2M* binding site on the NH2-terminal domain of cell surface GRP78, show 
agonistic upregulation of GRP78 and its antiapoptotic properties, conveying a worse 
prognosis.(211, 214) GRP78 on the cell surface of proliferating endothelial cells and 
a variety of stressed tumour cells serves as a binding site for Kringle 5 (K5), an 
angiogenesis inhibitor. K5 is a human plasminogen proteolysed product that can 
inhibit angiogenesis by causing apoptosis of proliferating endothelial cells. 
Recombinant K5 shows high affinity binding to cell surface GRP78 and can produce 
apoptosis selectively in hypoxic tumour cells via enhanced activity of caspase-
7.(308) 
A disadvantage of these GRP78 targeting compounds is their lack of specificity and 
the unknown effects upon other pathways. A compound that specifically targets 
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GRP78 is likely to be a useful tool for probing UPR pathways and given the 
implication of the UPR in cancer growth and development, is likely to provide novel 
anticancer strategies. 
1.3.5.2 Subtilase cytotoxin and EGF-SubA 
Subtilase cytotoxin (SubAB) is a recently discovered member of the AB5 toxin 
family which are important virulence factors for a number of notorious bacterial 
pathogens including Shiga toxins produced by Shiga toxigenic Escherichia coli 
(STEC) and Shigella dysenteriae, cholera toxin (Ctx) from Vibrio cholera, labile 
enterotoxins from enterotoxigenic E.coli, and pertussis toxin (Ptx) produced by 
Bordetella pertussis. It was discovered in a strain of Escherichia coli that caused an 
outbreak of haemolytic uraemic syndrome in Adelaide in 1998.(309) SubAB consists 
of a binding pentamer of B units and an active A subunit, similar to A and B subunits 
of Shiga toxins from strains of E.coli. The A subunit of SubAB, unlike Shiga toxin, 
is a subtilase-like serine protease that, when transported to the ER, selectively attacks 
GRP78. SubA kills cells by specifically cleaving GRP78 at a single amino acid point 
(Leu416 and Leu417) in an exposed loop that links two GRP78 domains: the ATPase 
and the substrate-binding domain.(310, 311) In contrast to the downregulation of 
GRP78 which does not significantly affect cell growth,(294) selective cleavage of 
GRP78 by SubA releases PERK, IRE1 and ATF6 leading to overwhelming 
activation of the UPR and subsequent apoptosis.(312, 313) 
To reduce the potential for significant systemic side effects of administering SubA as 
a potential therapeutic agent, tumour targeting must be achieved. EGFR is frequently 
overexpressed on the surface of tumour cells making it an attractive drug target. 
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Ligand binding to EGFR leads to internalisation and trafficking. An engineered 
fusion protein, epidermal growth factor (EGF)-Sub A, EGF and Sub A, can produce 
significant inhibition of human breast and prostate tumour xenografts and can 
dramatically increase the sensitivity of cancer cells to thapsigargin, an ER stress 
inducing drug, and vice versa.(314) Investigation locally within the Boyd laboratory 
have also demonstrated that EGF-SubA is cytotoxic in laryngeal squamous 
carcinoma cells at picomolar concentrations, produces at least an additive effect 
when combined with cisplatin and may act as a radiosensitising agent. (M. Aslam, 
thesis). No evidence exists as to the effects of EGF-SubA in other solid tumours or 
cell line derivatives. 
1.3.5.3 GRP78 and colorectal cancer 
GRP78 remains relatively understudied in human colorectal cancer. In colon cancer, 
Xing and colleagues found GRP78 expression to be upregulated with progression 
along the normal tissue-adenoma-carcinoma sequence suggesting a role in malignant 
transformation.(315) Liu and colleagues also confirmed GRP78 expression to be 
elevated in tumour but found no correlation with clinicopathological variables.(316) 
GRP78 overexpression in colon cancer is also noted in the presence of other 
molecular chaperones (cytosolic chaperonin, GRP94, HSC70).(317) 
Only one group has attempted to examine for any correlation between GRP78 
expression and survival following surgery for colorectal cancer. Takahashi and 
colleagues analysed post-surgical survival of 262 patients with 
adenocarcinoma.(318) Interestingly, a survival advantage of nearly 10% was 
observed for patients with elevated GRP78 expression although this did not reach 
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statistical significance (P=0.198). The authors have not discussed this potentially 
important observation any further. This data suffers however as survival analysis did 
not take account of any adjuvant treatment received post-operatively and 
immunohistochemistry was performed using an antibody (sc-1050, Santa Cruz 
Biotechnology) which I believe to be non-specific for GRP78 as I will demonstrate 
in this thesis. 
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1.4 Aims and objectives 
1.4.1 GRP78 expression as a predictive biomarker of response to adjuvant 
fluorouracil-based therapy in colorectal cancer 
Colorectal cancer remains a major cause of mortality. At the molecular level, 
colorectal cancer is a heterogenous disease and this accounts for differences in 
survival and responsiveness to chemotherapy. As a result, many patients do not 
benefit from treatment, while others may require combination therapy as oppose to a 
single agent. Furthering the understanding of drug resistance in colorectal cancer by 
identifying prognostic and predictive biomarkers is vital. Although well 
characterised in vitro, the understanding of the influence of GRP78 in human cancers 
is very limited, with a paucity of data for colorectal cancer. Its relationship to drug 
sensitivity in vitro and its ease of detection by immunohistochemistry make GRP78 a 
potentially attractive biomarker. The aims of this project therefore were: 
1. To identify a suitable antibody to detect GRP78 on a colorectal tissue 
microarray and optimise conditions for immunohistochemistry. 
2. To examine if GRP78 expression correlated with malignancy and was 
predictive of survival or benefit from 5-FU based chemotherapy. 
3. To determine how depleting endogenous GRP78 in vitro would alter the 
cellular response to 5-FU. 
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1.4.2 Pre-clinical investigation of GRP78 as a potential therapeutic target in 
colon cancer using a novel engineered fusion protein; EGF-SubA. 
Limited data exist suggesting that EGF-SubA is highly toxic to several cancer cell 
lines and may reduce tumour growth in mouse xenograft models. Recent work in the 
Division of Surgery and Oncology, University of Liverpool indicates that EGF-SubA 
was toxic to head and neck squamous cell carcinoma (HNSCC) cell lines and toxicity 
correlated with cell surface EGFR expression. Furthermore, and of relevance to head 
and neck cancer, EGF-SubA showed evidence of synergy with cisplatin and potential 
as a radiosensitising agent. 
To our knowledge, no data currently exist as to the effect of this agent in the setting 
of colorectal cancer. The aims of this project were: 
1. To characterise the EGFR surface expression of a panel of colon cancer cell 
lines and correlate this with sensitivity to EGF-SubA. 
2. To explore the mechanism of action of EGF-SubA with regard to its 
biological activity and pharmokinetics, its inhibitory effects upon 
proliferation, and ability to induce apoptosis. 
3. To evaluate the potential role of EGF-SubA in the setting of the 
contemporary adjuvant treatment of colorectal cancer. 
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All water used in the experiments described was >18MΩ resistance purity. 
2.1 Immunohistochemistry 
2.1.1 Initial Sample Preparation: Deparaffinization and rehydration 
Formalin fixed, paraffin embedded tissue sections mounted on glass slides, provided 
by the Liverpool University Tissue Bank, were labelled by pencil and mounted in a 
slide rack. Slides were deparaffinised and rehydrated by placing two times in Xylene 
for 10 minutes followed by 30 seconds in each of the graded alcohol solutions 
moving from 100%, 95%, 90%, to 70%. Slides were then treated in a beaker of tap 
water for 5 minutes. 
2.1.2 Blocking and antigen retrieval 
Table 2.1-1: Composition of PBS/Tween 
Concentration Reagent Source 
0.065 M Na2 HPO4.2H2O Reidel-de Haen 
0.015 M NaH2PO4.2H2O Fluka 
0.075 M NaCl GPR 
0.1% v/v Tween 20 Sigma 
 
Table 2.1-2: Endogenous peroxidase blocking buffer 
Concentration Reagent Source 
99% v/v Methanol Fisher Scientific 
1% v/v H2O2  
 
Endogenous peroxidise was blocked by placing in buffer (1% H2O2 in Methanol) for 
12 minutes, then slides were washed in PBS/Tween-20 for 5 minutes. Any slides not 
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to be subjected to antigen retrieval were separated. Slides for antigen retrieval were 
boiled in 10 mM citric Acid buffer (pH6) in a microwave for 25 minutes then left to 
cool for 20 minutes. A further wash in PBS/Tween-20 was performed and slides 
transferred to a moistened chamber to air dry. Tissue was marked with a PAP pen to 
form a hydrophobic barrier. 
2.1.3 Indirect immunostaining 
Table 2.1-3: Primary antibodies used in this project for immunohistochemistry 
Protein Antibody Source Raised in 
Working 
concentration 
GRP78 sc-1050 (N20) 
Santa Cruz 
Biotechnology 
Goat polyclonal 1:100 
GRP78 
sc-13968 
(H129) 
Santa Cruz 
Biotechnology 
Rabbit 
polyclonal 
1:50 
 
Table 2.1-4: Biotinylated secondary antibodies used in this project for 
immunohistochemistry 
Target Antibody Source Raised in 
Working 
concentration 
Anti-Rabbit BA-1000 Vector Labs Goat 1:200 
Anti-Goat BA-5000 Vector Labs Rabbit 1:200 
 
Slides were incubated at room temperature for 30 minutes in 2.5% normal serum 
(Vector Laboratories) of the species in which the secondary antibody was raised. As 
an example, for anti-GRP78 sc13968, 250 µl of goat serum was added to 10 ml 
Dulbecco’s phosphate buffered saline (PBS) (Sigma) and mixed well. For anti-
GRP78 (sc1050), 250 µl of rabbit serum was added to 10 ml PBS and mixed well. 
Approximately 100-200 µl of blocking serum is needed per slide. 
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The blocking solution is then removed carefully and the tissue then covered with the 
primary antibody diluted with blocking solution, covered and incubated at room 
temperature for 1 hour. Omission of the primary antibody is used as a negative 
control. It is important to avoid the edges of the tissue drying out while the antibody 
is applied. 
Wash slides in PBS/Tween-20 for 5 minutes then incubate at room temperature for 
30 minutes with diluted (1:200 in buffer containing 2.5% serum) biotinylated 
secondary antibody. Wash in PBS Tween-20 for 5 minutes. This washing step is very 
important to minimise background. 
After blotting off excess PBS/Tween-20, slides were incubated in Vectastain ABC 
reagent (Vector Laboratories) for 30 minutes then washed again in PBS/Tween-20 
for 5 minutes. 
2.1.4 Developing and counterstaining 
DAB is used as a chromogenic substrate. The antibodies were revealed by DAB SK-
4100 peroxidase substrate kit (Vector Laboratories) at room temperature for 10 
minutes in the dark. The reaction was stopped by rinsing in water for 5 minutes then 
slides were counterstained in haematoxylin for 45 seconds followed by a further 
rinse in running tap water until clear. Dehydrate samples with alcohol and xylene, 30 
seconds in each alcohol solution moving from 70%, 90%, 95% and 100% then twice 
in Xylene for 5 minutes. Slides were then mounted with coverslips to view. 
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2.1.5 Imaging 
Immunohistochemical images produced in this thesis were obtained from a Nikon 
Eclipse E800 upright microscope using MetaMorph® Imaging System Version 3.0 
for Microsoft® Windows™ from Universal Imaging Corporation. 
2.2 Cell Culture Techniques 
All tissue culture work was performed using aseptic technique in a class II laminar 
flow tissue culture cabinet. Cells were routinely maintained in a 175 cm
2
 tissue 
culture flask (nunc™) and subcultured every 48-72 hours. All media and solutions 
were pre-warmed in a 37
0
C water bath prior to use.  
For all cell lines, base medium was RPMI-1640 (Sigma) supplemented with 10% 
foetal bovine serum (Sigma), Penicillin 100 U/ml and Streptomycin 100 µg/ml 
(Sigma). 
2.2.1 Subculture 
Cells were routinely passaged at 70-90% confluence. Culture medium was removed 
and discarded. Cells were then rinsed with 5 ml of sterile PBS to remove any traces 
of residual media containing trypsin inhibitor. The PBS was removed, then, 2 to 3 ml 
of Trypsin-EDTA solution (Sigma) was added evenly to cells, by gently tilting the 
flask to ensure coverage, and the flask incubated at 37
0
C until the cell layer had 
dispersed, as observed under an inverted microscope. The trypsin was then 
neutralised by adding an equal or greater volume (usually 6 to 8mls) of growth 
media. Cells were then aspirated by gentle pipetting to produce a single cell 
suspension and aliquoted as desired or replated at the desired concentration for each 
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cell line (typically 1:8). Flasks were then made up with growth media, normally 25 to 
30 ml. 
2.2.2 Preparation of frozen cell stocks 
Cells were subcultured as described, then transferred to a 15 ml centrifuge tube 
(Falcon). Cells were centrifuged at 300g, 4
0
C for 5 minutes. After discarding the 
supernatant, the cell pellet was resuspended in freeze media (FBS/10% v.v. DMSO) 
at a concentration of c.2x10
6
 cell/ml. 1ml aliquots of cells were transferred to a 1.5 
ml polypropylene cryotube (Eppendorf) and immediately placed in a -80
0
C freezer 
for 24hrs prior to long term storage in liquid nitrogen. 
As required, frozen stocks were defrosted in a 37
0
C water bath and immediately 
transferred to pre-warmed culture media. 
2.3 Cell lines 
All cells were grown from existing frozen stocks held by the Division of Surgery and 
Oncology, University of Liverpool, unless otherwise stated. These stocks originated 
from the American Type Culture Collection (ATCC), Virginia, USA. The 
authenticity of all cell lines is regularly checked by DNA profiling. 
2.3.1 HCT116 (p53 +/+, +/-, -/-) 
HCT116 was initiated from an adult male patient with colon cancer. p53 status is 
documented as wild type. p53 heterozygous +/- and homozygous -/- contain a ΔN40 
mutation on one or both alleles respectively. 
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2.3.2 LoVo 
LoVo was initiated in 1971 from a fragment of a metastatic tumour nodule in the left 
supraclavicular region of a 56-year-old Caucasian male patient with a histologically 
proven diagnosis of adenocarcinoma of the colon.(319) The original tumour was 
Duke’s C, Grade IV. p53 status documented as wild type. 
2.3.3 SW480 
SW480 was established from a primary Duke’s B adenocarcinoma of the colon in a 
50 year old Caucasian male in 1978.(320) The cells express elevated levels of p53 
protein. 
2.3.4 SW620 
SW620 was isolated from the tissue of the same 51-year-old Caucasian male as was 
SW480, 1 year after initial colon resection. A recurrence of the malignancy resulted 
in a wide-spread metastasis from the colon to an abdominal mass. SW620 was 
initiated by A. Leibovitz, et al.,(320) from a lymph node in the same manner as was 
the primary adenocarcinoma from which SW480 was derived the previous year. 
Levels of p53 protein expression are elevated. Although the SW620 cell line is 
established from a later metastasis, it only has one p53 mutation whereas the tumour 
specimen cell line SW480 established one year previously carries two missense 
mutations.(321) 
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2.3.5 HT-29 
HT-29 originated from a primary colon adenocarcinoma in a 44 year old Caucasian 
female in 1964. The cells express elevated levels of mutant p53. 
2.4 siRNA knockdown 
2.4.1 siRNA delivery 
Short interfering RNA (siRNA) oligonucleotide knock-down experiments were 
performed in 6 well tissue culture plates (Corning, USA). Cells were harvested from 
their normal culture flask as described earlier and seeded aiming for a confluence of 
30-50% on the day of transfection. 
The siRNA was reconstituted in 1X siRNA buffer (diluted with RNase-free water 
from 5X siRNA buffers – Dharmacon) according to the manufacturer’s directions to 
produce a 20 µM stock. The siRNA oligonucleotides were used at a final 
concentration of 40 nM. 
Lipofectamine™ 2000 (Invitrogen) was used as a transfection reagent. 
Lipofectamine is a cationic lipid that forms a positively charged liposome/siRNA 
complex that can fuse with the negatively charged cell membrane and then enter via 
endocytosis. Once inside the cell, the cationic lipids are believed to destabilise the 
endosome membrane thereby releasing the siRNA complex into the cytoplasm.(322) 
The siRNA molecules dissociate from the lipid complex and enter the nucleus 
becoming a part of the RNA-induced silencing complex (RISC). Guided by the 
antisense strand of the siRNA, RISC cleaves the target mRNA inhibiting its 
translation.(323) 
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 On the day of transfection, usually 24hr after seeding, the cells were washed with 
sterile PBS and 1.5 ml of antibiotic free fresh media were applied per well. Opti-
MEM®I Reduced Serum Media (Invitrogen) was pre-incubated to 37
o
C. For each 
transfection, the oligomer-Lipofectamine complex (500 µl/well) was prepared by 
initially producing two solutions. For each well of a 6 well plate, 4 µl of 20µM stock 
siRNA (80picomoles) is diluted in 246 µl Opti-MEM®I Reduced Serum Media 
(Invitrogen) to make up to 250 µl/well. This solution was vortexed gently and 
allowed to stand for 5 minutes. A further solution containing 4 µl/well Lipofectamine 
and 246 µl/well Opti-MEM is made up, tapped gently with a finger and left to stand 
for 5 minutes. After the 5 minute incubation period, the two solutions are combined, 
mixed gently and allowed to stand for 25 minutes. Transfection is performed by 
adding the oligomer-Lipofectamine complex evenly in a drop wise manner to each 
well then mixing gently by rocking the plate back and forth to avoid concentration of 
siRNA/Lipofectamine complexes in the well. The addition of the 
siRNA/Lipofectamine solution gives a final transfection volume of 2 ml and a final 
siRNA concentration of 40 nM. The cells were incubated in transfection reagent for 
6 hours and then the media was replaced with growth media to minimise potential 
toxic effects due to prolonged exposure to the Lipofectamine reagent. All volumes of 
Lipofectamine, OptiMEM and siRNA should be multiplied by 1.5 to account for loss 
during pipetting. Due to the growth characteristics of the colon cancer cells, it was 
often necessary to split the cells 24hr after transfection and replate them in a larger 
10cm culture dish prior to drug treatment. Analysis of knockdown efficiency was 
performed at the protein level by standard SDS-PAGE and western blotting. 
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2.4.2 siRNA oligonucleotides 
The following siRNAs, obtained from Dharmacon were used: 
2.4.2.1 GRP78  
siGENOME D-008198-03: 
Target sequence: 5’-CCA CCA AGA UGC UGA CAU U-3’ 
siGENOME D-008198-04: 
Target sequence: 5’-GAA AGG AUG GUU AAU GAU G-3’ 
siGENOME D-008198-05: 
Target sequence: 5’-CGA CUC GAA UUC CAA AGA U-3’ 
siGENOME D-008198-18: 
Target sequence: 5’-CAG AUG AAG CUG UAG CGU A-3’ 
2.4.2.2 Scrambled 
Target sequence: 5’-GGA CGC AUC CUU CUU AAU U-3’ 
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2.5 Western Blotting 
2.5.1 Cell lysate preparation 
The desired cells were subcultured and harvested by trypsinisation and pelleted by 
centrifugation as described. Cell pellets were lysed on ice in SLIP in the presence of 
protease inhibitors: aprotinin (2 μg/ml), leupeptin (0.5 μg/ml), pepstatin A (1 μg/ml), 
soybean trypsin inhibitor (100 μg/ml) and phenylmethylsulfonyl fluoride (PMSF) 
(1 mM). The cell lysate was then centrifuged at 12,000g, 4
0
C for 10 minutes in an 
Eppendorf 5415R centrifuge, to remove cellular debris. The resulting supernatant 
was utilised and the pellet discarded. 
Table 2.5-1: SLIP (Stuart Linn Immunoprecipitation) buffer 
Concentration Reagent Source 
50 nM 
HEPES, Molecular Biology Grade, 
pH7.5 
Calbiochem 
150 mM NaCl VWR 
10% (v/v) Glycerol, ≥99.5%, A.C.S. reagent Sigma 
0.1% (v/v) Triton X-100 Amersham Biosciences 
 
Table 2.5-2: Protease inhibitor cocktail 
Concentration Reagent Source 
2 μg/ml Aprotinin Roche 
0.5 μg/ml Leupeptin Roche 
1 μg/ml Pepstatin A Roche 
1 mM Phenylmethylsulfonyl fluoride (PMSF) Fluka 
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2.5.2 Bradford assay for determination of protein concentration in cellular 
extract 
Bradford reagent (Bio-Rad) was diluted 1:5 in H2O. A series of protein standards 
was prepared by adding bovine serum albumin (Sigma) in a concentration of 20 
mg/ml to 1ml of SLIP lysis solution in a clean 1.5ml Eppendorf tube. 0.5ml was 
serially extracted and added to a further 1.5 ml Eppendorf containing 0.5 ml of dilute 
Bradford reagent resulting in prepared protein standards of 20, 10, 5, 2.5, 1.25, 
0.625, 0.3125 and 0 mg/ml. The optical density at 595 nm of each standard protein 
concentration was measured using a spectrophotometer (Eppendorf Biophotometer). 
A variance of <5 in the c.v. reading was deemed acceptable. 
Table 2.5-3:  Protein sample loading buffer (4X) 
Concentration Reagent Source 
250 mM Tris, pH 6.8 Calbiochem 
8% (v/v) Sodium dodecyl sulphate (SDS) BDH Prolabo 
40% (v/v) Glycerol, ≥99.5%, A.C.S. reagent Sigma 
1% (v/v) Β-mercaptoethanol Sigma 
4 mg/ml Bromophenol blue Sigma 
 
Protein concentrations of each supernatant were determined by adding 2 µl of 
supernatant to 1ml of dilute Bradford reagent and measuring on the 
spectrophotometer. Samples were then adjusted to load 50 µg of protein/20 µl in 1X 
protein sample buffer. If protein yield was too high (>20 mg/ml) then a further 100 
µl of SLIP lysis solution was used to dilute the supernatant and Bradford assay 
repeated for that sample. Samples were then stored at -80
0
C or prepared for western 
blot analysis. 
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2.5.3 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Table 2.5-4: Composition of SDS-PAGE gels (volume needed for 4 gels) 
Reagent Source 
Seperating Gel Stacking 
gel 7.5% 10% 12% 
H2O - 5.42 ml 4.8 ml 4.3 ml 7.225 ml 
40%(v/v) Acrylamide mix BDH 1.87 ml 2.5 ml 3 ml 1.275 ml 
1.5 M Tris-HCl (pH 8.8) 
Calbiochem 
2.5 ml 2.5 ml 2.5 ml - 
1 M Tris-HCl (pH 6.8) - - - 1.25 ml 
10% SDS BDH 0.1 ml 0.1 ml 0.1 ml 0.1 ml 
10%(w/v) Ammonium 
persulfate (APS) 
Sigma 0.1 ml 0.1 ml 0.1 ml 0.1 ml 
N,N,N’,N’-
tetramethylenediamine 
(TEMED) 
BDH 
0.008 
ml 
0.008 
ml 
0.008 
ml 
0.01 ml 
 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed using a Bio-Rad Mini-Protean III Cell Electrophoresis System. 0.75 mm 
glass plates were cleaned with 70% ethanol and mounted. Adequate positioning of 
the glass plates on the mount was confirmed by testing with H2O before pouring the 
gels. First, a separating gel was poured between the plates to within 1.5 cm of the 
top, usually 4mls. The percentage acrylamide mix of the gel used depended upon the 
expected size of the target protein, with the 10% gel most commonly used. The gel 
was covered with 1ml of H2O and left to polymerise for 1 hour before adding the 
stacking gel. The H2O was poured off and the stacking gel poured to the top of the 
glass plates. Having carefully positioned a 10 well comb, the gel was left to set for 
15 minutes. Once set, the comb was removed and the wells irrigated with H2O. The 
gel and plates were positioned in the electrophoresis chamber and Tris-Glycine 
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buffer (25 mM Tris-HCl, 250 mM Glycine, 0.1% (v/v) SDS) poured to fill the central 
chamber and half fill the outer chamber (500 ml per chamber). The protein samples 
to be analysed were first boiled on a hot block at 99
0
C for 5 minutes then centrifuged 
(Eppendorf 5804R) at 14000, 4
0
C for 2 minutes. 50 µg (20 µl) of total protein in 1X 
sample buffer was added to each well and resolved alongside 15 µl of protein marker 
(New England Biolabs). Empty wells were loaded with 15 µl of 1X protein sample 
buffer. Proteins were separated by SDS-PAGE at 200 V for 45-60 minutes. 
2.5.4 Protein Transfer to Hybond ECL Nitrocellulose Membrane 
The proteins on the gel were transferred to a pre-cut (5x8 cm) Hybond ECL 
nitrocellulose membrane (Amersham Biosciences) using a Bio-Rad Mini Trans-Blot 
system. Sponges, membrane and pre-cut 3MM Whatman Chromatography paper 
were pre-soaked in transfer buffer (25 mM Tris-HCl, 192 mM glycine, 20% (v/v) 
methanol) before arranging the gel and membrane within a sandwich of 3MM 
Whatman paper (10x7cm) and sponge inside a cassette. The cassette was loaded so 
that the gel was toward the negative electrode and the membrane towards the positive 
electrode. 100 V was applied across the cassette for one hour in a transfer tank filled 
with transfer buffer and containing an ice block to aid cooling.  
When transfer was complete, the membrane was removed and stained with Ponceau 
S (0.2% (w/v) Ponceau S (Sigma), 5% (v/v) acetic acid (Merck)) for 1 minute to 
confirm equal protein transfer, washed in water and photographed. The membrane 
could be cut horizontally at this stage, at levels dependent upon which protein was 
being studied and guided by the protein marker as a guide. Membranes were then 
destained by several washes in PBS/Tween-20 and placed in 5% non-fat dry milk 
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(Bio-Rad) in PBS/Tween-20 overnight at 4
0
C, to block any non-specific protein 
binding sites. 
2.5.5 Immunoblotting 
Table 2.5-5:  Primary antibodies used for immunoblotting 
Protein 
Antibody 
(clone 
number) 
Source 
Species raised in 
and clonality 
Working 
concentration 
Actin sc-8432 (C-2) 
Santa Cruz 
Biotechnology 
Mouse 
monoclonal 
3 μg/ml 
GADD 153 
(CHOP) 
sc-7351 (B-3) 
Santa Cruz 
Biotechnology 
Mouse 
monoclonal 
3 μg/ml 
EGFR sc-03 (1005) 
Santa Cruz 
Biotechnology 
Rabbit polyclonal 3 μg/ml 
GRP78 sc-1050 (N20) 
Santa Cruz 
Biotechnology 
Goat polyclonal 3 μg/ml 
GRP78 
sc-13968 
(H129) 
Santa Cruz 
Biotechnology 
Rabbit polyclonal 3 μg/ml 
Hsp70 
(HSP72) 
SPA-810D 
Cambridge 
Bioscience 
Mouse 
monoclonal 
3 μg/ml 
LC3 
M152-3 
(4E12) 
Medical and 
Biological Labs Co. 
Mouse 
monoclonal 
3 μg/ml 
p53 Ab-6 (DO-1) Oncogene-Merck 
Mouse 
monoclonal 
1 μg/ml 
PARP P76420 
BD Transduction 
Labs. 
Mouse 
monoclonal 
3 μg/ml 
 
Membranes were blocked in PBS-Tween-20 (0.1% v/v) containing non-fat dry milk 
(BioRad) (5% w/v) for 1 h at room temperature before incubation with primary 
antibodies (each at 3 μg/ml, except anti-p53 at 1 μg/ml). Membranes were washed 
three times for 15 min in PBS-Tween-20 to remove any non-specific binding of the 
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antibody before addition of HRP-conjugated secondary antibody for 1 h at room 
temperature. Membranes were washed as before. 
Table 2.5-6: Horseradish peroxidase-linked secondary antibodies used for 
immunoblotting 
Target Antibody Source 
Raised 
in 
Working 
concentration 
Anti-Goat 305-036-003 Jackson ImmunoResearch Labs. Rabbit 1:20000 
Anti-Mouse RPN4201 GE-Healthcare Sheep 1:2500 
Anti-Rabbit NA934 GE-Healthcare Donkey 1:5000 
2.5.6 Enhanced chemilluminescence (ECL) 
Excess PBS/Tween-20 was carefully blotted from the membrane, which was then 
incubated for 1 minute with Western Lightening Chemilluminescence Plus Reagent 
(Perker Elmer) made up of equal volumes of Enhanced Luminol Reagent and 
Oxidising Reagent (typically 2 to 3 mls of ECL Reagent required per membrane). 
The ECL reagent was then removed thoroughly and luminescence detected using a 
Kodak IM4000 image station. 
2.6 MTT proliferation assay  
Yellow MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a 
tetrazole) is reduced to purple formazan in the mitochondria of living cells. This 
reduction takes place only when mitochondrial reductase enzymes are active, and 
therefore conversion can be related to the number of viable cells.(324, 325) 
Mitochondrial dehydrogenases cleave the tetrazolium ring, yielding purple MTT 
formazan crystals which are insoluble in aqueous solutions. The crystals can be 
dissolved in dimethyl sulfoxide (DMSO, Sigma). The resulting purple solution is 
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spectrophotometrically measured at a certain wavelength (usually between 500 and 
600nm). An increase in metabolically active cell numbers results in an increase in the 
amount of MTT formazan formed and an increase in absorbance. The MTT assay is 
reliable for the in vitro measurement of cell growth characteristics and cytotoxicity 
studies despite limitations influenced by the physiological state of cells and variance 
in mitochondrial dehydrogenase activity in different cell types.(326) It should be 
remembered that the MTT assay measures metabolic activity and therefore should be 
performed during an active cellular growth phase (viable cells do not necessarily 
equal metabolically active cells). 
2.6.1 Cell Seeding 
Cells were harvested when at 70-90% confluence from their standard culture flasks 
and transferred to a 50ml falcon tube containing an appropriate amount of warm 
media. Cell density was determined from the average of a minimum of 4 counts 
using a cell counter (Z™ Series COULTER COUNTER®, Beckman Coulter). The 
harvested cells were then diluted in warm standard growth media to a concentration 
of 15,000 cells/ml and seeded to a 96 well plate (nunc™ flat bottomed 96 microwell 
plate, Ref: 734-2097), adding 200µl of cells/well (3000 cells/well) using a 
multichannel pipette (Costar®). 4 wells per condition were seeded. Duplicate plates 
were seeded to allow measurements on consecutive days. Growth curves and 
cytotoxicity assays were typically performed over 5-7 days (one plate is required for 
each day including day 0). The 96 well plates were then incubated at 37
o
C, 5% CO2, 
for 24 hours prior to any treatment to allow cells to adhere. 
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2.6.2 MTT assay 
Following the desired incubation period, 20µl of MTT (Sigma) solution is added to 
each well and incubated for 3½ hours. After removal of the supernatant, taking care 
not to displace the formazan crystals at the bottom of each well, 100µl of DMSO was 
added to dissolve the formazan crystals, producing a violet solution. Absorbance was 
measures at 590 nm. Through an interface with a desktop computer, the data was 
stored and transferred to a Microsoft® Excel® 2010 program for analysis. 
2.7 Flow cytometry 
Flow cytometry was performed on a Becton Dickinson FACSCalibur™ flow 
cytometer and results were analysed using CellQuest software (Becton Dickinson). 
2.7.1 Preparation of materials and buffers 
Propidium iodide (Sigma P4170) stock solution was made up to 1 mg/ml in PBS and 
stored at 4
o
C in a foil wrapped 50ml Falcon tube to protect from the light.  
RNAse (Sigma R6513) was made up to 10 mg/ml in 0.01 M sodium acetate (pH 5.2) 
then boiled at 100
o
C on a heated stirrer block in a glass bottle with the lid placed 
loosely for 15 minutes to inactivate DNase contaminants. This was allowed to cool 
then 1/10
th
 volume of 1M Tris HCl (pH 7.4) was added. The stock solution was 
aliquoted into 1ml Eppendorf tubes and stored at -20
o
C. 
Citrate buffer with spermine (100 ml) was prepared as follows. A 3.4 mM citrate 
solution (10% citric acid, 90% tri-sodium citrate) was created by adding 0.34 ml 
citric acid to 3.06 ml trisodium citrate (3.4 ml of 0.1 M citrate into 100ml = 3.4 mM). 
To this was added 0.1% TritonX-100 (Fluka) and 0.5 mg/ml spermine 
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tetrahydrochloride (Sigma S1141). At this stage, the solution was adjusted to pH 7, 
followed by the addition of 1% FBS and 50μg/ml RNAase. 
2.7.2 Cell cycle analysis with Propidium iodide 
Propidium iodide (PI) is an intercalating agent and a fluorescent molecule that binds 
to DNA by intercalating between the bases. PI can also bind to double stranded RNA 
(thus the requirement for adding RNAse to remove RNA). When excited with 
488 nm wavelength light, it fluoresces red and can be detected with 562-588 nm 
band pass filter. Propidium iodide is used as a DNA stain to evaluate cell viability or 
DNA content by flow cytometry. 
Propidium iodide is not membrane permeable so requires permeabilisation of the 
cells' plasma membranes by incubating them in a buffer solution containing a 
detergent
 
such as Triton X-100, or by fixating them in ethanol.  
2.7.2.1 Isolation of cells 
Cells were harvested with media into a 15ml Falcon tube and pelleted by 
centrifugation at 170g for 5 minutes. The cells were then washed in cold PBS and 
centrifuged on two occasions. The PBS was carefully removed with care not to 
disturb the pelleted cells. 
2.7.2.2 Fixation/Permeabilisation 
The pellet was re-suspended to create a single cell suspension by flicking the falcon 
tube harshly with a finger. Ice-cold 70% Ethanol (stored at -20
o
C) was added drop 
wise to the cells while slowly vortexing constantly to prevent cell aggregation. A 
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total of 5 mls of Ethanol was added to each pellet and the cells left on ice for 1 hour. 
(If required, after fixing, the samples could be stored for up to 2 weeks in the fridge 
prior to PI staining and flow cytometric analysis). 
2.7.2.3 Staining with Propidium iodide 
Fixed cells were centrifuged at 170g for 5 minutes and washed twice in PBS/0.5% 
Tween-20 to remove residual ethanol, re-suspending after each wash. In-between 
washes, the cells were counted at the coulter counter to proceed with 1 x 10
6
 cells in 
total. After pelleting the cells for the final time, remove PBS/Tween-20 and re-
suspend the pellet in 100 µl of RNAse (10 mg/ml) and leave on ice for 5 minutes.  
A solution containing 850 µl of PBS and 50 µl of PI (1 mg/ml) per sample was 
prepared. 900µl of staining solution was added to each sample, mixed gently and left 
on ice, protected from light, for 30 minutes. Samples were then analysed on the flow 
cytometer. Typically 10,000 events were recorded. 
2.7.3 Bivariate cell cycle analysis with BrdU and Propidium Iodide 
Bromodeoxyuridine (5-bromo-2-deoxyuridine, BrdU) is a synthetic nucleoside that is 
an analogue of thymidine. BrdU is incorporated into newly synthesized DNA of 
replicating cells (during S phase), substituting for thymidine during DNA replication. 
Antibodies specific for BrdU can then be used to detect the incorporated chemical, 
thus indicating cells that were actively replicating their DNA. Flow cytometry allows 
simultaneous measurement of incorporated BrdU as well as the DNA content on a 
single cell level. Binding of the antibody requires denaturation of the DNA using 
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acid.(327) The BrdU technique offers more specific information regarding cell cycle 
kinetics than PI staining is able to provide. 
2.7.3.1 BrdU staining and isolation of cells 
Cells were treated with 20 μM (final concentration) of BrdU (from 1 mM stock, 
Sigma) for 60 minutes prior to harvesting media and cells into a 15 ml Falcon tube. 
Cells were centrifuged at 350 g for 5 minutes and washed in cold PBS, two times. 
Cell concentration was determined using the coulter counter and the protocol 
proceeded with 2 million cells per sample. 
Citrate buffer with spermine was added (1 ml per million cells) to allow extraction of 
nucleii, the sample vortexed gently, then left on ice for 10 minutes. Subsequently, 10 
ml of PBS was added and the sample centrifuged at 470 g for 5 minutes at 4°C. The 
pellet was washed in PBS/0.5% Tween-20 then centrifuged again. The PBS/Tween-
20 was aspirated leaving a small volume (50 μl) above the pellet. 
2.7.3.2 Fixation 
 The tube containing the sample was tapped vigorously several times to turn the 
pellet into a fine suspension. 3 ml of ice cold 70% Ethanol was added dropwise while 
vortexing constantly at low speed. The samples were then placed on ice for 1 hour. 
2.7.3.3 DNA denaturation 
The nuclei were centrifuged at 470 g for 5 minutes at 4°C and the Ethanol aspirated. 
Each sample was tapped vigorously to re-suspend the pellet which was then washed 
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with PBS/0.5% Tween-20, vortexed briefly, then centrifuged again. The PBS/Tween 
was aspirated following which 50 μl of stock RNAase was added to each pellet. 
The nuclei pellet was re-suspended by tapping and denatured by adding 1 ml of 2N 
HCL/0.5% TritonX-100 dropwise whilst constantly vortexing. The first few drops 
are added very slowly to prevent irreversible aggregation. The samples were 
incubated at room temperature for 30 minutes. This step denatures the DNA to 
facilitate binding of the primary antibody to BrdU. 
The acid is neutralised by adding double volume of 0.1 M sodium tetraborate 
(pH8.5) and incubating on ice for 10 minutes. Samples were then washed twice in 
PBS/0.5% Tween-20/1% BSA and centrifuged at 470 g for 5 minutes at 4°C. 
PBS/Tween-20/BSA was aspirated leaving 80 μl above the pellet. 
2.7.3.4 Immunofluorescent staining 
20µl of anti-BrdU mouse monoclonal antibody (BD Bioscience, BD347580) were 
added to each sample and the pellet re-suspended by gently vortexing. After 
incubating at room temperature for 30 minutes, a further wash with PBS/0.5% 
Tween-20/1%BSA was performed, nuclei were pelleted at 470 g for 5 minutes at 
4°C, and then the PBS/Tween-20/BSA aspirated leaving l00 μl above the pellet. 2.7 
µl of FITC-conjugated goat anti-secondary antibody (Sigma, F2012) were added to 
each sample which was then re-suspended by gentle vortexing and then incubated in 
the dark for 30 minutes. The sample was washed again in PBS/0.5% Tween-20 and 
pelleted as before. The supernatant was aspirated and the sample tube tapped 
vigorously and vortexed to turn the pellet into a fine suspension. 1 ml of propidium 
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iodide (10 μg/ml) was added to each sample, vortexed and then incubated on ice for 
30 minutes, protected from light, prior to analysing on the flow cytometer. 
2.7.4 Annexin V apoptosis detection 
During apoptosis, cells undergo a number of morphological changes, including 
surface changes, which eventually result in recognition and uptake by phagocytes. In 
apoptotic cells, loss of plasma asymmetry results in the membrane phospholipid 
phosphatidylserine (PS) being translocated from the inner to the outer leaflet of the 
plasma membrane, thereby exposing PS to the external cellular environment.(328) 
Annexin V is a 35-36 kDa Ca
2+
-dependent phospholipid-binding protein that has a 
high affinity for PS, and binds to cells with exposed PS. Annexin V may be 
conjugated to fluorochromes including FITC without loss of affinity and thus serves 
as a sensitive probe for flow cytometric analysis of cells that are undergoing 
apoptosis. Since externalization of PS occurs in the earlier stages of apoptosis, FITC 
Annexin V staining can identify apoptosis at an earlier stage than assays based on 
nuclear changes such as DNA fragmentation. 
FITC Annexin V staining precedes the loss of membrane integrity which 
accompanies the latest stages of cell death resulting from either apoptotic or necrotic 
processes. Therefore, staining with FITC Annexin V is typically used in conjunction 
with PI to evaluate sub populations at different stages of apoptosis. Viable cells with 
intact membranes exclude PI, whereas the membranes of dead and damaged cells are 
permeable to PI. For example, cells that are considered viable are FITC Annexin V 
and PI negative; cells that are in early apoptosis are FITC Annexin V positive and PI 
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negative; and cells that are in late apoptosis or already dead are both FITC Annexin 
V and PI positive.(329) 
2.7.4.1 Preparation of controls 
In order to set up the parameters on the flow cytometer and adjust for channel colour 
compensation, a positive control was created by inducing apoptosis in cells using 
staurosporine, a tyrosine kinase inhibitor. Staurosporine (LC Laboratories), made up 
in DMSO to stock 1 mM, was incubated with cells for 4 hours at a working 
concentration of 1 µg/ml. 
Negative controls were generated by incubating cells with a comparable volume of 
DMSO. 
Instrument settings used for the annexin V assay in this thesis are shown in the 
Appendix section 6.1. 
2.7.4.2 Isolation of cells and staining 
Cells and their media were harvested and centrifuged at 150 g for 5 minutes at 4°C 
(NB: floating cell populations within the media represent late stage apoptotic and 
necrotic cells and excluding these may compromise the results). The pellet was 
washed twice in cold PBS then resuspended in 1ml of cold 1X Aposcreen™ Annexin 
V binding buffer (1 part diluted in 9 parts H2O from 10X stock, Southern Biotech, 
10045-01) to a concentration of 1x10
6
 to 1x10
7
 cells/ml and kept on ice. 100 µl of 
each sample was aliquoted into a flow cytometer tube and 10 µl of Aposcreen™ 
Annexin V Fluorescein (FITC) conjugate (Southern Biotech, 10038-02) added. The 
samples were vortexed gently and left in ice for 15 minutes protected from the light. 
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380 µl of cold 1X binding buffer was then added to each sample followed by 10 µl of 
PI (50 µg/ml) and the samples analysed on the flow cytometer immediately. Results 
were obtained from 20,000 events. 
2.7.5 Detection of EGFR membrane expression 
Flow cytometry was used to detect surface expression of EGFR as opposed to total 
EGFR as measured by western blot.  
Cells (1x10
6
) were harvested and centrifuged at 400 g for 5 minutes at 4°C. Media 
was removed and the pellet resuspended in 1 ml of ice cold PBS/10% FBS. The 
sample was then incubated with 10 µl of Phycoerythrin-conjugated anti-EGFR 
antibody (ICR10, Abcam, ab27764) for 30 minutes protected from the light. The 
cells were then centrifuged at 400 g for 5 minutes at 4°C and washed three times in 
PBS/10%PBS. After the final wash, the cells were resuspended in PBS/10%FBS and 
taken for analysis whilst still protecting from the light. 
2.8 Statistical analysis 
Statview version 5·0 (SAS Institute Inc, Cary, North Carolina, USA) was used for 
statistical analysis. A P value of less than 0.05 was considered significant. 
Comparisons between groups were made using the non-parametric continuity 
corrected χ2 test. Survival analyses were performed using overall 5-year survival, 
calculated as time elapsed from the date of diagnosis to censoring at last contact with 
patient or death. Patients who died within 30 days of surgery were excluded from all 
survival analysis. Kaplan-Meier curves were used to evaluate the effect of GRP78 
expression on survival; P values were calculated using the logrank test. A univariate 
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Cox proportional hazard regression was performed to assess the statistical 
significance of each clinical or pathological factor in relation to survival. A 
multivariate Cox regression model was performed using a stepwise forward selection 
process informed by the Akaike information criterion or AIC,(330, 331) which is a 
statistical estimate of the trade-off between the likelihood of a model against its 
complexity, with a lower value indicating a better model. The likelihood ratio χ² 
statistic was also assessed as an indicator of the global goodness of fit of the Cox 
model. Thus, prediction bias due to over-fitting the model should be avoided.  
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3 GRP78 expression as a predictive biomarker of response to adjuvant 
fluorouracil-based therapy in colorectal cancer 
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3.1 Results 
3.1.1 Antibody validation and optimisation for immunohistochemistry 
In view of the mixed reports of GRP78 expression in different tumour types (see 
section 1.3.4), it was hypothesised that some of these differences may be due to 
antibody specificity. A literature search was performed to identify papers that used 
antibodies to human GRP78 in immunohistochemistry. The results are summarised 
in Table 3.1-1 below. 
Table 3.1-1: Papers studying immunohistochemical elevated expression of GRP78 
Tissue type Reference GRP78 antibody Survival 
Gastric (277) sc1050 (Santa Cruz Biotechnology) Worse 
Oesophagus (287) anti-GRP78 (abcam) Improved 
Breast 
(296) sc-1050 (Santa Cruz Biotechnology) Not specified 
(332) sc-13968 (Santa Cruz Biotechnology) Not specified 
Lung (285) 
Anti-GRP78 (Santa Cruz 
Biotechnology) Not specified 
Improved 
Prostate 
(280) sc-13968(Santa Cruz Biotechnology) Worse 
(279) sc-13968(Santa Cruz Biotechnology) Worse 
Head and 
Neck 
(275) sc-1050 (Santa Cruz Biotechnology) Not specified 
Melanoma (333) sc-13968(Santa Cruz Biotechnology) Worse 
Colon 
(315) sc-1050 (Santa Cruz Biotechnology) Not specified 
(316) 
Anti-GRP78 (Santa Cruz 
Biotechnology) Not specified 
Not specified 
(318) sc-1050 (Santa Cruz Biotechnology) Improved 
Liver (334) 
Anti-GRP78 (Santa Cruz 
Biotechnology) Not specified 
Not specified 
Neuroblastoma (286) 
Anti-GRP78 (Santa Cruz 
Biotechnology) Not specified 
Improved 
 
Results 1 
____________________________________________________________________ 
101 
 
Two antibodies used in published studies of GRP78 expression by 
immunohistochemical analysis (Santa Cruz Biotechnology antibodies to GRP78 sc-
1050 and sc-13968) were selected for pre-validation. Cells were cultured for 24 
hours in normal media or normal media supplemented with 1nM EGF-SubA 
(Sibtech. Inc.) or vehicle control. EGF-SubA (discussed in section 1.3.5.2) contains a 
fusion of EGF (which provides targeting to EGFR expressing cells) and the A sub-
unit of a bacterial AB5-type endotoxin with subtilisin-like proteolytic activity which 
has only one known substrate: GRP78 and cleaves a di-leucine motif (Leu416-Leu417) 
in an exposed loop that links two GRP78 domains: the ATPase and the substrate-
binding domain. Thus treating EGFR positive cells with EGF-SubA enables 
confirmation of the identity of c. 78kDa bands obtained by western blotting with 
antibodies to GRP78.  
Whereas the sc-1050 antibody () shows non-specific staining with a band running in 
advance of the 78kDa band that is not abolished by EGF-SubA treatment and we 
suspect is HSP72 (GRP78 shares 85% identity with HSP72), the sc-13938 antibody 
(Figure 3.1.1-2) shows minimal non-specific staining recognising a single protein 
band that is almost completely abolished following treatment with EGF-SubA 
inferring suitability for use in IHC.  
Also note that sc-1050 with epitope mapping at the N-terminus of GRP78 detects the 
cleaved N-terminus 44 kDa fragment whereas sc-13968 with epitope mapping the C-
terminus of GRP78 detects the cleaved C-terminus 28 kDA fragment following 
exposure to EGF-SubA. 
In order to confirm if the additional band seen with sc-1050 is HSP72, SW480 cells 
were cultured for 24 hours in normal media or media supplemented with 
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Geldanamycin (LC Laboratories, NSC-122-750) with or without 1 nM EGF-SubA or 
vehicle control. Geldanamycin is a HSP90 inhibitor that is known to up-regulate 
HSP72.(335) Geldanamycin treatment resulted in increased expression of HSP72 
(and GRP78 to a lesser degree) on western blot (see lanes 2 and 3) and this signal co-
migrated with the band detected using the anti-GRP78 antibody sc-1050 (lanes 5 and 
6, Figure 3.1.1-3). Although HSP72 closely resembles GRP78 it lacks the di-leucine 
motif (Leu416-Leu417) cleavage site and is therefore not subject to cleavage by EGF-
SubA. In vitro, high doses of purified SubA are unable to cleave even the most 
closely related chaperones of the HSP70 family.(311) Importantly, it was observed 
that the band detected with sc-1050 is not degraded in the presence of EGF-SubA 
(lane 6, Figure 3.1.1-3). 
It can thus be concluded that the sc-1050 antibody recognises HSP72 at higher levels 
in colorectal cells than GRP78 and this antibody clearly is not appropriate for use in 
IHC where subtleties of protein mass cannot be discriminated. Since the anti-GRP78 
antibody sc-13968 predominantly detects only GRP78 we proceeded to use this to 
investigate GRP78 expression in our cohort of CRC samples. 
Initial trial staining of paraffin-embedded formalin-fixed tissue sections, using the 
method described in section 0, was performed using sc-13968 anti-GRP78 antibody 
at varying concentrations from 1:50, 1:100 and 1:200 to identify the optimal 
concentration to use on the tissue microarray. At concentrations of 1:100 and 1:200, 
GRP78 staining was too weak for accurate interpretation whereas at 1:50, good 
cytoplasmic staining was evident without excessive non-specific staining so this was 
used as the final working concentration. GRP78 expression was detected in the 
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cytoplasm of all carcinoma sections with sparing of the nucleus as shown in Figure 
3.1.1-4. 
 
Figure 3.1.1-1:Western blot demonstrating immunostaining for GRP78 with sc-1050. 
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Cells were incubated with 1 nM EGF-SubA (SibTech) or vehicle control for 24 hr then harvested. Cell lysate 
from a head and neck cell line with confirmed GRP78 expression was used as a control. Cell lysates (50 µg per 
lane) were subject to western blot using goat polyclonal anti-GRP78 antibody (sc-1050, Santa Cruz) that 
recognises GRP78 and the 44 kDa cleaved GRP78 fragment. A further band c.70 kDa that is not subject to 
cleavage by EGF-SubA is also noted with this antibody. 
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Figure 3.1.1-2: Western blot demonstrating immunostaining for GRP78 with sc-13968 
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Performed essentially as in  but using the rabbit polyclonal anti-GRP78 antibody (sc-13968, Santa Cruz) that 
recognises GRP78 and the 28 kDa cleaved fragment. Cells were incubated with 1 nM EGF-SubA (SibTech) or 
vehicle control for 24 hr then harvested. Cell lysate from a head and neck cell line with confirmed GRP78 
expression was used as a control. Cell lysates (50 µg per lane) were subject to western blot using rabbit 
polyclonal anti-GRP78 antibody 
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Figure 3.1.1-3: Western blot comparing detection of GRP78 using two different 
monoclonal antibodies; sc-1050 and sc-13968. 
 
 
 
 
 
Figure 3.1.1-4: Representative sections of colon cancer stained with an antibody to 
GRP78 demonstrating cytoplasmic immunoreactivity with nuclear sparing.  
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SW480 cells were incubated with either EGF-SubA 1 nM (SibTech) or Geldanamycin 10 µM (LC Labs), a 
combination of these, or vehicle control for 24 hr. Cell lysates were subjected to western blot using antibodies to 
GRP78 (sc-13968 and sc-1050, Santa Cruz) and mouse monoclonal antibody to HSP72 (Cambridge Bioscience). 
Tubulin was used as a loading control. 
FFPE sections of colon cancer were subject to immunohistochemistry using anti-GRP78 antibody sc-13968 
(Santa Cruz). Original magnification x40. (A) Colon carcinoma section stained using sc13968 anti-GRP78 
antibody. (B) Colon carcinoma stained without primary antibody as a control. 
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Following discussion with Dr Fiona Campbell (Consultant Pathologist) and Mr Andy 
Dodson (Dept. of Pathology) after initial trial staining on tissues section, it was 
suggested that the DAB time (see section 2.1.4) could be slightly prolonged without 
causing excessive non-specific staining and that excessive haematoxylin 
counterstaining should be avoided as this can mask areas of weak DAB staining. 3, 
3’ Diaminobenzidine (DAB) is a widely used chromogen for immunohistochemical 
staining and immunoblotting. In the presence of horseradish peroxidase and 
hydrogen peroxide, DAB oxidatively polymerizes to a brown polymer that is 
insoluble in alcohol and xylene. Due to the kinetics of DAB staining, the DAB time 
can be extended to some extent without causing significant non-specific staining.  
 
Figure 3.1.1-5: Illustration of the effect of DAB time on non-specific staining.  
 
 
Following these modifications, a tissue microarray was examined for GRP78 
expression.  
DAB Time
Non-specific 
staining
A B C
A, insufficient chromogenic staining; B, optimal staining; C, risk of non-specific staining. (Personal 
communication from Mr Andy Dodson) 
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3.1.2 Patients 
Appropriate ethical approval for use of this material for my research was obtained 
from Liverpool Adults Research Ethics Committee (REC 04/Q1505/125). Written 
consent for procurement and storage of tissue samples was sought before surgery 
after a full written and verbal explanation. Three hundred and ninety-six (194 colon, 
202 rectal) consented patients who underwent surgery for colorectal cancer at the 
Royal Liverpool University Hospital, UK, between 1993 and 2003 were studied. 
Overall 5 year survival for this cohort was 46%. 114 patients (29%) received 
fluoropyrimidine-based adjuvant chemotherapy delivered at Clatterbridge Centre for 
Oncology NHS Foundation Trust, Wirral, UK. Of these, five patients with stage II 
disease were randomised to receive chemotherapy according to the QUASAR 
protocol (six 5-day courses every 4 weeks or as 30 once-weekly courses of 
intravenous (i.v.) fluorouracil (FU) (370 mg/m2) with high-dose (175 mg) L-folinic 
acid (FA) or low-dose (25 mg) FA),(83) and two patients were randomised to receive 
additional oxaliplatin as part of the MOSAIC trial (a 2-hour infusion of 200 mg of 
leucovorin per square meter of body-surface area followed by a bolus of FU (400 
mg/m
2
) and then a 22-hour infusion of FU (600 mg/m
2
) given on 2 consecutive days 
every 14 days, for 12 cycles plus a two-hour infusion of oxaliplatin (85 mg/m
2
) on 
day 1, given simultaneously with leucovorin).(92) A further two patients received 
additional irinotecan (Irinotecan 180 mg/m
2
 i.v.) for metastatic disease. The 
remaining patients received treatment according to local protocol which was i.v. FU 
and FA as per QUASAR or a modified de Gramont regimen (fixed dose leucovorin 
350 mg (or 175 mg) as a 2-hour i.v. infusion; then i.v. FU bolus over 5 min; then 46-
hour FU infusion, repeated every 14 days).(336) Decisions regarding adjuvant 
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chemotherapy were determined by patient choice, performance status and co-
morbidities. 41 patients received further chemotherapy for relapse using additional 
agents such as irinotecan, oxaliplatin, and mitomycin C. Short course pre-operative 
radiotherapy was given to 13% with rectal cancer as part of the CR07 trial (25 Gy 
administered in 5 fractions over 1 week followed by surgery within 1 week)(111) and 
15% received long course radiotherapy (45 Gy in 25 daily fractions over 5 weeks 
followed by surgery after 6-10 weeks). Tumours were staged using the TNM method 
(337). Median follow up was 49.5 months (range 0.23-146.5). 
3.1.3 The colorectal tissue microarray 
In order to examine whether the expression of GRP78 in colorectal tumours affects 
patients survival and response to adjuvant chemotherapy, I made use of a large 
colorectal tissue microarray (TMA) that exists locally due, in a large part, to the 
efforts of Ms Elizabeth Tweedle. A database with matched clinicopathological data 
was made available by Ms Tweedle including mortality data obtained from the North 
West Cancer Intelligence Service, Liverpool. Further data regarding chemotherapy, 
obtained from Clatterbridge Centre for Oncology, Wirral, was kindly provided by Mr 
Chin Wee Ang. 
Tissue microarrays were created from 482 formalin-fixed paraffin-embedded 
primary tumours obtained from the Liverpool Tissue Bank Research Centre, 
University of Liverpool, and include two to six representative cores from each 
carcinoma and 16 cores each of normal kidney, liver, and testis which served as 
internal control tissues. The cores were arranged over 7 TMA’s which were stained 
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simultaneously using the same stock of anti-GRP78 antibody (sc-13968) as used in 
the optimisation experiments. 
Some patients were excluded from analysis due to cores being lost from the slides 
during processing or cores were too fragmented to interpret. Of the original 482 
patients, acceptable cores and full data were available for 396 patients. 
3.1.4 Scoring the tissue microarray 
A review of immunohistochemical studies in human cancers reveals no standard 
scoring system of immunoreactivity of GRP78. A number of semi-quantitative 
scoring systems have been described with results demonstrating statistically 
significant correlations with clinical outcome. These consist of scoring systems based 
upon intensity of immunoreactivity (negative, weak, moderate and strong in most 
cases), and the percentage of cells with reactivity (0-100%). In the majority of 
studies, a final score is awarded based upon either the sum of intensity and 
percentage reactivity or their factor.(277, 280, 285-287, 316, 333, 334) 
The integral control tissues of testis, normal kidney, and liver meant that each TMA 
essentially had a range of positive controls with testis staining weakly, liver staining 
strongly (not surprising given that the major function of hepatocytes is protein 
synthesis), and kidney showed intermediate staining. A row of control tissue is 
highlighted in Figure 3.1.4-1 above.  
GRP78 immunoreactivity was seen ubiquitously in the cytoplasm of colonic 
carcinoma cells, and all tumour cells in a given patient stained equally. Minimal 
staining was evident in stromal tissue. Staining was categorised semi-quantitatively 
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using a scale of 0-3: 0 = negative, 1 = weak positive, 2 = intermediate positive and 3 
= strongly positive (Figure 3.1.4-2).  
The addition of a percentage positivity score was omitted in view of the uniform 
pattern of staining seen among tumour cells. The highest score from duplicate cores 
on the microarray was accepted for analysis. For data analysis, GRP78 expression 
was dichotomised based upon the mean score from the whole cohort (1.5) into either 
low expression (intensity 0 or 1), or high expression (intensity 2 or 3). Scoring was 
performed by a gastrointestinal histopathologist (Dr Fiona Campbell) who had no 
knowledge of the clinicopathological data of the patients. 
 
 
 
Figure 3.1.4-1: A section of the colorectal tissue microarray.  
 
Row of 
control cores 
An example of one of the slides holding a section of the colorectal tissue microarray following staining and 
fixation. From this picture it is possible to identify differential staining of the individual cores of tissue. 
Results 1 
____________________________________________________________________ 
111 
 
 
Figure 3.1.4-2: Immunohistochemical analysis of GRP78 expression in representative 
samples.  
 
 
 
A B
C D
E F
G H
The TMA was stained using the rabbit polyclonal antibody specific for GRP78 (sc13968, Santa Cruz). This figure 
illustrates magnified views of representative cores from TMA. Control tissues (A) normal colon, (B) testis, (C) 
kidney, and (D) liver, gave a range of staining intensity for each section of the TMA; and colorectal cancer 
samples demonstrating  (E) no staining=0, (F) weak staining=1, (G) moderate staining=2, and (H) strong 
staining=3. Original magnification x40. 
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3.1.5 GRP78 expression in colorectal cancer 
Of 41 cases where matched normal colonic epithelium was available to score, 
GRP78 expression was significantly elevated (intensity 2 or 3) in 16 of 41 cancers 
vs. 1 of 41 matched normal colonic epithelium (P<0.001, Error! Reference source 
not found.).  
Table 3.1-2:GRP78 expression in 41 patient-matched normal colon tissue and colonic 
adenocarcinoma 
Tissue type 
(n=41) 
Staining intensity P 
 0 1 2 3  
Normal tissue 7 33 1 0  
Adenocarcinoma 0 25 14 2 P<0.001 
Data are number of patients. χ2 test was used for comparison of variables. 
 
3.1.6 Correlation of GRP78 with clinicopathological parameters 
In keeping with a previous study,(316) no correlation could be found between 
GRP78 expression and gender, age, nodal status (pN stage), differentiation, tumour 
size, resection margin status, or administration of preoperative radiotherapy. There 
was a significant association between GRP78 expression and depth of invasion (pT, 
P=0.029) and stage (P=0.032) as shown in Table 3.1-3. This effect was largely due to 
GRP78 expression in rectal cancer and not colon cancer as shown in Table 3.1-4 and 
Table 3.1-5. Also of note is the observation that the administration of preoperative 
radiotherapy to rectal cancers did not lead to any difference in GRP78 expression. 
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Table 3.1-3: Association between GRP78 expression and clinicopathological parameters 
in 396 patients with colorectal cancer treated by surgery 
Characteristic 
  
GRP78 High GRP78 Low P-Value  
  n=396 % n=162 % n=234 %   
Gender 
       
Male 248 62.6 102 63.0 146 62.4 
 
Female 148 37.4 60 37.0 88 37.6 0.964 
Age 
       
<68 yrs 178 45 69 42.6 109 46.6 
 
68yrs≤ 218 55 93 57.4 125 53.4 0.433 
pT 
       
T1 19 4·8 7 4.3 12 5.1 
 
T2 59 14.9 16 9.9 43 18.4 
 
T3 265 66.9 110 67.9 155 66.2 
 
T4 53 13.4 29 17.9 24 10.3 0.029 
pN 
       
N0 222 56.1 82 50.6 140 59.8 
 
N1 99 25.0 46 28.4 53 22.6 
 
N2 75 18.9 34 21.0 41 17.5 0.19 
Stage 
       
I 60 15.2 16 9.9 44 18.8 
 
II 162 40.9 66 40.7 96 41.0 
 
III 174 43.9 80 49.4 94 40.2 0.032 
Differentiation 
       
Well 10 2.5 3 1.9 7 3 
 
Moderate 354 89.4 147 90.7 207 88.5 
 
Poor 28 7.1 12 7.4 16 6.8 
 
Unrecorded 4 1.0 0 0 4 1.7 0.755 
Tumour size 
       
<60mm 275 69.4 115 71.0 160 68.4 
 
>60mm 121 30.6 47 29.0 74 31.6 0.579 
Resection margin 
      
Clear 351 88.6 138 85.2 213 91.0 
 
Involved 44 11.1 23 14.2 21 9.0 
 
Unrecorded 1 0.3 1 0.6 0 0 0.099 
Adjuvant chemotherapy 
      
No 282 71.2 110 67.9 172 73.5 
 
Yes 114 28.2 52 32.1 62 26.5 0.226 
Stage I, pT1-2/pN0; Stage II, pT3-4/pN0, Stage III, pT1-4/pN+ 
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Table 3.1-4: Association between GRP78 expression and clinicopathological parameters 
in colon cancers 
 
Colon Cancers 
Characteristic 
  
GRP78 High GRP78 Low   P-Value 
  n=194 % n=83 % n=111 %   
Gender 
       
Male 101 52.1 44 53 57 51.4 
 
Female 93 47.9 39 47 54 48.6 0.819 
Age 
       
<68 yrs 79 40.1 35 42.2 44 40 
 
68yrs≤ 115 59.9 48 57.8 67 60 0.723 
pT 
       
T1 12 6.2 5 6 7 6.3 
 
T2 18 9.3 5 6 13 11.7 
 
T3 127 65.5 55 66.3 72 64.9 
 
T4 37 19.1 18 21.7 19 17.1 0.533 
pN 
       
N0 114 58.8 47 56.6 67 60.4 
 
N1 43 22.2 21 25.3 22 19.8 
 
N2 37 19.1 15 18.1 22 19.8 0.66 
Stage 
       
I 24 12.4 10 12 14 12.6 
 
II 90 46.4 37 44.6 53 47.7 
 
III 80 41.2 36 43.4 44 39.6 0.871 
Differentiation 
       
Well 4 2.1 1 1.2 3 2.7 
 
Moderate 175 90.2 76 91.6 99 89.2 
 
Poor 13 6.7 6 7.2 7 6.3 
 
Unrecorded 2 1.0 0 0 2 1.8 0.745 
Tumour size 
       
<60mm 125 64.4 55 66.3 70 63.1 
 
>60mm 69 35.6 28 33.7 41 36.9 0.649 
Resection margin 
      
Clear 179 92.3 74 89.2 105 94.6 
 
Involved 14 7.2 8 9.6 6 5.4 
 
Unrecorded 1 0.5 1 1.2 0 0 0.249 
Adjuvant chemotherapy 
     
No 147 75.8 60 72.3 87 78.4 
 
Yes 47 24.2 23 27.7 24 21.6 0.327 
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Table 3.1-5: Association between GRP78 expression and clinicopathological parameters 
in rectal cancers 
 
Rectal Cancers 
Characteristic 
  
GRP78 High GRP78 Low P-Value  
  n=202 % n=79 % n=123 %   
Gender 
       
Male 147 72.8 58 73.4 89 72.4 
 
Female 55 27.2 21 26.6 34 27.6 0.869 
Age 
       
<68 yrs 99 49 34 43 65 52.8 
 
68yrs≤ 103 51 45 57 58 47.2 0.174 
pT 
       
T1 7 3.5 2 2.5 5 4.1 
 
T2 41 20.3 11 13.9 30 24.4 
 
T3 138 68.3 55 69.6 83 67.5 
 
T4 16 7.9 11 13.9 5 4.1 0.031 
pN 
       
N0 108 53.5 35 44.3 73 59.3 
 
N1 56 27.7 25 31.6 31 25.2 
 
N2 38 18.8 19 24.1 19 15.4 0.098 
Stage 
       
I 36 17.8 6 7.6 30 24.4 
 
II 72 35.6 29 36.7 43 35.0 
 
III 94 46.5 44 55.7 50 40.7 0.007 
Differentiation 
       
Well 6 3 2 2.5 4 3.3 
 
Moderate 179 88.6 71 89.9 108 87.8 
 
Poor 15 7.4 6 7.6 9 7.3 
 
Unrecorded 2 1.0 0 0 2 1.6 0.952 
Tumour size 
       
<60mm 150 74.3 60 75.9 90 73.2 
 
>60mm 52 25.7 19 24.1 33 26.8 0.659 
Resection margin 
      
Clear 172 85.1 64 81.0 108 87.8 
 
Involved 30 14.9 15 19.0 15 12.2 
 
Unrecorded 0 0 0 0 0 0 0.185 
Adjuvant chemotherapy 
     
No 135 66.8 50 63.3 85 69.1 
 
Yes 67 33.2 29 36.7 38 30.9 0.392 
Neoadjuvant radiation 
     
No 143 70.8 55 69.6 88 71.5 
 
Yes 59 29.2 24 30.4 35 28.5 0.769 
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3.1.7 Survival and pathological factors 
The overall 5-year survival for this cohort was 47% (Figure 3.1.7-1). This is in 
keeping with national figures from the late 1990’s that quote five-year survival of 
47% for colon cancer in both sexes, and 49% and 51% for rectal cancer in men and 
women respectively.(6)  
As expected, survival was worse with increasing stage (P<0.001), presence of nodal 
metastasis (P<0.001), incomplete (R1) excision of the tumour (P<0.002), and poor 
differentiation (P=0.023). 
The survival for patients with stage III disease is within the range of figures 
commonly quoted of between 27% and 60% (48) depending upon depth of invasion 
and degree of nodal involvement, however, the survival of patients with stage I and 
stage II is comparatively low. There are several possible explanations for this. As 
well as there being fewer stage I cancers than II or III, subgroup analysis reveals a 
difference in the mean age of patients at time of diagnosis between cancer stages; 
69.9yrs (+/- 8.6yrs) for stage I, 68.5yrs (+/- 10.4yrs) for stage II, and 66.5yrs (+/- 
11.8) for stage III disease. The older age of the stage I subgroup may in part 
contribute to the observed poor survival. Furthermore, and probably of more 
significance, the Mersey region has some of the lowest life expectancy (76yrs for 
men and 81yrs for women), (338) and worst cancer survival figures in the whole of 
England and Wales, both during the study period and to the present day.(339) The 
relatively low proportion of patients with stage I disease would suggest that patients 
in our region generally have more advanced disease at presentation. Evidence to 
support this comes from a European study (EUROCARE high resolution study on 
colorectal cancer)(340) that examined data from 11 European regions between 1988 
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and 1991, and reported that, in addition to one of the worst 3 yr survival rates in the 
regions studied (44% compared with highest of 59%), Mersey also had a 
proportionately higher number of Dukes C and D, and lower number of Dukes A and 
B cases during this period. 
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Figure 3.1.7-1: Kaplan-Meier plots demonstrating overall 5yr survival for the whole 
cohort (excluding those who died within 30 days of surgery) stratified by pathological 
variables. 
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3.1.8 GRP78 expression, survival and benefit from adjuvant chemotherapy 
Better overall five-year survival was associated with elevated GRP78 expression in 
the whole cohort (53% v 42%; P=0.036, Figure 3.1.8-1A). Patients with stage II 
cancers treated by surgery alone with high GRP78 expression had improved survival 
(71% v 50%; P=0.032, Figure 3.1.8-1B). Insufficient numbers of stage II patients 
received adjuvant chemotherapy (n=32) to perform meaningful analysis of the 
influence of GRP78 expression. 
Eighty patients with stage III cancer (46 rectal and 34 colon cancers) received 5-FU 
based adjuvant chemotherapy with a survival benefit of 10% at 5 years (40% v 30%; 
P=0.15, Figure 3.1.8-2). Of all patients who received adjuvant chemotherapy, 
elevated GRP78 predicted a better overall survival than low GRP78 (56% v 32%; 
P=0.008, Figure 3.1.8-2). As Figure 3.1.8-3 clearly demonstrates, elevated GRP78 
predicts significant benefit from adjuvant chemotherapy (52% v 28%; P=0.026), 
whereas patients with low GRP78 failed to benefit (28% v 32%; P=0.805). Overall 
5yr survival of stage III patients treated by surgery alone was not significantly 
different between high and low GRP78 expression (28% v 30%), however median 
survival was better by 7 months in the elevated GRP78 compared with the low 
GRP78 group (2·668 v 2·094 yrs, data not shown). 
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Figure 3.1.8-1: Kaplan-Meier plots showing overall 5yr survival according to GRP78 
expression in the whole cohort (A); Stage II cancers (excluding patients who received 
adjuvant chemotherapy) (B). (Adj.CT=adjuvant chemotherapy) 
 
  
Figure 3.1.8-2: Kaplan-Meier plot demonstrating, (A) overall survival according to 
treatment in Stage III cancers; (B) overall survival in those who received adjuvant 
chemotherapy (all stages) according to GRP78 expression. 
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Figure 3.1.8-3: Kaplan-Meier plots showing overall survival according treatment in 
Stage III cancers with high GRP78 (A), or low GRP78 (B).  
 
3.1.9 Univariate and Multivariate analysis 
Following the observation that patients whose tumours exhibited elevated GRP78 
expression had better overall 5yr survival than those with low GRP78, a univariate 
and multivariate Cox proportional hazards regression analysis was performed to see 
if GRP78 was an independent prognostic indicator in this cohort. The Cox model 
was constructed as described in section 2.8 on page 97.  
Multivariate analysis demonstrated low GRP78 to be an independent prognostic 
indicator of overall 5-year survival (P=0.004; HR=1.551; 95%CI 1.155-2.082). Age 
(P=0.009; HR=1.017; 95%CI 1.004-1.030), positive nodal status (P<0.001; 
HR=1.871; 95%CI 1.399-2.502), complete excision (P=0.01; HR=0.585; 95%CI 
0.390-0.878) and poor differentiation (P=0.035; HR=1.703; 95%CI 1.039-2.791)  
were also found to be independent prognostic indicators (Table 3.1-6).  
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As a key finding of the survival analysis was the observation that patients who 
benefitted the most from adjuvant chemotherapy were those with elevated GRP78, 
the univariate and multivariate analysis were repeated on the subgroup of 114 
patients who received chemotherapy following surgery. The results are demonstrated 
below in Table 3.1-7. Weak GRP78 expression remains a significant predictor of 
poor prognosis in the subgroup of patients who received adjuvant chemotherapy 
(P=0.016; HR=1.896; 95%CI 1.128-3.189). This observation suggests GRP78 has 
value as a treatment predictive biomarker. 
In contrast, when a similar analysis is performed on patients treated by surgery alone 
(all stages), with no adjuvant chemotherapy, (Table 3.1.9-) the prognostic value of 
GRP78 was not as robust in the Cox analysis (P=0.067; HR=1.393; 95%CI 0.977-
1.988). This raises doubt as to the value of GRP78 as a potential prognostic 
biomarker when applied across all stages of disease. However, when this analysis 
was restricted to those with Stage II disease, weak GRP78 did predict poorer 
prognosis (P=0.015; HR=2.164; 95%CI 1.165-4.021). 
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Table 3.1-6: Association between GRP78 expression and overall 5 year survival for the 
whole cohort. 
  
 
Univariate  Multivariate 
Variable n HR 95%CI χ2  P-value HR 95%CI χ2  P-value 
Age 389 1.012 0.999-1.025 3.157 0.076 1.017 1.004-1.030 6.856 0.009 
Tumour size 
         
<60mm 271 0.893 0.662-1.206 0.542 0.462 - - - - 
>60mm 118 1 - - - - - - - 
pT 
         
T1 19 0.452 0.187-1.091 3.122 0.077 - - - - 
T2 58 0.934 0.564-1.545 0.072 0.789 - - - - 
T3 262 0.836 0.557-1.257 0.739 0.39 - - - - 
T4 50 1 - - - - - - - 
pN 
         
N0 220 1 - - - 1 - - - 
N1-N2 169 1.93 1.462-2.547 21.549 <0.001 1.871 1.399-2.502 17.828 <0.001 
Resection margin 
        
Clear 345 0.538 0.365-0.794 9.759 0.002 0.585 0.390-0.878 6.720 0.01 
Involved 43 1 - - - 1 - - - 
Differentiation 
        
Well/Mod 358 1 - - - 1 - - - 
Poor 27 1.717 1.070-2.756 5.023 0.025 1.703 1.039-2.791 4.458 0.035 
Grp78 expression 
        
Weak 229 1.359 1.019-1.813 4.356 0.037 1.551 1.155-2.082 8.525 0.004 
Elevated 160 1 - - - 1 - - - 
HR, Hazard Ratio; CI, confidence interval 
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Table 3.1-7: Association between GRP78 expression and overall 5 year survival for 
patients who received adjuvant chemotherapy. 
  
 
Univariate  Multivariate 
Variable n HR 95%CI χ2  P-value HR 95%CI χ2  P-value 
Age 114 1.027 0.996-1.058 2.931 0.087 1.03 0.998-1.063 3.329 0.068 
Tumour size 
         
<60mm 78 1.238 0.719-2.133 0.593 0.441 - - - - 
>60mm 36 1 - - - - - - - 
pT 
         
T1 2 0.924 0.121-7.066 0.006 0.939 - - - - 
T2 10 1.424 0.567-3.576 0.565 0.452 - - - - 
T3 81 0.898 0.484-1.668 0.116 0.734 - - - - 
T4 21 1 - - - - - - - 
pN 
         
N0 34 1 - - - - - - - 
N1-N2 80 1.372 0.789-2.386 1.255 0.263 - - - - 
Resection margin 
        
Clear 93 1.338 0.681-2.627 0.714 0.398 - - - - 
Involved 20 1 - - - - - - - 
Differentiation 
        
Well/Mod 107 1 - - - 1 - - - 
Poor 5 3.240 1.294-8.112 6.300 0.012 2.927 1.145-7.481 5.032 0.025 
Grp78 expression 
        
Weak 62 1.964 1.179-3.271 6.716 0.01 1.896 1.128-3.189 5.825 0.016 
Elevated 52 1 - - - 1 - - - 
HR, Hazard Ratio; CI, confidence interval 
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Table 3.1.9-3: Association between GRP78 expression and overall 5 year survival for 
patients treated by surgery alone. 
  
 
Univariate  Multivariate 
Variable n HR 95%CI χ2  P-value HR 95%CI χ2  P-value 
Age 275 1.015 0.998-1.032 3.086 0.079 1.01 0.993-1.026 1.334 0.248 
Tumour size 
         
<60mm 193 0.773 0.538-1.109 1.961 0.161 - - - - 
>60mm 82 1 - - - - - - - 
pT 
         
T1 17 0.414 0.150-1.140 2.915 0.088 - - - - 
T2 48 0.857 0.454-1.618 0.226 0.634 - - - - 
T3 181 0.819 0.474-1.415 0.512 0.474 - - - - 
T4 29 1 - - - - - - - 
pN 
         
N0 186 1 - - - 1 - - - 
N1-N2 89 2.310 1.646-3.243 23.419 <0.001 2.099 1.480-2.977 17.311 <0.001 
Resection margin 
        
Clear 252 0.250 0.154-0.407 31.215 <0.001 0.281 0.170-0.465 24.572 <0.001 
Involved 23 1 - - - 1 - - - 
Differentiation 
        
Well/Mod 251 1 - - - - - - - 
Poor 22 1.522 0.875-2.647 2.215 0.137 - - - - 
Grp78 expression 
        
Weak 167 1.172 0.826-1.662 0.791 0.374 1.393 0.977-1.988 3.351 0.067 
Elevated 108 1 - - - 1 - - - 
HR, Hazard Ratio; CI, confidence interval 
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3.1.10 siRNA knockdown of GRP78 
No other studies to date have examined the consequences of GRP78 expression and 
sensitivity to 5-FU in colon cancer cells. The observation of an association between 
low GRP78 and worse outcome following treatment with fluorouracil-based adjuvant 
chemotherapy in the Liverpool cohort suggests a possible functional relationship 
between GRP78 and response to 5-FU. This is potentially highly relevant as there are 
no biomarkers presently available that can predict response to 5-FU, and 
furthermore, the potential applicability of a cheap and simple immunohistochemical 
test makes GRP78 a very attractive potential biomarker. 
I performed in-vitro experiments using siRNA-transfection to elucidate a potential 
mechanistic relationship between GRP78 and 5-FU sensitivity. From the observation 
in our cohort, I hypothesised that a depletion of endogenous GRP78 would reduce 
the efficacy of 5-FU in vitro. 
I selected the HCT116p53wt cell line for several reasons. They have documented 
sensitivity to 5-FU in vitro, are easy to transfect with siRNA and in preliminary 
experiments, exhibited elevated levels of GRP78 in a non-induced state and gave 
good results on the flow cytometer as they are easy to harvest by trypsinisation. 
A set of 4 siGENOME siRNA targeting GRP78 with documented efficacy were 
purchased from Dharmacon. HCT116p53wt cells were transfected and the 
transfection efficiency was assessed by western blot to see which siRNA reagent 
produced the most effective GRP78 knockdown. I was interested to see if GRP78 
depletion remained apparent at 72 hours post transfection as this was the time point 
at which cells were to be harvested for further experiments. Short interfering RNA 
(siRNA) oligonucleotide knock-down experiments were performed as described in 
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section 2.4.1 on page 80, using a final siRNA concentration of 40 nM. A mock 
transfection control was prepared identically except for omitting the siRNA 
oligonucleotide.  
GRP78 levels were depleted by all four of the siRNA reagents selected, and this 
remained apparent after 72 hours (Figure 3.1.10-1), but siGENOME D-008198-03 
produced the most effective knockdown and was selected for further use. 
 
Figure 3.1.10-1: Western blot demonstrating GRP78 depletion after transfection with a 
panel of GRP78-targeting siRNA in HCT116p53wt cells.  
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Cells were transfected with 40nM scrambled siRNA or GRP78 siRNA using Lipofectamine 2000 as a transfection 
reagent. Mock transfected cells were treated identically except for omission of the siRNA oligomer. Cells were 
harvested at 24, 48 and 72 hrs and cell lysates subjected to western blot. Transfection efficiency was detected 
using a rabbit polyclonal antibody specific for GRP78 (sc13968, Santa Cruz). Actin was used as a loading control. 
(03 = siGENOME D-008198-03; 04 = siGENOME D-008198-04; 05 = siGENOME D-008198-05; 18 = 
siGENOME D-008198-18; all from Dharmacon). 
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3.1.11 siRNA knockdown of GRP78 reduces cell apoptosis in response to 5-FU 
I examined the effect of depleting endogenous GRP78 using siRNA in HCT116 
cells. Two days following mock treatment or transfection with GRP78-targeting or 
scrambled siRNAs, cells were treated +/-100µM 5-FU (the concentration required to 
cause 50% growth inhibition of HCT116 cells at 24 hours).(341)  
When HCT116 cells were transfected with GRP78 siRNA (siGENOME D-008198-
03) or a scrambled siRNA control, a 10% increase in cell apoptosis was measured as 
compared with a mock treated control. However, cells transfected with GRP78 
siRNA demonstrated substantially less 5-FU-induced apoptosis than the scrambled 
siRNA transfected or mock treated control at 24hrs, 19·81% versus 52·4% and 
48·54% respectively (Figure 3.1.11-1), as demonstrated by Annexin V apoptosis 
assay (section 2.7.4.). It is notable that the level of apoptosis in 5-FU treated cells 
with reduced GRP78 expression is comparable to that observed in cells in the 
absence of 5-FU treatment (Figure 3.1.11-1B), suggesting an important role for 
GRP78 in 5-FU induced apoptosis in these cells. Thus it appears that GRP78 
expression levels determine cellular sensitivity to 5-FU treatment and thus my in 
vitro data accord with the clinical data and suggest a deterministic role for GRP78 in 
the adjuvant response. This experiment was repeated using a different siRNA 
targeting GRP78 (siGENOME D-008198-05), with similar findings (see Appendix 
section 6.3). 
Analysis of knockdown efficiency was performed at the protein level by standard 
SDS-PAGE and western blotting for each experiment (Figure 3.1.11-2A). 
In support of the above findings, decreased cleaved PARP levels were detected in 5-
FU-treated GRP78 siRNA-transfected HCT116p53wt cells at 24 hours relative to 5-
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FU-treated mock treated or scrambled siRNA controls (Figure 3.1.11-2B). Together, 
these results indicate that GRP78 expression promotes apoptosis in response to 5-FU. 
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Figure 3.1.11-1:  siRNA knockdown of GRP78 attenuates the apoptotic response to 5-
FU.  
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Cells were seeded 24 hours prior to transfection with a final siRNA concentration of 40 nM. A mock transfection 
control was prepared identically except for omitting the siRNA oligonucleotide. 48 hr after transfection, cells 
were treated +/- 100 µM 5-FU (medac GmbH, Germany) for 24 hr then harvested for flow cytometry. (A) 
Bivariate distributions of Annexin V (AV)-positivity (apoptosis, FL1 parameter, x-axis) vs. Propidium iodide 
(PI)-positivity (necrosis, FL2 parameter, y-axis) were generated for each population. Viable cells were measured 
as those in the lower left quadrant (PI/AV –ve); early apoptotic cells are in the right lower quadrant (PI –ve/AV 
+ve, late apoptotic cells are in the right upper quadrant (PI +ve/AV +ve); remaining cells in the left upper 
quadrant were deemed necrotic or dead (PI +ve/AV –ve). (B) These analyses were used to generate percentages 
of viable (PI/AV –ve), apoptotic (AV +ve) or dead (PI +ve/AV-ve) cells at 24 hr of treatment.  
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Figure 3.1.11-2: siRNA knockdown of GRP78 results in reduced PARP cleavage 
following exposure to 5-FU. 
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(A) Western blot confirming GRP78 knockdown by siRNA transfection compared with mock treated and 
scrambled siRNA controls, in HCT116 p53 wild-type cells. (B) Mouse monoclonal anti-PARP antibody that 
recognises both the cleaved and uncleaved isoform (BD Transduction) reveals PARP cleavage for drug-treated 
HCT116p53wt cells at 24 hours of treatment with 100 µM 5-FU. Actin was used as a loading control. 
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3.1.12 Cell cycle analysis following siRNA knockdown of GRP78 and treatment 
with 5-FU. 
Following GRP78 depletion by siRNA, cell cycle analysis of treated or untreated 
HCT116 cells was performed (Figure 3.1.12-1) using propidium iodide as detailed in 
section 2.7.2 on page 91.  
In the p53 wild-type setting, treatment of HCT116 cells with 100 µM 5-FU for 24 
hours resulted in an increase in the number of cells in S-phase, together with a 
reduction of G1 and G2/M phase cells. This response to 5-FU is consistent with 
previous reports.(342-344) An accumulation of cells in sub G1 is also noted 
following exposure to 5-FU. It is notable that the cell cycle profile was not 
significantly affected by GRP78 siRNA transfection.  
In contrast, p53 null HCT116 cells demonstrated no such S-phase arrest after 
exposure to 5-FU (Figure 3.1.12-2), but did show a reduction of cells in G2/M, 
largely as a result of an increased number of cells in G1. This G1 arrest may 
contribute to resistance to 5-FU induced apoptosis in these p53 null cells.(126) There 
were far fewer cells in sub G1 in p53 null cells treated with 5-FU relative to drug 
treated p53 wild-type cells. Again, as in the wild-type p53 cells, GRP78 knockdown 
did not significantly affect the cell cycle. 
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Figure 3.1.12-1: siRNA knockdown of GRP78 has minimal effect upon the cell cycle. 
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(A) DNA content was measured on asynchronously growing cells using propidium iodide staining 72 hr 
following transfection with siRNA GRP78 or mock/scrambled controls. Cells were exposed to 100 µM 5-FU or 
vehicle control for 24 hr prior to harvesting. (B) The percentages of cells in various stages of the cell cycle. Sub 
G1 indicates dead cells with fragmented DNA, G1 indicates cells in the quiescent state of the cell cycle, S phase 
is a period of DNA synthesis, and G2/M indicates the period of rapid growth and mitosis. 
 
Results 1 
____________________________________________________________________ 
134 
 
 
Figure 3.1.12-2: siRNA knockdown of GRP78 has minimal effect upon the cell cycle in 
p53 null HCT116 cells. 
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(A) Cell cycle profile of HCT116p53null cells treated in the same manner as in the legend for Figure 3.1.12-1.  
DNA content was measured on asynchronously growing cells using propidium iodide staining 72 hr following 
transfection with siRNA GRP78 or mock/scrambled controls. Cells were exposed to 100 µM 5-FU or vehicle 
control for 24 hr prior to harvesting. (B) The percentages of cells in various stages of the cell cycle. 
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3.2 Discussion 1 
This study represents the largest series of colorectal cancers examined for GRP78 
expression and the first to examine its relationship to survival and its potential as a 
predictive biomarker for adjuvant chemotherapy. Having established a role for 
GRP78 in sensitivity to 5-FU in-vitro, we present evidence that GRP78 is elevated in 
colorectal cancer, is an independent prognostic indicator, and a positive predictor of 
benefit from fluoropyrimidine-based adjuvant chemotherapy. 
The reported 5-year survival rate for stage II disease is 75% after surgery but a 
subgroup of patients have survival similar to stage III patients of 50%.(345) The data 
presented here are in keeping with this with low GRP78 stage II patients showing 
overall 5 year survival of 50% (compared with 71% with high GRP78). 
Contemporary clinicopathological high risk features for stage II disease such as 
elevated carcinoembryonic antigen, obstruction or perforation, T4 stage, inadequate 
nodal resection (<12 nodes), lymphovascular invasion, and high-grade disease may 
predict worse outcome, but they do not predict response to chemotherapy.(84-86) 
Importantly, although low GRP78 can predict a poor prognostic group, our data from 
stage III disease suggest these patients may not benefit from a fluoropyrimidine-
based regimen.  
Following recent negative reports,(96-98, 346) the role of new targeted therapies for 
adjuvant treatment remains uncertain and thus, there continues to be reliance upon 
fluoropyrimidine-based chemotherapy as a mainstay of drug treatment for colorectal 
cancer. Patients with stage III disease and elevated GRP78 had a 20% higher 5-year 
survival compared with patients with low GRP78 who received the same adjuvant 
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treatment. Indeed, in this cohort, patients with low GRP78 failed to benefit from 
adjuvant chemotherapy. This important finding warrants further investigation. The 
possibility of predicting a treatment group with a higher risk of treatment failure, 
such as those with tumours expressing low levels of GRP78, could allow better 
selection and counselling of patients for targeted combination therapy, although this 
would require validation in prospective clinical trials. 
Another group recently reported that GRP78 can serve as a predictive biomarker for 
response to doxorubicin/taxane-based adjuvant chemotherapy in breast cancer.(347) 
When considered with our data, this may necessitate a re-evaluation of our 
understanding of the role of GRP78 in cancer. With a few exceptions,(285, 286) 
GRP78 expression in human cancers is typically associated with more aggressive 
phenotype and poor prognosis.(275-277, 280, 287, 296, 333, 334) The influence of 
GRP78 is likely to be tissue and drug specific, however, some studies suffer from 
small numbers of enrolled patients, heterogeneous tissue preparation, use of different 
GRP78 antibodies (in some cases not specific for GRP78 as we have demonstrated), 
and different scoring systems. Furthermore, in many cases, analysis did not extend to 
patients who had received adjuvant therapy. Similarly, in-vitro studies typically 
report that ER-stress leads to anti-apoptotic properties and drug resistance.(276, 296)  
However, the difficulty of in-vitro modelling of GRP78 expression is that, in many 
cases, the conditions used to induce ER-stress, such as glucose deprivation or 
pharmacological influence, result in cell cycle arrest,(348) a well recognised cause of 
drug resistance,(349) and therefore make interpretation of simple assays that only 
measure proliferation problematic (see Appendix 6.4 Difficulties of modulating 
GRP78 and assessing chemosensitivity in-vitro). These conditions almost certainly 
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fail to accurately model the prolonged physiological stress encountered during 
tumour growth. Methods not reliant upon cell proliferation, such as flow cytometry, 
may be superior for detecting alteration in chemosensitivity upon manipulation of 
GRP78. We chose to perform siRNA knockdown of GRP78 that had minimal effect 
on the cell cycle, rather than inducing ER-stress which might otherwise confound 
interpretation through the pleiotropic effects of the stress. As these experiments are 
based upon endogenous levels of GRP78, therefore we are modulating 
physiologically relevant levels of GRP78. 
Much remains to be elucidated regarding how UPR activation elicits such different 
cellular responses. It is possible that in patients with high GRP78, tumours are 
primed toward pro-apoptotic pathways of the UPR and, as such, are more susceptible 
to chemotherapy. Alternatively, one can envisage a model in which cells that have 
successfully adapted to the tumour microenvironment demonstrate persistently 
elevated expression of GRP78 and are therefore better equipped to process or remove 
proteins from the ER, thus preventing accumulation of misfolded proteins and 
avoiding activation of the UPR and cell-cycle arrest. This allows continued 
proliferation and thus sensitivity to cytotoxic agents. In contrast, the ER has a 
reduced capacity to handle protein in cells with low levels of GRP78, so although 
cellular function can be maintained in the absence of increased protein burden, these 
cells are more sensitive to perturbations in the tumour microenvironment that trigger 
the prosurvival arm of the UPR. Whilst in vitro this can lead to inhibition of 
translation and cell cycle arrest, the in vivo consequences of this are not yet 
understood and may well lead to altered tumorigenicity. In this scenario, cells with 
low GRP78 are therefore more likely to display resistance to 5-FU. Models 
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proposing adaptation to chronic ER stress such as this are not novel,(350) and 
furthermore, it has been demonstrated that over-expression of GRP78 in vitro is 
tolerated and, for example, does not result in cell cycle alteration.(289) The 
observation that tumours expressing low GRP78 did not seem to respond to 
treatment with 5-FU suggests that these cells are concentrating resources on 
mitigating stress rather than on growth and division, in keeping with the siRNA 
knockdown experiment presented here. We speculate that tumours with elevated 
GRP78 may have successfully adapted to their microenvironment through induction 
of chaperones and modulation of their metabolic state,(229) thus allowing continued 
proliferation and sensitivity to cytotoxic agents. In the case of tumours with low 
availability of GRP78, when further stress is applied, the protein-folding capacity of 
the ER becomes overwhelmed and the UPR is activated leading to cell cycle arrest 
and drug resistance. However, our results raise the question of whether GRP78 may 
contribute to chemosensitivity through mechanisms other than direct activation of the 
UPR. In support of this, recent developments suggest that GRP78, traditionally 
believed to be an ER-resident, can be identified in the cytoplasm and on the cell 
surface of cancer cells, and furthermore, is biologically active and may affect cell 
viability at both of these sites.(351) We must also be cautious that the observations 
made in vitro, using specialised cell lines, may not always reflect the true in vivo 
endogenous mechanisms. 
In view of the multiple genetic alterations which define the evolution of colorectal 
cancer,(24) much attention is currently focused on identifying molecular or genetic 
factors that may help predict survival or response to chemotherapy. Mutation of p53, 
KRAS mutation, defective DNA mismatch repair (dMMR) and loss of 
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heterozygosity on the long arm of chromosome 18 are all important steps in the 
development of colorectal cancers.(352) However, examination for genetic mutations 
such as these is often complex and expensive and in view of many conflicting reports 
in the literature, with the exception of KRAS,(353) the routine use of these 
biomarkers is not currently recommended.(87) A recent study using tissue from the 
QUASAR study has also failed to identify biomarkers predictive of benefit from 
chemotherapy.(353) GRP78 is easily detectable by immunohistochemistry using 
highly specific commercially available antibodies and may provide a simple and 
cheap alternative tool for risk stratification. 
Clearly, the gold standard for evaluating a potential predictive biomarker such as 
GRP78 is a prospective randomised-controlled trial. Nonetheless, our study has 
several important strengths. Firstly, the prospective uniform nature of specimen 
collection for all subjects by our pathology department minimises potential 
systematic bias from this study. The study cohort was essentially a random sample of 
the expected target population and the chemotherapy delivered represents real world 
practice. Secondly, we used an antibody that we were able to validate using siRNA 
and EGFSubA whereas some antibodies to GRP78 cross react with related, 
potentially more abundant, proteins such as HSP72 as shown. Finally, our clinical 
findings support our in vitro data demonstrating a functional role for endogenous and 
thus physiologically relevant levels of GRP78 in cellular responses to 5-FU. 
In this study, overall survival (OS) was chosen as an unambiguous and clinically 
relevant end point. Traditionally in clinical trials, OS rate at 5 years has been the 
most typically quoted metric for judging the success or a particular treatment 
regimen. It is easy to measure and interpret, and clinically meaningful. A major 
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drawback of this approach however is that in a retrospective non randomised, cohort 
study such as this, it is not entirely possible to isolate any causal effect of the GRP78 
on the efficacy of fluorouracil-based therapy from the many other factors that may 
have influenced treatment decisions at the time, for example, age, comorbidity, 
patient choice, etc. In this Liverpool cohort, analysis reveals that those receiving 
adjuvant chemotherapy were on average 8.75 years younger than those who did not 
(61.71yr vs. 70.46yrs, p<0.001). Thus, other factors may be having an influence on 
overall survival. In larger randomised trials, factors such as age, performance status 
are controlled for by the process of randomisation but this cannot be the case in a 
retrospective study such as this. Ideally, such retrospective biomarker analysis would 
be conducted against data from a well-conducted randomised controlled trial (RCT), 
with samples available from a large number of patients.(354) By example, KRAS 
was identified as a predictive biomarker in advanced colorectal cancer using 
validation from a previous RCT.(355) Even the multivariate analysis does not 
completely account for these confounding effects on survival.  Progression-free 
survival (PFS) is increasingly used in RCT’s of new agents in cancer treatment and 
in the case of colorectal cancer, has been proven to be a useful surrogate for overall 
survival.(356) In a study on adjuvant chemotherapy, it might be argued that the 
greatest effect will be on PFS as a marker of change in tumour burden in response to 
treatment. This does not always necessarily convert to a benefit to patients as 
significant absolute degrees of improvement in PFS may not always translate into 
meaningful improvement in OS. PFS is more difficult to measure than OS in which 
the date of death is exact and defining PFS will be biased by timing of follow up 
measurement  and other forms of bias.(357) The retrospective nature of this study 
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and limitations of access to accurate mortality data meant that overall survival was 
the most viable and robust end point. 
A number of questions need to be addressed. Can patients with stage II disease and 
high GRP78 be spared adjuvant chemotherapy regardless of clinical or pathological 
parameters or conversely, might these be the subgroup of stage II patients who do 
benefit from adjuvant 5-FU? Are patients with low GRP78 likely to benefit from 
combination or non-fluoropyrimidine-based chemotherapy? These questions need 
answering through larger prospective studies. 
In conclusion, the expression of GRP78 in colorectal cancer is an independent 
marker of survival in colorectal cancer and may be especially useful in identifying a 
poor prognostic group in stage II disease. In addition, GRP78 predicts and 
determines response to fluoropyrimidine-based adjuvant chemotherapy allowing 
identification of a group with a high chance of failure to respond who could be 
offered alternative therapy. 
 
3.3 Addendum 
The external examiner has pointed out that the prognostic and treatment predictive 
modelling in chapter 3 is incomplete, which has led to over-interpretation of the role 
of GRP78 expression. The conclusion of chapter 3 should read that the data suggest 
that GRP78 is a treatment predictive biomarker for mainly 5-FU based adjuvant 
chemotherapy in patients with colorectal cancer, but GRP78 does not have 
prognostic characteristics. This interpretation is important to the design of future 
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studies to further test and quantity the treatment predictive characteristics of GRP78 
in patients with colorectal cancer undergoing adjuvant chemotherapy. 
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4 Pre-clinical investigation of GRP78 as a potential therapeutic 
target in colon cancer using a novel engineered fusion protein; 
EGF-SubA. 
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4.1 Results 
4.1.1 Characterisation of Epidermal Growth Factor Receptor (EGFR) 
expression on a panel of colorectal cell lines. 
EGF-SubA has been shown to undergo EGFR-mediated internalisation, in the same 
manner as EGF, and cytotoxicity to tumour cells via GRP78 cleavage is documented 
to be dependent upon levels of EGFR expression with PC3 (prostate cancer) or 
MDA231luc (breast cancer) cells expressing EGFR being substantially more 
sensitive to this drug than EGFR-negative F98 (engineered rat glioma) or U226-B1 
(human myeloma) cells. (314) 
To date, the cytotoxicity of EGF-SubA upon colon cancer cells has not been 
assessed. I therefore sought to characterise EGFR expression in a panel of available 
colon cancer cell lines prior to investigating the potential cytotoxic effect of EGF-
SubA treatment and examine whether this was indeed dependent upon EGFR 
expression. 
As Figure 4.1.1-1 demonstrates, all cell lines express EGFR with the exception of 
SW620 which is EGFR-deficient. Interestingly, the sister cell line SW480 expresses 
relatively higher levels of EGFR. This discrepancy is due to a well documented 
functional knockout of EGFR in SW620 cells, as EGFR copy number is in fact 
identical to SW480.(358) The p53 status of each cell line was also confirmed in this 
figure. 
As EGF-SubA targets cell surface EGFR, the expression of cell surface EGFR on 
colon cancer cell lines was assessed using flow cytometry as described in section 
2.7.5 (as opposed to western blotting that measures total cellular EGFR). 
Results 2 
____________________________________________________________________ 
145 
 
Flow cytometry revealed that cell surface EGFR expression was present for all cell 
lines assessed with the exception of SW620 (Figure 4.1.1-2), in keeping with total 
EGFR as measured by western blot below. This is highlighted in Figure 4.1.1-3. 
 
Figure 4.1.1-1: Western blot of EGFR expression in a panel of colon cancer cell lines. 
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Cells were harvested at 80-90% confluence and cell lysates were subjected to western blot using a rabbit 
polyclonal antibody for EGFR (Santa Cruz). The p53 status is also examined in this figure using a mouse 
monoclonal antibody (Oncogene-Merck). Mouse monoclonal antibody for Actin (Santa Cruz) was used as a 
loading control. 
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Figure 4.1.1-2: Surface EGFR expression of colon cancer cells as determined by flow 
cytometry.  
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Cells were incubated with PE-conjugated anti-human EGFR-specific antibody (abcam) for 30 mins then washed 
in PBS buffer and analysed by flow cytometry. Mean fluorescent intensity (MFI) is indicated. Controls illustrated 
for HCT116p53wt and SW620 by way of example were performed by omitting the primary antibody to indicate 
non-specific fluorescence. EGFR positive HCT116p53wt cells (solid purple fill) show increased MFI versus its 
control (solid red line), whereas the EGFR negative SW620 show minimal difference to the control. 
Results 2 
____________________________________________________________________ 
147 
 
 
Figure 4.1.1-3: Cell surface EGFR expression of HCT116p53wt (EGFR-positive) and 
SW620 (EGFR-negative) as determined by flow cytometry.  
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The histograms have been overlaid for comparison. 
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4.1.2 EGF-SubA–induced cytotoxicity is EGFR-dependent 
In order to assess the inhibitory effects of EGF-SubA upon colorectal cancer cells, I 
performed a MTT assay as described in section 2.6. Representative growth curves 
(Figure 4.1.2-1) and dose-response curves (Figure 4.1.2-2) are demonstrated below. 
In agreement with the observations of Backer et al. in other cell lines,(314) a 
negative correlation (Pearson’s correlation coefficient = -0.83) was noted between 
EGFR surface expression and sensitivity to EGF-SubA in colon cancer cell lines 
(Figure 4.1.2-3). The cytotoxicity of EGF-SubA to colon cancer cells was EGFR-
dependent because EGFR-negative SW620 cells were more than 20-fold less 
sensitive to EGF-SubA than EGFR-positive SW480 cells (Table 4.1-1).  
The observed correlation can be quantified using the Spearman rank correlation 
coefficient which is a non-parametric measure of statistical dependence between two 
variables.(359) The perfect Spearman correlation of +1 or −1 occurs when each of 
the variables is a perfect monotone function of the other. If the dependent variable 
increases as the independent variable increases, the Spearman correlation coefficient 
is positive; if the dependent variable decreases as the independent variable increases, 
the Spearman correlation coefficient is negative. Using the data in Table 4.1-1, the 
Spearman rank correlation coefficient (Rho) =-0.829 (P=0.064). However, upon 
observing the data in Table 4.1-1, HCT116p53null may be regarded as an outlier in 
that its IC50 is comparatively high for its EGFR expression compared with the other 
cell lines. If HCT116p53null is excluded from the analysis, Rho=-1.0 (P=0.046), 
indicating a good correlation. 
This raises the question of why the HCT116 p53 null cell line should be an outlier. It 
is widely accepted that p53 is implicated in numerous processes including cell 
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growth, differentiation, senescence, apoptosis and angiogenesis.(360) In addition, 
there is now a body of evidence that p53 has a role in regulating the transcription of 
the EGFR promoter,(361, 362) and thus it is possible that the p53 null derivative of 
HCT116, as well as being less sensitive to cytotoxic agents than its p53wt sister, may 
have altered transcriptional regulation of EGFR. 
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Figure 4.1.2-1: EGF-SubA inhibits growth of colon cancer cell lines at picomolar 
concentration.  
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A panel of colon cancer cells, including EGFR positive HCT116, HT29, Lovo and SW480 cells, and the EGFR 
negative cell line SW620 were seeded onto duplicate 96 well plates at a concentration of 3000 cells/well. After 24 
hr, cells were treated with varying concentrations of EGF-SubA or vehicle control (PBS) as illustrated and 
incubated for 5 days. Media and drug were changed daily. MTT assay was performed daily and scores plotted on 
a line graph. Error bars represent the standard error from the mean (s.e.m.). for 4 separate wells. 
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Figure 4.1.2-2: EGF-SubA dose response curves.  
 
0
20
40
60
80
100
120
1 10 100 1000C
e
ll 
vi
ab
ili
ty
 (
%
 C
o
n
tr
o
l)
EGFSubA/pM
HCT116wtp53 EGFSubA
0
20
40
60
80
100
120
1 10 100 1000C
e
ll 
vi
ab
ili
ty
 (
%
 C
o
n
tr
o
l)
EGFSubA/pM
HCT116p53null EGFSubA
0
20
40
60
80
100
120
1 10 100 1000C
e
ll 
vi
ab
ili
ty
 (
%
 C
o
n
tr
o
l)
EGFSubA/pM
HT29 EGFSubA
0
20
40
60
80
100
120
1 10 100 1000C
e
ll 
vi
ab
ili
ty
 (
%
 C
o
n
tr
o
l)
EGFSubA/pM
SW480 EGFSubA
0
20
40
60
80
100
1 10 100 1000C
e
ll 
vi
ab
ili
ty
 (
%
 C
o
n
tr
o
l)
EGFSubA/pM
LoVo EGFSubA
0
20
40
60
80
100
120
1 10 100 1000C
e
ll 
vi
ab
ili
ty
 (
%
 C
o
n
tr
o
l)
EGFSubA/pM
SW620 EGFSubA
Results are extrapolated from growth curves in Figure 4.1.2-1 at day 4. 
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Figure 4.1.2-3: Cell surface EGFR expression (MFI) in colon cancer cell lines correlates 
negatively with EGF-SubA sensitivity. 
 
 
 
 
Table 4.1-1: Cell surface EGFR expression (MFI) in colon cancer cell lines correlates 
negatively with EGF-SubA sensitivity (IC50). 
Cell line MFI 
IC50 
EGFSubA/pM 
SW620 7.14 550 
HCT116p53wt 21.37 75 
Lovo 22.16 45 
HT29 27.72 35 
HCT116p53null 33.91 55
* 
SW480 38.36 25 
Rho=-1.0 (P=0.046); *excluded from 
Spearman rank correlation analysis 
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Dot plot created using the IC50 obtained from the EGF-SubA dose response curves and mean fluorescent 
intensity (MFI) of PE-conjugated anti-EGFR antibody using flow cytometry for a panel of colon cancer cell 
lines. (IC50 = inhibitory concentration required to cause 50% growth inhibition at day 4). Pearson’s correlation 
coefficient =-0.83 
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4.1.3 EGF-SubA activates EGFR trafficking 
Ligand binding leads to rapid internalisation of EGFR within minutes.(363, 364) 
Proteosomes are implicated in the regulation of EGFR endocytosis and proteosome 
inhibitors such as MG132 can reduce EGFR degradation.(365) Internalised ligand 
bound EGFR complexes are delivered to early endosomes where they are trafficked 
for recycling or degradation. For degradation, EGFRs are transported to 
prelysosomal late endosomes then degraded by lysosomes. This EGF-induced down-
regulation of EGFR is a major negative feedback regulatory mechanism that controls 
the density and duration of receptor signalling.(366) 
By demonstrating trafficking of the EGFR following treatment with EGF-SubA, it 
can be concluded that the EGF moiety is functionally active. An initial pilot western 
blot demonstrated that EGFR was down-regulated following exposure to EGF-SubA 
(Figure 4.1.3-1). 
I hypothesised that if the observed reduction in EGFR following treatment with 
EGF-SubA is due to internalisation and lysosomal degradation via complexing with 
the EGF moiety, then it should be possible to inhibit this process using proteosome 
inhibitors such as MG132 or Leupeptin.  
Indeed, when cells were exposed to EGF-SubA in the presence of MG132, EGFR 
expression is rescued. Leupeptin seemed less active in this experiment. Treatment 
with proteosome inhibitors does not however abrogate GRP78 cleavage (Figure 
4.1.3-2). 
This data is in keeping with that of Backer et al., who confirmed that EGF-SubA was 
able to induce EGFR-tyrosine autophosphorylation at comparable concentrations to 
recombinant EGF.(314) In my experiment, it can be observed that while both 
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recombinant EGF and EGF-SubA cause reduced levels of EGFR, only EGF-SubA 
causes cleavage of GRP78. Again, Backer concluded that EGFR-mediated 
endocytosis was critical for delivery of EGF-SubA into cells following the 
observation that GRP78 cleavage was significantly delayed using untargeted 
SubA.(314) 
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Figure 4.1.3-1: EGFR expression is reduced following exposure to EGF-SubA.  
 
 
 
Figure 4.1.3-2: Proteasome inhibitor MG132 rescues EGFR expression following 
exposure to EGF-SubA, but does not prevent cleavage of GRP78.  
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Cells were seeded into six-well plates at 30% confluence in standard media which was changed to low serum 
(1%) after 6hrs to enhance EGFR expression then incubated for 24hrs prior to treatment. For combination 
treatment, Leupeptin (25 µg/ml) or MG132 (100µM) were added 1 hr prior to EGF (100 ng/ml) or EGF-SubA (1 
nM). Treatments were terminated at 4hrs by exchanging media and cells were then harvested for western blot. 
Cells were seeded into six-well plates at 30% confluence in standard media which was changed to low serum 
(1%) after 6hrs to enhance EGFR expression then incubated for 24hr prior to treatment with 1nM EGF-SubA. 
Cells were harvested after 24hr for western blot. 
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4.1.4 The EGFR-mediated proteolytic activity of EGF-SubA is dose-
dependent. 
Having demonstrated that EGF-SubA cytotoxicity correlates with EGFR, I evaluated 
if cleavage of GRP78 was also defined by EGFR expression. Western blot using an 
antibody specific for GRP78 (sc13968) confirmed EGF-SubA cleavage of GRP78 
revealing a 28 kDa fragment. Equivalent amounts of EGF-SubA were unable to 
induce significant cleavage of GRP78 in SW620 cells (EGFR-negative) compared 
with the other cell lines analysed as shown below in Figure 4.1.4-1. 
Interestingly, it was observed that all cell lines, including SW620 cells, respond to 
continuous EGF-SubA exposure by upregulating GRP78 expression. This can be 
noted in Figure 4.1.4-1 whereby the band density of intact GRP78 is seen to increase 
up to a dose of 100 pM for HCT116p53wt, HCT116p53null and HT29 cells; up to 60 
pM in the sensitive SW480 cells, and even at 1 nM in SW620. At higher doses, the 
amount of GRP78 cleavage by EGF-SubA seems to overwhelm this compensatory 
mechanism and the amount of intact GRP78 is reduced. 
To examine the kinetics of the EGFR-mediated proteolytic activity of EGF-SubA, 
HCT116p53wt cells were selected for a time course experiment. Apparent as early as 
45 minutes to 1.5 hours following exposure to EGF-SubA, a substantial decrease in 
intact GRP78 is observed by 3 hours but by 24 hours of continuous GRP78 cleavage, 
HCT116p53wt cells respond by upregulating GRP78 (Figure 4.1.4-2). Similarly, a 
cleaved 28 kDa fragment of GRP78 can be detected by 1.5 hours. One must 
acknowledge that interpretation of GRP78 protein levels may be complicated by the 
SubA mediated cleavage. 
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It is known that selective cleavage of GRP78 by SubA toxin releases PERK, IRE1 
and ATF6 leading to overwhelming activation of the UPR and subsequent apoptosis 
(312, 313). Therefore, upregulation of GRP78 is likely to be secondary to activation 
of the unfolded protein response, which is a slow compensatory mechanism (>24 
hours) compared with the rapid (minutes) cleavage of GRP78 as observed in 
HCT116p53wt cells. 
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Figure 4.1.4-1: Western blot demonstrating EGF-SubA mediated cleavage of GRP78.  
 
Figure 4.1.4-2: EGF-SubA causes rapid proteolytic cleavage of GRP78.  
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Cells were seeded into six-well plates and 24hr later exposed to varying doses of EGF-SubA or vehicle control as 
indicated After 24hr cells were harvested, and protein extracts were subject to western blotting to demonstrate 
GRP78 cleavage. Actin was used as a loading control. 
HCT116p53wt cells were seeded on to 10cm plates. After 24 hr 1 nM EGF-SubA was added and cells harvested 
at varying time points as indicated, and protein extracts subjected to western blotting. 
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4.1.5 Activation of the unfolded protein response by EGF-SubA leads to cell 
cycle arrest. 
As discussed above, rapid GRP78 cleavage results in release of the UPR effectors 
PERK, IRE1 and ATF6. To examine the downstream effects of EGF-SubA-mediated 
cleavage of GRP78, I examined for the well described UPR target C/EBP 
homologous protein (CHOP), also known as GADD153, a known pro-apoptotic 
factor (as discussed in section 1.3.3.3.1 on page 59).(261) 
ER stress can induce transcription of CHOP via multiple UPR pathways including 
ATF4, spliced ATF6, and XBP-1 derived from spliced Xbp1 mRNA.(367) CHOP 
induction as a result of GRP78 cleavage has been previously documented,(311, 313) 
and is indicative a severe ER stress. Although known for its pro-apoptotic effects, 
CHOP is also implicated in causing G1/S-phase cell cycle arrest.(368) This is of 
further interest when it is also considered that SubAB-treated Vero and HeLa cells 
are known to arrest in G1 phase, and this is due to cyclin D1 downregulation or 
proteosomal degradation.(369) 
In my experiments, evidence of UPR activation following exposure to EGF-SubA 
indicated by compensatory upregulation of GRP78 and increased expression of 
CHOP, and the observation that EGF-SubA inhibits cell proliferation, led me to 
believe that cellular responses to EGF-SubA were likely to be due to cell cycle arrest. 
To investigate this I performed cell cycle analysis with Propidium iodide using flow 
cytometry as described in section 2.7.2.  
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An initial analysis of HCT116p53wt cells demonstrated that greater than 80% of 
cells were in G1 after treatment with EGF-SubA; in contrast 69% of untreated cell 
were in G1 ( 
Figure 4.1.5-2: EGF-SubA induces G1 cell cycle arrest.). 
Although measuring the DNA content of cells using propidium iodide is a useful way 
of measuring changes in the cell cycle, the S-phase cells cannot be accurately 
determined using this method. A more accurate analysis is allowed by performing S-
phase analysis using bromodeoxyuridine uptake. As discussed in section 2.7.3, the 
determination of the percentage of cells in S-phase is dependent upon the detection 
of a thymidine analogue, bromodeoxyuridine (BrdU), which when added to culture 
medium is incorporated into DNA during DNA replication. Via flow cytometry, a 
bivariate analysis is performed of total DNA content using propidium iodide staining 
along the X-axis plotted against BrdU incorporation detected via FITC labelled 
antibody to BrdU on the Y-axis. Only those cells that have been actively synthesising 
DNA during the time that BrdU is present will be positive for it. Simultaneous 
staining with propidium iodide allows the DNA content to be assessed and thus, the 
percentage of cells in G1, S-phase and G2/M can be determined. 
As predicted, treatment with EGF-SubA resulted in a reduction in S-phase with arrest 
in G1. Only the EGFR-negative cell line SW620 was resistant to this effect with 
minimal change in cytokinetics (Figure 4.1.5-3, Figure 4.1.5-4, Table 4.1-2). 
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Figure 4.1.5-1: GRP78 cleavage induces transcription of the stress-inducible CHOP.  
 
 
 
 
Figure 4.1.5-2: EGF-SubA induces G1 cell cycle arrest. 
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HCT116p53wt cells were seeded into six-well plates and after 24 hr were treated with 1 nM EGF-SubA or 
vehicle control. After 48 hr, cell cycle analysis was performed on fixed permeabilised cells stained with 
Propidium iodide. 
Cells were treated essentially as in Figure 4.1.4-1. Cells were seeded into six-well plates and 24hr later exposed 
to varying doses of EGF-SubA or vehicle control as indicated After 24hr cells were harvested, and protein 
extracts were subject to western blotting. Actin was used as a loading control. 
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Figure 4.1.5-3: Flow cytometric cell cycle analysis of BrdU incorporation demonstrates 
G1 arrest following exposure to EGF-SubA.  
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Cells were seeded in six-well plates and after 24 hr exposed to a dose equivalent to 3 x IC50 of EGF-SubA for a 
further 24 hr. Cells were treated with 10 µM of BrdU for 60 mins prior to harvesting for flow cytometry as 
described in section 2.7.3. 
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Figure 4.1.5-4: Histogram representing the effect on the cell cycle of exposure to EGF-
SubA.  
 
 
Table 4.1-2: Table demonstrating the percentage reduction of cells in S-phase following 
exposure to EGF-SubA compared with controls.  
 
Cell line 
% Reduction in S-phase 
after EGF-SubA 
HT29 93 
HCT116p53wt 89 
Lovo 78 
HCT116p53null 50 
SW480 32 
SW620 5 
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Data extrapolated from BrdU assay in Figure 4.1.5-3. 
 
Data extrapolated from BrdU assay in Figure 4.1.5-3. 
 
Results 2 
____________________________________________________________________ 
164 
 
4.1.6 EGF-SubA is a weak inducer of apoptotic cell death 
I have shown that EGF-SubA can produce growth inhibition and cell cycle arrest in 
colon cancer cells at picomolar concentrations. Western blotting of samples 
incubated with EGF-SubA has revealed that EGF-SubA is a potent inducer of ER 
stress, as indicated by a rapid upregulation of GRP78 and induction of CHOP. As 
discussed in the introduction to this thesis, severe or prolonged ER stress can lead to 
apoptosis. The ability of EGF-SubA to induce CHOP, a known proapoptotic factor 
would suggest that EGF-SubA may be able to cause apoptosis. 
PARP (poly(ADP-ribose) polymerase) is an abundant nuclear protein with important 
functions in DNA repair in response to numerous cytotoxic insults. Caspase-
mediated cleavage of PARP is a useful indicator of apoptotic cell death (as oppose to 
necrotic death) and reflects irreversible cell damage and commitment to the apoptotic 
pathway.(370, 371) Despite the apparent potency of EGF-SubA as an inhibitor to 
cancer cell proliferation, western blot revealed that EGF-SubA was not a potent 
inducer of PARP cleavage (Figure 4.1.6-1), even at a dose far above that required to 
inhibit growth (1 nM). 
As the above experiment used cells treated for 24 hours with 1 nM EGF-SubA, I 
treated cells with an even higher dose of 2 nM and assessed for apoptotic cell death 
at 24 hour intervals to see if this higher dose could induce apoptosis over a longer 
period of time. Figure 4.1.6-2 demonstrates that only a modest amount of apoptosis 
could be detected by annexin V assay (20% increase compared with control), and 
this was not apparent until 48 hours of treatment with no further increase at 72 hours. 
(For comparison, one can compare the marked apoptosis resulting from combination 
treatment with 5-FU and oxaliplatin later in Figure 4.1.8-3.) Analysis of the data 
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reveals a small increase in early apoptosis (PI–ve/AV+ve, lower right quadrant on 
bivariate analysis) at 24 hours that increases by 48 hours and by 72 hours, most 
apoptotic cells are demonstrating late apoptosis (PI+ve/AV+ve, upper right 
quadrant), with a consequent reduction of early apoptosis. It is notable that the 
amount of necrotic cell death (PI+ve/AV–ve, upper left quadrant) is minimal or zero 
for all conditions. 
Thus it can be concluded that in contrast to its potent inhibitory effect on 
proliferation in colon cancer cells, EGF-SubA is only a weak inducer of apoptosis. 
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Figure 4.1.6-1: EGF-SubA is not a strong inducer of PARP cleavage. 
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A panel of colon cancer cells were incubated in 6 well plates with varying doses of EGF-SubA for 24 hr prior to 
harvest. Cell lysates were subject to SDS-PAGE using 15% polyacrylamide gel for separation prior to 
immunoblotting with mouse monoclonal anti-PARP antibody (BD Transduction) that recognises both the 
uncleaved and cleaved forms of PARP. Actin was used as a loading control. 
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Figure 4.1.6-2: EGF-SubA is a weak inducer of apoptosis. 
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HCT116p53wt cells were seeded to 10cm plates and exposed to 2 nM EGF-SubA or vehicle control for 24, 48 
and 72 hr. At each timepoint, cells were harvested analysed by flow cytometry. (A) Bivariate distributions of 
Annexin V (AV)-positivity (apoptosis, FL1 parameter, x-axis) vs. Propidium iodide (PI)-positivity (necrosis, FL2 
parameter, y-axis) were generated for each population. Viable cells were measured as those in the lower left 
quadrant (PI/AV –ve); early apoptotic cells are in the right lower quadrant (PI –ve/AV +ve, late apoptotic cells 
are in the right upper quadrant (PI +ve/AV +ve); remaining cells in the left upper quadrant were deemed necrotic 
or dead (PI +ve/AV –ve). (B) These analyses were represented by histogram. 
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4.1.7 EGF-SubA and conventional drug treatment of colorectal cancer 
I have observed that EGF-SubA may cause cell cycle arrest and inhibit proliferation 
of colon cancer cell lines at picomolar concentrations. This raises the important 
question of whether EGF-SubA may have a potential role in the drug treatment of 
colorectal cancer. As discussed earlier, the mainstay of treatment of colorectal 
cancer, in both the adjuvant and metastatic setting, is the combination of 5-FU/FA 
and Oxaliplatin. 
EGF-SubA has been shown to synergise with the ER-stress inducing drug 
thapsigargin.(314) Thapsigargin inhibits ER calcium-dependent ATPase, thus 
depleting ER calcium stores and impairing chaperone function, leading to increased 
unfolded proteins and consequently activating the UPR. I could find no evidence that 
either 5-FU or oxaliplatin are known to induce ER-stress. Therefore, I would not 
expect either drug to synergise with EGF-SubA, however, as these drugs exhibit 
common systemic toxicity, any additive effect that allows a reduction of dose may 
still be relevant. 
Combination assay of EGF-SubA and Oxaliplatin performed on HT29 and 
HCT116p53wt cells demonstrated some evidence of synergy with combination 
indices (CI) of less than 1 for one data point on the ED50 Isobologram in each cell 
line, however, in the case of HCT116 cells, it was possible to deduce two further data 
points both of which gave a CI of 1 indicating an additive effect (Figure 
4.1.7-3).(372) 
Combination assay of EGF-SubA and 5-FU revealed two data points with a CI of 
less than 1 suggesting synergy, whilst two further data points gave a CI equal to 1 
indicating an additive effect (Figure 4.1.7-6). 
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Figure 4.1.7-1: Proliferation and dose response curves for Oxaliplatin. 
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HT29 and HCT116p53wt were seeded onto 96 well plates at a concentration of 3000 cells/well., and treated with 
varying concentrations of Oxaliplatin as shown or vehicle control. Drugs and media were changed daily. MTT 
assay was performed daily.  Error bars represent the s.e.m. from four duplicate wells. Dose response curves were 
calculated from day 4 data to calculate the IC50 dose. 
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Figure 4.1.7-2: EGF-SubA in combination with Oxaliplatin.  
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Cells were seeded into 96 well plates as previously and treated with varying doses of EGF-SubA and/or 
Oxaliplatin. Drugs and media were changed daily. MTT assay was performed on day 4. The histograms represent 
% survival compared with control with error bars showing the s.e.m. from four duplicate wells. The dose 
response curves to the right were used to calculate combination IC50 doses. 
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Figure 4.1.7-3: ED50 Isobologram for EGFSubA and Oxaliplatin.  
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The Isobologram demonstrates the data points for each combination of doses that produce an IC50 as determined 
from the dose response curves. If the data point falls on the hypotenuse (solid black oblique line connecting each 
individual IC50), an additive effect is indicated. If the data points fall on the lower left, or on the upper right, 
synergism or antagonism are indicated, respectively. The combination index (CI) is indicated for each data point, 
and is calculated using the formula demonstrated where (Dx)1 and (Dx)2 is the dose of each drugs which, when 
used alone produces a fixed affect (in this case the IC50). The numerators D1 and D2 are the doses of each drug 
which when used in combination, achieve the same fixed effect. 
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Figure 4.1.7-4: Dose response curve for 5-FU.  
 
 
 
 
Figure 4.1.7-5: Combination of EGF-SubA and 5-FU.  
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Performed essentially as previously for EGF-SubA and Oxaliplatin. Cells were seeded into 96 well plates as 
previously and treated with varying doses of EGF-SubA and/or 5-FU. Drugs and media were changed daily. 
MTT assay was performed on day 4. The histograms represent % survival compared with control with error bars 
showing the s.e.m. from four duplicate wells. The dose response curves to the right were used to calculate 
combination IC50 doses. 
HCT116p53wt cells were seeded into a 96 well plate. After 24 hr, 5-FU was added in varying doses as indicated. 
Drugs and media were changed daily. MTT assay was performed after 4 days. Error bars are present but are too 
narrow to be visible on the figure. 
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Figure 4.1.7-6: ED50 Isobologram for combination treatment of HCT116p53wt cells 
with EGFSubA and 5-FU. 
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4.1.8 EGF-SubA reduces the apoptotic response to 5-FU and Oxaliplatin 
It is clear that EGF-SubA can induce cell cycle arrest, and may have an additive or 
mildly synergistic effect upon reducing proliferation when combined with 5-FU or 
Oxaliplatin, as measured by MTT assay in the previous experiment. I was interested 
to establish if this effect could be attributed to increase in apoptosis. 
Using HCT116p53wt cells, I performed an Annexin V assay using flow cytometry to 
assess relative apoptosis following treatment with EGF-SubA with or without 5-FU. 
High doses of each drug were used in order to obtain measurable degrees of 
apoptosis over a period of 24 hours. Cells cultured for each condition were also 
retained for staining with propidium iodide for cell cycle analysis. 
As a single agent, even at a high dose of 2 nM, EGF-SubA did not result in 
significant apoptotic cell death at 24 hr of treatment. In a striking comparison to the 
additive effect seen in the combination data obtained using the MTT assay, there was 
a significant reduction in apoptotic cell death when EGF-SubA was combined with 
5-FU (24% reduction) compared with treatment with 5-FU alone (Figure 4.1.8-1). 
Minimal necrotic cell death was seen with either treatment at 24 hours. 
5-FU is an antimetabolite drug whose cytotoxicity results from the misincorporation 
of its active metabolites into RNA and DNA and its inhibition of thymidylate 
synthase, which is necessary for DNA replication and repair.(73) Thus it is most 
active against cells replicating their DNA in S-phase of the cell cycle.  
I performed cell cycle analysis to determine if the effects of EGF-SubA upon 5-FU 
described above might be explained by G1 arrest and a concomitant reduction of 
cells entering S-phase where they are most susceptible to treatment with 5-FU. As 
shown in Figure 4.1.8-2, 24 hours of 5-FU treatment resulted in the accumulation of 
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cells in late G1 and S-phase, a concurrent loss of G2 cells, as well as a significant 
increase of cells in the sub G1 apoptotic phase, consistent with previous reports. 
(342-344) In earlier observations, treatment with EGF-SubA resulted in the majority 
of cells accumulating in G1. By way of contrast, following exposure to both drugs in 
combination, the majority of cells remain in G1, however, the number of cells in S-
phase was higher compared with control, or single agent EGF-SubA treated cells. 
There were also significantly fewer cells in the sub G1 phase compared with 5-FU 
treated cells. 
Together, these profiles characterise the differences in cell cycle progression that 
may underlie the observed reduction in apoptosis seen when EGF-SubA is combined 
with 5-FU. It is likely that the arrest of cells in the G1 phase reduces the number of 
cells that, when treated with 5-FU, can progress into S-phase and undergo apoptosis. 
These findings also raise a question regarding the role of GRP78 in sensitivity to 5-
FU. EGF-SubA causes highly specific cleavage of GRP78 and it is possible that an 
acute reduction in cellular GRP78 following exposure to EGF-SubA, whether it be 
within the endoplasmic reticulum or elsewhere within the cell, may somehow affect 
the apoptotic response to 5-FU. This argument is strengthened by the analysis of the 
clinical data presented earlier in this thesis where I demonstrated that patients whose 
tumours weakly expressed GRP78 failed to respond to 5-FU based adjuvant 
chemotherapy, whereas those with elevated GRP78 had a good response (see section 
3.1.8). It is also interesting to contrast the effects of GRP78 depletion by EGF-SubA 
with that caused by transient transfection with siRNA targeting GRP78 (see section 
3.1.11). In both cases, depletion of GRP78 led to a reduced effect of 5-FU treatment 
in vitro; however, siRNA transfection did not lead to any major correction of the cell 
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cycle, unlike EGF-SubA which led to G1 arrest. Both these data add to the argument 
that GRP78 may have an, as yet undetermined, functional role in the response to 5-
FU. This may include effects mediated by GRP78 residing outside of the 
endoplasmic reticulum that may affect pathways other than the unfolded protein 
response.(373) 
As contemporary drug treatment for colorectal cancer relies upon the combination of 
5-FU/FA and Oxaliplatin (as discussed in section 1.1.8.3), I proceeded to examine 
apoptotic response to this combination and the effects of adding EGF-SubA. As 
Figure 4.1.8-3 demonstrates, Oxaliplatin as a single agent is not particularly effective 
at inducing apoptosis (14% increase in apoptosis), even at the high non-clinically 
relevant doses used in this experiment. However, in combination with 5-FU, a 
dramatic apoptotic response (74% increase apoptosis) is seen in the HCT116p53wt 
cells. This is consistent with the synergism observed in preclinical studies of 5-FU 
and Oxaliplatin,(374) and the subsequent confirmation by phase III trials that show 
significant improved response rates and survival for the combination.(79) As in the 
previous experiment, the response to 5-FU as a single agent is reduced when in 
combination with EGF-SubA (15% reduction compared with control). Similarly, the 
response to Oxaliplatin is also reduced by EGF-SubA but to a lesser degree (3% 
reduction compared with control). When EGF-SubA was combined with 5-
FU+Oxaliplatin, a large reduction in apoptotic events (46% reduction) was seen 
compared with the combination of 5-FU and Oxaliplatin alone. 
The cell cycle profiles for the combination experiment with 5-FU, Oxaliplatin and 
EGF-SubA are shown in Figure 4.1.8-4. When HCT116p53wt cell are treated with 
Oxaliplatin for 24 hours, the majority of cells arrest in G2/M (20% increase 
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compared with control). There is also a small increase of cells in sub G1 (2% 
increase). The cell cycle profile after treatment with 5-FU is similar to the previous 
experiment. The combination of the two drugs led to the majority of cells arresting in 
S-phase, similar to treatment with 5-FU alone, however a greater number of cells are 
seen in sub G1 (9% v. 3%, for 5-FU and Oxaliplatin compared with 5-FU alone, 
respectively). The addition of EGF-SubA to Oxaliplatin attenuates the G2/M arrest. 
In combination with 5-FU and Oxaliplatin, EGF-SubA led to a reduction in S-phase 
arrest, with more cells residing in G1 and G2/M phases and a reduction of apoptotic 
sub G1 cells. 
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Figure 4.1.8-1: EGF-SubA attenuates the apoptotic response to 5-FU. 
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(A) HCT116p53wt cells were incubated with EGF-SubA (2 nM) and/or 5-FU (380 µM), or vehicle control (PBS). 
After 24 hr of incubation cells were harvested for Annexin V assay. (A) Bivariate distributions of Annexin V 
(AV)-positivity (apoptosis, FL1 parameter, x-axis) vs. Propidium iodide (PI)-positivity (necrosis, FL2 parameter, 
y-axis) were generated for each population. Viable cells were measured as those in the lower left quadrant (PI/AV 
–ve); early apoptotic cells are in the right lower quadrant (PI –ve/AV +ve, late apoptotic cells are in the right 
upper quadrant (PI +ve/AV +ve); remaining cells in the left upper quadrant were deemed necrotic or dead (PI 
+ve/AV –ve). (B) These analyses were used to generate percentages of viable (PI/AV –ve), apoptotic (AV +ve)  
or dead (PI +ve/AV-ve) cells at 24 hr of treatment. 
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Figure 4.1.8-2: Cell cycle progression in HCT116p53wt cells treated with EGF-SubA 
and/or 5-FU. 
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HCT116p53wt cells were incubated with 2 nM EGF-SubA and/or 380 µM 5-FU for 24 hr before harvest. The 
cells were stained with propidium iodide followed by flow cytometry analysis for cell cycle profile. (A) 
Representative cell cycle distribution of treated and untreated cells at 24 hr. (B) Histogram summarising cell cycle 
distribution from (A). 
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Figure 4.1.8-3: EGF-SubA reduces apoptotic response to 5-FU and Oxaliplatin in 
combination. 
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Experiment performed essentially as in the legend to Figure 4.1.8-1. Oxaliplatin (Hospira UK Ltd.) was added at a 
dose of 20 µM. 
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Figure 4.1.8-4: Cell cycle progression in HCT116p53wt cells treated with EGF-SubA 
and/or 5-FU and/or Oxaliplatin. 
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HCT116p53wt cells were incubated with 2 nM EGF-SubA and/or 380 µM 5-FU and/or 20 µM Oxaliplatin for 24 
hr before harvest. The cells were stained with propidium iodide followed by flow cytometry analysis for cell cycle 
profile. (A) Representative cell cycle distribution of treated and untreated cells at 24 hr. (B) Histogram 
summarising cell cycle distribution from (A). 
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4.2 Discussion 2 
Glucose-regulated protein 78 (GRP78), an endoplasmic reticulum (ER)-resident 
molecular chaperone, is essential for correct protein folding and assembly, and binds 
unfolded proteins so they can be repaired or targeted for proteosomal degradation. 
Micro-environmental stress and a requirement for increased protein synthesis, typical 
of solid tumours such as colorectal cancer, disrupts ER homeostasis causing 
accumulation of misfolded proteins. The ability of GRP78 to dissociate from several 
ER-resident transmembrane proteins during ER stress leads to a cascade of signal 
transduction pathways, known as the unfolded protein response (UPR), modulating 
cell survival or, if the stress is significantly severe, apoptosis.(202) The UPR allows 
cells to cope with an increase in unfolded proteins in the ER and may also prepare 
the cell for longer term adaptation through induction of chaperones such as GRP78 
and modulation of the cells metabolic state.(229) 
In the first section of this thesis, immunohistochemistry was used to confirm that 
GRP78 expression was increased in colorectal cancers compared with control normal 
mucosa. The proposed dependence upon GRP78 for cancer cell survival raises the 
potential of targeting this adaptive mechanism in cancer therapy.(202) Unlike other 
compounds which can reduce expression of GRP78, EGF-SubA causes highly 
specific cleavage at a single amino acid.(202, 314) This property led to the 
investigation of the therapeutic potential of targeting GRP78 in vitro. Using 
techniques including western blotting, MTT assay and flow cytometry, I have for the 
first time investigated the effects of EGF-SubA in colon cancer cells and also 
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assessed its combinatorial potential with contemporary drug treatments, namely 5-
FU and oxaliplatin. 
The weak apoptotic response to a 24hr oxaliplatin exposure may be regarded as a 
limitation in the above experiments, however the synergistic interaction with 5-FU 
can clearly be noted in the combination assays performed. Although cancer cells are 
highly sensitive to oxaliplatin in vitro, short exposure may only result in DNA-strand 
breaks and induction of apoptosis may require longer exposure to 48hr.(375, 376) 
Additionally, the above experiments did not explore the effect of a variable timing 
schedule in the delivery of 5-FU and oxaliplatin as both drugs were administered 
simultaneously. Any differential effects of timing schedule are likely to have been 
small however and previous data suggest that a synergistic interaction occurs 
whatever the tested combination schedule.(377) A more clinically relevant drug 
sequence consisting of Oxaliplatin for 2hr followed by 5-FU for 48 h (De Gramont 
regimen)(82) may have been a suitable option. 
As reported for other cell lines,(314) colon cancer cells were highly sensitive to 
EGF-SubA at picomolar concentrations and sensitivity was a function of cell surface 
EGFR expression, with EGFR positive cells demonstrating a far greater reduction of 
proliferation in the presence of EGF-SubA than EGFR negative cells. EGF-SubA 
resulted in rapid cleavage of GRP78 and the evidence presented here suggests that 
this leads to activation of the UPR and increased expression of the chaperone 
GRP78, in keeping with the documented activity of subtilase cytotoxin 
(SubAB).(313) In addition to the induction of GRP78, increased transcription of the 
downstream UPR effector CHOP is also observed. In addition to its proapoptotic 
functions, CHOP is also known to mediate cell cycle arrest and analysis of 
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cytokinetics with flow cytometry confirmed that EGF-SubA causes a marked G1 
arrest in EGFR-positive colon cancer cells. 
In contrast to its potent effects upon proliferation, EGF-SubA was not found to be a 
strong inducer of apoptotic cell death, even when applied at high doses over several 
days. This raises the question of whether UPR activation by EGF-SubA might allow 
the cell to concentrate resources on mitigating stress rather than on growth and 
division, as indicated by the cell cycle arrest. Furthermore, when EGF-SubA was 
combined with 5-FU and oxaliplatin, the apoptotic response was significantly 
reduced, and this is likely to be due, at least in part, to cell cycle arrest. (Interestingly, 
elsewhere in this thesis it is shown that targeting GRP78 with siRNA, which had less 
effect upon the cell cycle, may also inhibit response to 5-FU and oxaliplatin, 
suggesting a possible wider role for GRP78 in the response to these drugs.) 
Tumour cells are dependent upon pathways such as the UPR for survival. Is it 
possible that EGF-SubA, by way of its highly specific mode of action, is merely 
strengthening or enhancing the prosurvival response, rather than overwhelming or 
diminishing it? Through EGF-SubA mediated cleavage, simultaneous activation of 
PERK, IRE1 and ATF6 stress-signalling pathways occurs through dissociation from 
GRP78.(313) This in turn will lead to transcription of downstream UPR target genes. 
Although GRP78 is the master regulator of the UPR, removing it (via cleavage with 
EGF-SubA) does not impair the prosurvival effects of the UPR. The cell seems to 
respond to GRP78 cleavage in the same manner it would if GRP78 were to dissociate 
from its ER transmembrane sensors due to accumulation of misfolded protein in the 
ER. 
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Apoptosis resistance is a hallmark of malignancy. Tumour cells are able to overcome 
the apoptotic machinery and, hence, the propensity to be naturally eliminated. 
Conventional chemotherapy has limited effectiveness at least in part due to apoptosis 
resistance.(378) Cell cycle arrest will also lead to resistance to current cancer 
therapies that target actively dividing cells. The propensity for EGF-SubA to cause 
cell cycle arrest and resistance to apoptosis is likely to limit its potential as an 
anticancer therapy, particularly in the adjuvant setting where the aim is to eradicate 
micrometastatic deposits in patients who would otherwise be destined to have cancer 
recurrence. In the palliative setting, it could be envisaged that EGF-SubA might be 
able to halt progression of advanced disease and prolong survival but this is pure 
speculation. 
Overall, the results in terms of the potential therapeutic value of targeting GRP78, 
are somewhat disappointing, especially given the optimism portrayed in previous 
reports of EGF-SubA.(314) In Backer’s report, it was stated that EGF-SubA may 
synergize with ER stress-inducing drugs to kill cancer cells. In fact, what was 
actually demonstrated was that EGF-SubA inhibited proliferation (as determined by 
MTT assay) and this effect was increased in combination with thapsigargin. No 
evidence of ‘killing’ is actually presented and the authors actually comment that,  
‘....Interestingly, a 24-hour treatment with EGF-SubA alone did not result in any 
significant cleavage of α-fodrin or procaspase-7.’ 
In conclusion, despite its potency at inhibiting proliferation of tumour cells in vitro, 
the potential therapeutic value of EGF-SubA in the management of colorectal cancer 
is likely to be limited by its inhibition of apoptosis in combination with 
contemporary cytotoxic compounds, and the potential to activate prosurvival 
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mechanisms in colon cancer cells (which may in fact increase the likelihood of 
recurrence). Due to its highly specific cleavage of GRP78, EGF-SubA is certainly 
likely to remain useful as a research tool for investigating activation of the unfolded 
protein response. 
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Optimal surgery with complete resection of the tumour is the primary treatment for 
patients with resectable colorectal cancer. An additional survival benefit can be 
obtained from chemotherapy but selecting patients who are most likely to benefit 
from adjuvant therapy is complicated by lack of consistent data from biomarker 
studies, and thus in reality many patients are receiving treatment with a 
disadvantageous risk-benefit ratio. GRP78 has potential as a biomarker in that it is 
easily detectable; is well characterised as influencing tumour cell behaviour, drug 
sensitivity and malignant phenotype in vitro; is elevated in human tumours and less 
so in normal tissue, and expression is related to outcomes. Additionally, the role of 
GRP78 in tumorigenesis and adaptation to the hostile microenvironment found in 
solid tumours suggests that targeting GRP78 by small molecules may offer a 
potential therapeutic approach to cancer. 
Using a validated antibody, GRP78 expression was characterised on a large cohort of 
surgically treated patients with colorectal cancer, many of whom received 5-FU 
based adjuvant chemotherapy. Tumours with low GRP78 expression were associated 
with worse survival and failure to benefit from chemotherapy. By targeting 
endogenous GRP78 using both siRNA and a novel engineered fusion protein, EGF-
SubA, it was observed that in vitro, reduction of GRP78 reduced the efficacy of 5-
FU through modulation of the cell cycle and apoptosis.  
This exciting finding warrants further validation of GRP78 as a predictive biomarker 
through clinical research. The route to the use of such a biomarker in clinical practise 
though represents a considerable challenge. This may be achieved through 
retrospective or prospective methods. Due to the time and expense required to 
perform a prospectively designed randomised controlled trial (RCT), the possibility 
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to validate the predictive ability of GRP78 using data from a previously well-
conducted RCT which compares adjuvant chemotherapy for which GRP78 is 
proposed to be predictive is a more feasible option. This would follow the CRUK 
Biomarker Roadmap with progression to the CTAAC/BIDD BM Qualification-Stage 
1.(123) The essential elements required for a retrospective validation study are 
highlighted by Mandrekar and Sargent,(354) and are listed below: 
1. Data from a well-conducted randomised controlled trial 
2. Availability of samples on a large majority of patients to avoid selection bias 
3. Prospectively stated hypothesis, analysis techniques, and patient population 
4. Predefined and standardized assay and scoring system 
5. Upfront sample size and power justification 
An example of a suitable RCT to validate GRP78 would be the QUASAR trial.(83) 
This was a multicentre international RCT enrolling over 3000 patients and conducted 
during the same period of time the Liverpool cohort was recruited, and patients 
received comparable adjuvant chemotherapy regimens. Tissue from trial patients is 
held on tissue microarray and would be suitable for immunohistochemistry, thus, the 
reproducibility and accuracy of GRP78 analysis by this method could be established. 
Such an analysis would potentially provide compelling evidence for GRP78 as a 
potential predictive tool to select patients who may or may not benefit from 
fluorouracil-based chemotherapy. 
The gold standard for validation of a predictive biomarker is a prospective RCT 
(CRUK CTAAC/BIDD BM Qualification-Stage2,(123)). Providing that retrospective 
analyses confirmed its potential as a predictive biomarker then a GRP78 stratified 
trial could be designed.(379) Rather than restrict eligibility to a trial, stage 3 patients 
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could be stratified using a priori cut-off points into GRP78 high and GRP78 low, 
then randomly assigned to either standard therapy (FOLFOX) or an experimental 
group receiving, for example, FOLFOX plus a new treatment such as Bevacizumab 
(Figure 4.1.8-1). 
 
Figure 4.1.8-1: Marker-by-treatment-interaction design for a prospective predictive 
marker validation. 
This study design is similar to conducting two independent RCT’s, one in each 
GRP78-based subgroup. One may envisage that the GRP78 low group may receive 
the most potential benefit of addition of Bevacizumab over FOLFOX alone. 
In-vitro, EGF-SubA mediated GRP78 cleavage was toxic to colon cancer cells with 
sensitivity governed by EGFR expression at the cell surface. Cleavage of GRP78 
resulted in activation of the UPR and cell cycle arrest but EGF-SubA was not a 
potent inducer of apoptosis and combinations of EGF-SubA with 5-FU and 
Oxaliplatin were actually antagonistic. These findings suggest that despite targeting a 
prosurvival mechanism, EGF-SubA is not likely to have a therapeutic role in 
colorectal cancer management. However, due to its highly specific cleavage of 
GRP78, EGF-SubA is of value as a scientific tool with which to study GRP78 and 
the UPR in vitro. Its role in other tumour types is yet to be determined. 
Together, the findings of this research demand a re-evaluation of our understanding 
of the role of GRP78, a well characterised mediator of drug resistance in cancers.  I 
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propose that cells lacking GRP78 are more likely to activate the UPR, undergo cell 
cycle arrest and therefore exhibit drug resistance, whereas cells with abundant 
GRP78 are successfully adapted to their microenvironment and by their proliferative 
state, are more sensitive to cytotoxic agents such as 5-FU. This poses the question of 
in which situation is a patient better off; to have a slow growing tumour that exhibits 
drug resistance, or a tumour freed from the confines of its microenvironment that can 
grow but is more sensitive to chemotherapy? 
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6.1 Commonly used chemotherapy regimens in colorectal cancer 
Table 6.1-1: Commonly used chemotherapy regimens in colorectal cancer. 
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6.2 Flow cytometer setting for bivariate Annexin V/Propidium iodide 
analysis 
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6.3 Targeting of GRP78 using a different siRNA 
6.3.1 siRNA targeting GRP78, siGENOME D-008198-05 
 
Figure 6.3.1-1: Knockdown of GRP78 with a different siRNA produces similar 
reduction of apoptosis. 
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The experiment performed as per Figure 3.1.11-1 but using a different GRP78 targeting siRNA (siGENOME D-
008198-05). Cells were seeded 24 hours prior to transfection with a final siRNA concentration of 40 nM. A mock 
transfection control was prepared identically except for omitting the siRNA oligonucleotide. 48 hr after 
transfection, cells were treated +/- 100 µM 5-FU (medac GmbH, Germany) for 24 hr then harvested for flow 
cytometry. 
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6.4 Difficulties of modulating GRP78 and assessing chemosensitivity in-
vitro 
6.4.1 Overview 
During the work performed for this thesis, some of the challenges of trying to model 
the UPR and manipulate GRP78 in vitro became increasingly apparent.  
The induction of GRP78 is well established as a marker for ER stress.(225) A 
number of researchers have used low glucose stress as a means of upregulating 
GRP78 expression and modelling the effects of the UPR.(276, 296) Indeed, GRP78 
was first characterised because of its induction by glucose deprivation.(192) Others 
have induced ER stress and upregulation of GRP78 by treating cells with the NAD 
antagonist 6-aminonicotinamide (6AN) or inhibitors of glucose metabolism such as 
2-deoxyglucose (2dG).(288, 292) The use of the glycosylation inhibitor 
tunicamycin,(265) and depletion of intracellular calcium using calcium ionophores or 
thapsigargin are also well documented.(193, 200) 
As a starting point, I investigated the effects of glucose starvation in colon cancer 
cells. Culture under conditions of progressive glucose deprivation for 24 hours 
induced expression of GRP78 on western blotting (Figure 6.4.1-1). This effect did 
not appear to be short lived as further investigation demonstrated that GRP78 
remained elevated at 96 hr of culture in low glucose (Figure 6.4.1-2). 
Having demonstrated that low glucose stress can induce expression of GRP78 in 
vitro, I initially assumed that this model could be used to study the effects of 
modulating GRP78 upon drug sensitivity. As an example, I used the MTT assay in 
several experiments to assess the response to treatment with oxaliplatin under 
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conditions of low glucose stress known to induce GRP78 expression. The results of 
these experiments demonstrate that culture of cells in low glucose media (that will 
cause ER stress and induce GRP78 expression) can cause resistance to oxaliplatin as 
deduced by the increased survival compared with the control (Figure 6.4.1-3). The 
conclusion may be drawn that the drug resistance is due to elevated GRP78. 
However, this experiment and the conclusions drawn from it are flawed as shall be 
demonstrated. If this experiment is repeated to include analysis of the proliferation of 
cells under each of the conditions, the reasons behind the flaw become clear. 
Although the data represented by histograms of relative percentage survival indicates 
increased survival in low glucose following oxaliplatin treatment, the proliferation 
curves demonstrate that this effect is due to a marked reduction in proliferation in the 
cells exposed to 1 mM glucose (Figure 6.4.1-4). As these cells are barely 
proliferating, any additional inhibition due to drug treatment appears to account for a 
relatively smaller percent than those cultured in standard growth media. Therefore it 
is incorrect to draw the conclusion that it is specifically the elevated GRP78 
responsible for drug resistance. This conclusion has been drawn in published reports 
using this technique. I found two papers, one in the British Journal of Cancer and the 
other in the European Journal of Gastroenterology & Hepatology, which use this 
technique to conclude that increased GRP78 is responsible for resistance to 
doxorubicin and 5-FU in breast and hepatocellular carcinoma.(296, 380) Both papers 
have been cited a number of times. One should in fact conclude that it is UPR 
activation and reduced proliferation leading to drug resistance, and that elevated 
levels of GRP78 are only a marker for ER stress and not causative. This experiment 
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has not tested specific modulation of GRP78 as the conditions used have other 
effects upon proliferation. 
Analysis of alterations in chemosensitivity upon manipulation of GRP78 may be best 
performed using an assay that is not so reliant upon the effects of cell proliferation, 
such as flow cytometry. It is interesting to compare the results of an Annexin V assay 
with those of the MTT assay when used to assess response to 5-FU in cells cultured 
in low glucose conditions. Figure 6.4.1-5 demonstrates that cells cultured in 2 mM 
glucose have a significant reduction in apoptosis compared with cells in standard 
media when exposed to 5-FU, and as Figure 6.4.1-6 reveals, this is largely due to cell 
cycle arrest caused by low glucose stress. Therefore, the conclusion is that cell stress, 
brought about by culture in low glucose medium, leads to cell cycle arrest and 
reduced sensitivity to 5-FU. It is not elevated GRP78 independently that is causing 
resistance. 
Similarly, when I performed a combination study of EGF-SubA and 5-FU (as 
described in section 4.1.7), isobolograms constructed using data from MTT assay 
suggested an additive, if not synergistic, effect of combining these drugs. However, 
subsequent experiments using the Annexin V assay revealed that EGF-SubA 
significantly reduces the apoptotic effects of 5-FU (see Figure 4.1.8-1). The paradox 
is that EGF-SubA, known to cause highly specific cleavage of GRP78, can cause 
additional growth inhibition when combined with 5-FU, but at the same time is 
inhibiting the apoptotic effects. EGF-SubA, due to its specificity, is a useful tool for 
studying GRP78 in vitro but in addition to its rapid and specific depletion of 
intracellular GRP78, the SubA component is also a major activator of the UPR and 
can cause cell cycle arrest.(313, 369) Cell cycle arrest in G1 was confirmed in my 
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experiments and is a possible explanation for the reduced efficacy of 5-FU (see 
Figure 4.1.5-3 and Figure 4.1.8-2). 
The difficulty that presented itself was that the above methods of modulating GRP78 
led to activation of the UPR which might otherwise confound interpretation through 
the pleiotropic effects of the stress. It is also possible that such severe, acute forms of 
stress do not accurately model conditions in vivo and may be resulting in non-
physiological levels of GRP78. These issues led me to investigate the use of GRP78 
knockdown using siRNA. The technique benefits from the fact that it is modulating 
physiologically relevant levels of endogenous GRP78. Although western blots 
confirm good reduction of the levels of GRP78, the effect on the cell cycle was 
minimal, in contrast to the effects seen with EGF-SubA or glucose starvation (Figure 
6.4.1-6). 
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Figure 6.4.1-1: Western blots of colon cancer cell line lysates after exposure to culture 
conditions with varying glucose concentrations to demonstrate GRP78 expression. 
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Standard Dulbecco’s Modified Eagle’s Medium (DMEM) HEPES Modified (Sigma) containing 25 mM glucose 
(Sigma) was combined with glucose free DMEM (Gibco) to give a range of glucose concentrations. Cells cultured 
in 6 well plates were harvested after 24 hr of exposure to different glucose concentrations and cell lysates were 
subjected to western blot. Actin was used as a loading control. 
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Figure 6.4.1-2: Western blot demonstrating that GRP78 remains elevated at 96 hours 
of low glucose stress. 
 
Figure 6.4.1-3: Relative % toxicity for HT29 cells under normal and glucose-deprived 
culture conditions when exposed to previously determined IC50 doses of Oxaliplatin.  
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Relative % survival (mean +/- s.e.m.) for HT29 cells under normal and glucose-deprived culture conditions when 
exposed to 0.3 µM Oxaliplatin for 72 hr. Viability of control untreated cells was defined as 100%. Survival 
appears significantly higher under conditions of low glucose compared with standard culture conditions. Data 
derived from quadruplicate repeats, P values calculated using student t-test. 
Appendix 
____________________________________________________________________ 
202 
 
 
Figure 6.4.1-4: Higher survival after oxaliplatin treatment is a function of reduced 
proliferation under low glucose culture rather than reduced sensitivity. 
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Colon cancer cells were seeded to 96 well plates and allowed to settle for 24 hr after which fresh standard growth 
media or media containing 1 mM glucose supplemented with a predetermined IC50 dose of oxaliplatin or vehicle 
control was added. MTT assay was performed daily to chart proliferation. Media and drugs were changed daily. A 
histogram representing relative % survival (mean + s.e.m.) at day 4 is presented for each cell line. Viability of 
control untreated cells was defined as 100%. Data derived from quadruplicate repeats, P values calculated using 
student t-test. 
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Figure 6.4.1-5: 5-FU induced apoptosis is reduced in cells cultured in low glucose 
media. 
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Figure 6.4.1-6: Glucose starvation of colon cancer cells in vitro leads to cell cycle arrest 
in G1 and abrogates the effects of 5-FU upon the cell cycle. 
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Figure 6.4.1-7: Targeting GRP78 with siRNA has minimal effect upon the cell cycle. 
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